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Multiple myeloma (MM) is a largely incurable haematological malignancy 
characterised by the clonal proliferation of neoplastic immunoglobulin-producing 
plasma cells (PCs) within the bone marrow (BM). Previous studies from our laboratory, 
and those of others, have shown that gene and protein expression of the homophilic cell-
cell adhesion and signalling molecule, N-cadherin, is up-regulated in PCs in 
approximately 50% of newly-diagnosed MM patients. Notably, increased expression of 
N-cadherin is associated with inferior prognosis in these patients. In this thesis, 
bioinformatic and in vitro analyses were performed to determine the mechanisms 
responsible for the up-regulation of N-cadherin expression in MM. The histone 
methyltransferase MMSET, universally dysregulated in the 10-15% of MM patients 
which harbour the chromosomal translocation t(4;14), was a positive regulator of CDH2 
expression in human MM cell lines, suggesting it is a key driver of in N-cadherin 
expression in t(4;14)+ MM. Several additional candidate molecules and pathways (e.g. 
miR-190 and IL-6/JAK2/STAT3 signalling) were also identified which may represent 
previously unknown, MMSET-independent regulators of N-cadherin expression in 
t(4;14)- MM.  
 The development, progression and relapse of MM is underpinned by the 
trafficking, or dissemination, of MM PCs from one tumour site to distant BM sites via 
the circulation. Previous studies suggest that inhibition of MM PC adhesion to the 
endothelium may represent a potential therapeutic modality to prevent the extravasation 
and dissemination of MM PCs. In this thesis, pre-treatment of C57Bl/KaLwRij mice 
with the cyclic pentapeptide N-cadherin antagonist ADH-1 inhibited tumour 
development following intravenous injection of 5TGM1 MM PCs. This effect was not 
seen in mice treated with ADH-1 after tumour establishment, suggesting that N-
cadherin plays a role in the extravasation and BM homing of MM PCs. In support of 
this, N-cadherin was found to mediate the adhesion of MM PCs to endothelial cells 
(ECs), which represents a key step in the extravasation of circulating MM PCs. These 
studies suggest that ADH-1 may be clinically useful in the prevention of MM PC 
dissemination, thereby delaying disease progression and relapse. 
 In addition to its role in MM pathogenesis, N-cadherin is critical in the 




perturbation of N-cadherin function disrupts established EC-EC and EC-mural cell 
junctions resulting in increased permeability of the EC barrier to macromolecules in 
vitro and in vivo. This thesis describes the identification of a small molecule 
peptidomimetic of ADH-1, LCRF-0006, as a novel vascular disrupting agent which 
enhances vascular permeability in vitro and in vivo, and synergistically increases the 
efficacy of the anti-MM agent bortezomib in C57Bl/KaLwRij mice with established 
MM disease. To this end, LCRF-0006 may be clinically useful in increasing the depth 
of MM tumour response to bortezomib, which is currently used in MM patients as 
induction therapy, maintenance therapy, and in the relapse setting. In addition, we 
speculate that the potential ability of LCRF-0006 to augment the enhanced permeability 
and retention (EPR) effect could be utilised to increase the delivery, and therefore anti-
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In many types of solid tumours, the aberrant expression of the cell adhesion molecule 
N-cadherin is a hallmark of epithelial-to-mesenchymal transition, resulting in the 
acquisition of an aggressive tumour phenotype. This transition endows tumour cells 
with the capacity to escape from the confines of the primary tumour and metastasise to 
secondary sites. In this review, we will discuss how N-cadherin actively promotes the 
metastatic behaviour of tumour cells, including its involvement in critical signalling 
pathways which mediate these events. In addition, we will explore the emerging role of 
N-cadherin in haematological malignancies, including bone marrow homing and 
microenvironmental protection to chemotherapeutic agents. Finally, we will discuss the 
evidence that N-cadherin may be a viable therapeutic target to inhibit cancer metastasis 


























Cancer metastasis is a leading cause of cancer-related mortality. The metastasis of 
cancer cells within primary tumours is characterised by localised invasion into the 
surrounding microenvironment, entry into the vasculature and subsequent spread to 
permissive distant organs (reviewed in Valastyan & Weinberg, 2011 and Friedl & 
Alexander, 2011).1,2 In many epithelial cancers, metastasis is facilitated by the genetic 
reprogramming and transitioning of cancer cells from a non-motile, epithelial phenotype 
into a migratory, mesenchymal-like phenotype, a process known as epithelial-to-
mesenchymal transition (EMT) (reviewed in Thiery et al., 2009 and De Craene & Berx, 
2013).3,4 A common feature of EMT is the loss of epithelial cadherin (E-cadherin) 
expression and the concomitant up-regulation or de novo expression of neural cadherin 
(N-cadherin). This so-called "cadherin switch" is associated with increased migratory 
and invasive behaviour (reviewed in Wheelock et al., 2008 and Gheldof & Berx, 
2013)5,6 and inferior patient prognosis.7-10 A major consequence of E-cadherin down-
regulation is the loss of stable epithelial cell-cell adhesive junctions, apico-basal cell 
polarity and epithelial tissue structure, thereby facilitating the release of cancer cells 
from the primary tumour site (reviewed in Kourtidis et al., 2017 and Perl et al., 
1998)11,12. In contrast to the migration-suppressive role of E-cadherin, N-cadherin 
endows tumour cells with enhanced migratory and invasive capacity, irrespective of E-
cadherin expression (reviewed in Hazan et al., 2004).13 Thus, the acquisition of N-
cadherin appears to be a critical step in epithelial cancer metastasis and disease 
progression. 
In this review, we will discuss how N-cadherin promotes the metastatic 
behaviour of tumour cells by directly mediating cell-cell adhesion, and by its 
involvement in modulating critical signalling pathways implicated in metastatic events. 
In addition, we will discuss the emerging relevance of N-cadherin in haematological 
malignancies, namely leukaemias and multiple myeloma. Finally, we will review the 
emerging evidence that N-cadherin may be a viable therapeutic target to inhibit cancer 
metastasis and overcome chemotherapeutic resistance. 
 
1.3 Structure and formation of the N-cadherin adhesive complex 
N-cadherin is a calcium-dependent adhesion molecule which directly mediates 
homotypic and heterotypic cellular interactions, thereby facilitating cell-cell recognition 
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and sorting. N-cadherin is a classical type I cadherin consisting of 5 extracellular 
domains linked to a functional intracellular domain. The engagement between N-
cadherin monomers on opposing cells occurs by reciprocal insertion of a Trp residue 
side-chain on its first extracellular domain (EC1) into the hydrophobic pocket of the 
partner N-cadherin EC1 (trans adhesion). In addition, the stabilization of N-cadherin-
mediated adhesion requires the interaction, or clustering, of adjacent monomers on the 
surface of the same cell, involving the His-Ala-Val (HAV) sequence on EC1 and a 
recognition sequence on the second extracellular domain (EC2) of the lateral N-
cadherin monomer (cis adhesion).14-16 The membrane expression and lateral clustering 
of N-cadherin is dependent upon p120 catenin, which localizes N-cadherin at 
cholesterol-rich microdomains.17,18 The initial ligation of N-cadherin extracellular 
domains triggers the activation of the Rho GTPase family member Rac, which 
stimulates localized actin filament assembly and the formation of membrane protrusions 
at points of cell-cell contact (reviewed in Yap & Kovacs, 2003 and Ratheesh et al., 
2013).19,20 The subsequent activation of the Rho GTPase family member RhoA, at the 
expense of Rac function, facilitates the maturation of N-cadherin-based cell-cell 
junctions by triggering the sequestration of β-catenin to the cadherin intracellular 
domain.21,22 β-catenin serves as a critical link to α-catenin which accumulates at nascent 
cell-cell junctions and suppresses actin branching. In addition, α-catenin facilitates the 
anchorage of the N-cadherin-catenin complex to the actin cytoskeleton via actin-binding 
proteins such as cortactin and α-actinin, thereby promoting the maturation of cell-cell 
contacts (reviewed in Niessen et al., 2011 and Pokutta & Weis, 2007)23,24 (Figure 1.1). 
The stability of the N-cadherin-catenin complex is highly dependent on the 
phosphorylation status of N-cadherin and the associated catenins, which is regulated by 
tyrosine kinases, such as Fer and Src, and the tyrosine phosphatase PTP1B (reviewed by 
McLachlan & Yap, 2007 and Lilien & Balsamo, 2005).25,26 
 
1.4 The functional role of N-cadherin in solid tumour metastasis 
In the normal physiological setting, N-cadherin plays a functional role in a variety of 
cell types including neuronal cells, myocytes, endothelial cells, stromal cells and 
osteoblasts.21,27-31 While N-cadherin is typically absent, or expressed at low levels, in 
normal epithelial cells, the aberrant expression of N-cadherin in cancer cells is a well-
documented feature of disease progression in many epithelial malignancies.32-35 In a 
Figure 1.1.  Schematic representation of the N-cadherin-catenin adhesive complex. 
The extracellular domains of N-cadherin monomers engage in trans and cis interactions 
with partner monomers, facilitated by p120-catenin (p120), resulting in a lattice-like 
arrangement. Interactions occur via a reciprocal insertion of tryptophan side-chains (in 
trans) and the HAV adhesion motif (in cis) (inset). Activation of RhoA sequesters β-
catenin (β-cat) and results in accumulation of α-catenin (α-cat) to the N-cadherin 
intracellular domain. This promotes anchorage of the N-cadherin-catenin complex to the 
actin cytoskeleton via actin-binding proteins, thereby stabilizing cell-cell contacts. 
Initial ligation of N-cadherin extracellular domains also triggers PI3K/Akt signalling 
which inactivates the pro-apoptotic protein Bad, resulting in activation of the anti-
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similar manner, studies have shown that the up-regulation of N-cadherin is also a 
feature of melanoma progression.36-38 Whilst the aberrant expression of N-cadherin in 
epithelial tissues is not considered to be oncogenic, or a promoter of solid tumour 
growth39-41, the up-regulated expression of N-cadherin expression in cancer is widely 
associated with cancer aggressiveness. Indeed, many studies have demonstrated a 
significant correlation between elevated N-cadherin levels in epithelial, and some non-
epithelial solid tumours, and clinicopathologic features such as increased localised 
tumour invasion and distant metastasis, and inferior patient prognosis. Multivariate 
analyses have also identified that elevated N-cadherin expression is independently 
associated with inferior patient prognosis in several epithelial malignancies including 
prostate, lung and bladder cancer7,8,42-76 (Table 1.1). The aggressive phenotype and 
inferior prognosis associated with up-regulated N-cadherin expression in solid tumours 
is also supported by a recent meta-analysis incorporating patients with various epithelial 
malignancies.77 
 Beyond the prognostic implications of aberrant N-cadherin expression, the 
relationship between N-cadherin and metastasis is not merely associative. Indeed, there 
is a wealth of evidence that increased N-cadherin expression endows tumour cells with 
a greater capacity to migrate. In addition to directly mediating cancer cell adhesion to a 
variety of cell types within tumour host microenvironments, including stromal cells, 
endothelial cells and osteoblasts29,78-81, early studies identified that increased N-cadherin 
expression enhances the migratory and invasive capacity of multiple tumour cell types 
in vitro.80,82-84 N-cadherin has also been shown to promote the capacity of melanoma 
cells to undergo in vitro trans-endothelial migration.85,86 The ability of N-cadherin to 
promote epithelial tumour metastasis in vivo was initially demonstrated using the MCF-
7 breast cancer cell line, following injection into the mammary fat pad of nude mice. In 
contrast to wild-type cells, MCF-7 cells ectopically expressing N-cadherin formed 
tumour metastases in several organs including the liver, pancreas and lymph nodes.78 
Similarly, N-cadherin expression in the mammary epithelium in the transgenic PyVmT 
murine breast cancer model resulted in a three-fold increase in the number of pulmonary 
metastatic foci without affecting the onset or growth of the primary tumour.40 Using an 
orthotopic mouse model of pancreatic cancer, the over-expression of N-cadherin in 
BxPC-3 cells increased the formation of disseminated tumour nodules throughout the 
abdominal cavity and induced the formation of N-cadherin-expressing lung micro-
metastases.84 Consistent with these findings, enforced expression of N-cadherin in 
 
Table 1.1.  Association of increased N-cadherin expression in cancer with clinicopathologic features and 
survival  
Cancer type 









Association with  
survival 
Reference 




574 IHC High grade & LN metastasis Shorter PFS (U) [42] 
 Early-stage invasive 1902 IHC 




Primary inoperable and LN 
negative 
275 IHC n.s. Shorter OS (U) [44] 
 Invasive; no prior therapy 94 IHC 




Clinically localized; radical 
prostatectomy 
104 IHC 
Poor differentiation, seminal 
vesicle invasion & pelvic LN 
metastasis  
Shorter time to 
biochemical failure (U), 
clinical recurrence (M) & 










Localized; no therapy prior to 
radical prostatectomy   
157 IHC 
Later stage, higher PSA & 
Gleason score, seminal vesicle 
invasion and LN metastasis  
n/a [47] 
 










49 IHC n/a Increased recurrence [49] 
Lung cancer 
No therapy prior to surgery 
(adenocarcinoma & squamous 
cell carcinoma) 
68 IHC 
Higher TNM stage & poor 
differentiation 
Shorter OS (M) [50] 
 
Primary adenocarcinoma; no 
therapy prior to surgery 
147 IHC n/a Shorter OS (M) [51] 
 
Surgical resection of 
adenocarcinoma; no prior 
therapy 
57 qPCR LN metastasis n/a [52] 
 No post-operative surgery 186 IHC Higher TNM stage & metastasis n/a [53] 
 
Blood collected prior to or up to 
3 weeks after platinum-based 
therapy (adenocarcinoma & 




n/a Shorter PFS [54] 
Urothelial  
cancers 
Radical cystecomy with pelvic LN 
dissection, clinically non-
metastatic bladder cancer 
433 IHC 
Higher clinical & pathologic 
tumour stage, LN metastasis & 
LN stage, lymphovascular 
invasion 
Shorter RFS (M), OS (U) 




Invasive bladder cancer 
undergoing radical cystectomy; 
no prior treatment 
30 qPCR n/a Shorter OS [56] 
 
Transurethral resection of non-
muscle-invasive bladder cancer 
115 IHC 
Higher incidence of intravesical 
recurrence 




Clinically-localized upper urinary 
tract carcinoma undergoing 
nephroureterectomy; cisplatin-
based therapy in late-stage 
patients 
59 IHC n/a 
Intravesical and 
extravesical RFS (M) 
[58] 
Liver cancer 
Resection of hepatocellular 
carcinoma 
100 IHC 
Higher histologic grade, 
multifocal tuimours & vascular 
invasion 




Surgical resection of  
hepatocellular carcinoma 
57 IHC n.s. 
Increased recurrence-




Surgical resection of intrahepatic 
cholangiocarcinoma (no prior 
therapy); adjuvant therapy in 
patients with recurrence  
96 IHC 
Higher recurrence of vascular 
invasion 
Shorter OS [61] 
Head & neck 
cancer 
Surgical specimen of HNSCC, 
patients are +/- LN metastasis 
119 IHC 
Greater tumour size, higher 
clinical stage & LN metastasis 
Shorter OS (M) [62] 
 
Table 1.1.  Association of increased N-cadherin expression in cancer with clinicopathologic features and 
survival (continued) 
All clinicopathologic and survival data shown is positively associated with increased N-cadherin expression. All data is statistically 
significant (P < 0.05), unless otherwise indicated. Abbreviations: PFS (progression-free survival), RFS (recurrence-free survival), 
OS (overall survival), U (univariate analysis), M (multivariate analysis), IHC (immunohistochemistry), qPCR (quantitative PCR), IF 
(immunofluorescence), ELISA (enzyme-linked immunosorbent assay), sN-cad (soluble N-cadherin), PSA (prostate specific 
antigen), LN (lymph node), TNM (tumour, node and metastases), CTCs (circulating tumour cells), CK (cytokeratin), n/a (not 
applicable), n.s. (not significant).    
 
Cancer type 












Epithelial cancers       
Head & neck 
cancer 
(continued) 
Blood collected following HNSCC 
resection (laryngeal, 




n/a Shorter OS [63] 
 
Radical surgery for laryngeal 
cancer; adjuvant therapy in 60% 
of cases 
50 IHC Higher grade Increased relapse [64] 
 Nasopharyngeal cancer 122 IHC 
LN involvement, distant 
metastasis & later clinical 
stage  





Colorectal cancer; no therapy 
prior to surgery 
37 qPCR 
Local invasion, Dukes staging 
& vascular invasion 
n/a [66] 
 
Colorectal cancer; no therapy 
prior to surgery 
102 IHC 
Larger tumour size, poor 
differentiation, tumour 
invasion, LN metastasis & 
distant metastasis 




Colon carcinoma; no therapy 
prior to surgery  
90 IHC 
Greater depth of tumour 
invasion & higher TNM stage 
n/a [68] 
 
Gastric cancer surgery with LN 
metastasis; no prior therapy 
89 IHC (on LN) 
LN involvement, higher 
pathological stage, lymphatic 
invasion & venous invasion 
Shorter OS [69] 
 
Curative surgery for gastric 
adenocarcinoma; no prior 
therapy, stage II patients 
received adjuvant therapy 
146 IHC Hematogenous recurrence Shorter survival [70] 
Renal cancer 
Blood collected from metastatic 
renal cell carcinoma patients 




(on CTCs; also 
CK-) 
n/a Shorter PFS [71] 
Ovarian cancer 
Surgical specimens of high-grade 
serous carcinoma 
167 IHC n/a Shorter PFS and OS (U) [72] 
Gallbladder 
cancer 
Adenocarcinoma (+/- surgery) 80 IHC 
Poor differentiation, larger 
tumour size, TNM stage, 
invasion & LN metastasis 
Shorter OS (M) [73] 
Squamous cell/adenosquamous 
carcinoma (+/- surgery) 
46 IHC 
Larger tumour size, invasion 
and LN metastasis 
Shorter OS (M) [73] 
Non-epithelial 
solid cancers  
      
Melanoma 
Removal of primary melanoma, 
various stages of disease 
394 IHC Increased Breslow thickness 
Distant metastasis-free 
survival (M; p = 0.13) 
[7] 
Sarcoma 
Surgical resection of 
osteosarcoma 
107 qPCR 
Later stage and distant 
metastasis 
Shorter survival [74] 
 
Blood collected from a variety of 





Larger tumour size & higher 
grade 
Shorter disease-free 




      
Multiple 
myeloma 
Blood collected from newly-
diagnosed patients; no prior 
therapy 
84 
Serum ELISA  
(sN-cad) 
n/a Shorter PFS and OS [76] 
 
Bone marrow aspirate from 






n/a Shorter PFS [76] 
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androgen-responsive prostate cancer cells promoted invasion of underlying muscle and 
lymph node metastasis following subcutaneous injection in castrated mice.87 Moreover, 
the ability of melanoma cells to extravasate (a key step in the metastatic cascade) and 
form lung metastases following intravenous injection in NOD/SCID mice was 
attenuated following N-cadherin knock-down in tumour cells.88 
 To appreciate how N-cadherin, a bona fide cell adhesion molecule, may actively 
promote cancer cell migration, it is important to consider that the N-cadherin-catenin 
complex is situated at the cross-roads of cell adhesion and activation of pro-metastatic 
signalling cascades, in both a physical and functional context. Notably, the adhesive 
function and migration-related signalling capacity of N-cadherin can occur 
simultaneously, or as antagonistic events, adding further complexity to its role in cancer 
metastasis. In the following section, we describe three key mechanisms by which N-
cadherin has been shown to actively promote the migratory capacity of tumour cells: 
facilitation of collective cell migration, augmentation of fibroblast growth factor-
receptor (FGFR) signalling and modulation of canonical Wnt signalling. 
 
1.4.1 N-cadherin promotes collective cell migration 
While the mesenchymal phenotype of carcinoma cells, that have undergone EMT, 
promotes the migration of individual cancer cells, the localised invasion and metastasis 
of epithelial tumour cells is also facilitated by their ability to migrate as sheets, clusters 
or strands, a process known as collective cell migration (reviewed in Clark & Vignjevic, 
2015 and Friedl & Alexander, 2011).2,89 Collectively migrating groups of cells maintain 
adhesive interconnectivity, collective cell polarity and co-ordinated cytoskeletal 
activity, resulting in a 'leader-follower'-type cell arrangement which promotes more 
directional and efficient migration than that of an individual migrating cell (reviewed in 
Mayor & Etienne-Manneville, 2016 and Etienne-Manneville, 2014).90,91 Several studies 
have demonstrated the importance of N-cadherin in collective cell migration in cancer. 
For instance, N-cadherin has been shown to promote the ability of lung or ovarian 
cancer cells to form aggregates and collectively invade three-dimensional (3D) collagen 
matrices or penetrate peritoneal mesothelium-like cell layers in vitro.92,93 Similarly, 
studies in transformed canine kidney epithelial cells (MDCK cells) have shown that N-
cadherin promotes aggregate formation which allows directional collective cell 
migration in a 3D collagen matrix. In these cells, deletion of the entire N-cadherin 
intracellular domain, or the β-catenin binding domain alone, resulted in greater 
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individual cell detachment and migration from cell clusters, highlighting the importance 
of the N-cadherin-actin cytoskeleton interaction in collective cell migration. Moreover, 
over-expression of an N-cadherin mutant in which the extracellular domain was fused to 
the anti-binding domain of α-catenin hindered the movement of follower cells, 
demonstrating that dynamic N-cadherin-actin linkage is required for efficient collective 
cell migration.94 
 In addition to maintaining multi-cellular aggregates of tumour cells, studies in 
N-cadherin-expressing non-tumour cells demonstrate that N-cadherin also promotes 
collective cell migration by polarizing Rho-family GTPase signalling (e.g. Rac1 and 
cdc42), known to play an important role in the co-ordination of cytoskeletal remodelling 
in collectively migrating cells (reviewed in Ridley, 2015 and Combedazou et al., 
2017).95,96 For example, models of arterial smooth muscle wound-healing and neural 
crest migration have shown that the asymmetric distribution of N-cadherin-mediated 
cell-cell adhesion at the lateral and posterior aspects of leader cells promotes directional 
cell alignment and increased cdc42 and Rac1 activity and protrusion formation at the 
free leading cell edge, resulting in enhanced migration.97,98 Mechanistically, studies in 
mouse embryonic fibroblasts have demonstrated that N-cadherin-adhesive complexes at 
the rear of cells suppress localized integrin-α5 activity, thereby polarizing integrin and 
Rac activity towards the free leading edge of the cell.99 Indeed, functional inhibition of 
N-cadherin in transformed mammary cells has been shown to reduce integrin-α5-
dependent cell migration on fibronectin in vitro.100 In a similar manner, silencing of N-
cadherin expression in melanoma cells perturbs α2β1-integrin-dependent collagen 
matrix invasion in vitro.101 Reciprocally, integrin signalling at focal adhesions has been 
shown to regulate the ability of HeLa cells to engage in N-cadherin-based connections 
and to promote collective cell migration.102 Given that integrins play an important role 
in the activation of Rho signalling (reviewed in Moreno-Layseca & Streuli, 2014 and 
Grande-Garcia et al., 2005)103,104, it is plausible that N-cadherin may polarize Rho-
family GTPase signalling via intercommunication with integrins, thereby promoting the 
collective migration of cancer cells (Figure 1.2A). 
 
1.4.2 N-cadherin augments fibroblast growth factor receptor signalling 
Functional interaction between the extracellular domains of N-cadherin and receptor-
tyrosine kinase FGFRs was first recognised as a mechanism by which N-cadherin 
promoted axonal outgrowth of rat cerebellar neuronal cells. These studies identified that 
Figure 1.2.  Schematic representation of cell signalling events modulated by 
increased N-cadherin expression in the context of cell migration. In addition to 
mediating cellular aggregation, N-cadherin may facilitate the collective migration of 
tumour cells by excluding focal adhesions and Rac1 activity, and promoting RhoA 
activity, at sites of N-cadherin-mediated cell-cell contact. The asymmetric distribution 
of N-cadherin adhesive complexes polarizes integrin function and Rac1 activity towards 
the free edges of cells, thereby directing focal adhesion and lamellipodia formation 
away from the cell cluster and promoting cell migration. Similar to Rac1, N-cadherin-
mediated cell-cell adhesion promotes cdc42 activity at the free edges of cells, resulting 
in filipodia formation (A). Functional interaction between the extracellular domains of 
N-cadherin and FGFR-1 potentiates FGF-2-activated FGFR-1 signalling by attenuating 
ligand-induced receptor internalisation. The resulting augmentation of down-stream 
MAPK-ERK and PI3K-Akt signalling pathways promotes the metastatic behaviour of 
cancer cells by increasing the production of invasion-facilitating molecules such as 
MMPs (B). N-cadherin-mediated adhesive complexes and Wnt/β-catenin signalling are 
thought to compete for the same cellular pool of β-catenin. While N-cadherin sequesters 
β-catenin from the nucleus, the N-cadherin adhesive complex provides a reservoir of β-
catenin which, upon Wnt activation, becomes available for nuclear translocation and 
TCF/LEF-mediated gene transcription (eg. CD44 and MMP genes), resulting in the loss 
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the fourth extracellular domain of N-cadherin (EC4) trans-activated FGFRs to promote 
neurite outgrowth independent of FGF ligands, suggesting that N-cadherin can act as a 
surrogate ligand of FGFRs.28,105 Notably, the physical interaction of N-cadherin and 
FGFRs has also been shown in breast and pancreatic cancer cells.106-109 Evidence that 
FGFR played a functional role in N-cadherin-mediated cancer metastasis was initially 
demonstrated in breast cancer cells, whereby FGFR inhibition reduced the migratory 
capacity of N-cadherin-expressing human breast cancer cells, but not N-cadherin-
negative cells.83 In addition, FGF-2 increased the invasiveness of N-cadherin-expressing 
MCF-7 human breast cancer cells, but not control MCF-7 cells.78 To this end, it has 
been shown that N-cadherin potentiates FGF-2-activated FGFR-1 signalling by 
attenuating ligand-induced FGFR-1 internalisation, thereby stabilising FGFR-1 
expression.106,108 In turn, the sustained activation of the down-stream MAPK-ERK 
signalling pathway results in increased production of the extracellular matrix (ECM)-
degrading enzyme matrix metalloproteinase-9 (MMP-9) and enhanced breast cancer cell 
invasiveness.78,106 In line with these findings, the over-expression of N-cadherin in 
mammary epithelium in transgenic mouse models of breast cancer resulted in an 
increased propensity for lung metastasis, compared with control mice.40,110 Examination 
of tumour cell isolates from these mice showed that N-cadherin potentiates breast 
cancer cell migration and invasion in an FGFR-dependent manner.40 These studies 
suggested that the ability of N-cadherin-FGFR interactions to promote breast cancer 
metastasis may also involve activation of phosphatidylinositide-3 kinase (PI3K)/Akt 
signalling via Akt2110 (Figure 1.2B). 
Two lines of evidence suggest that N-cadherin-FGFR-1 interactions promote the 
invasive behaviour in both collectively migrating and individual cancer cells. Firstly, N-
cadherin-FGFR-1 interactions have been shown to occur over most of the cell 
membrane, but are excluded from sites of cell-cell adhesion, suggesting that the 
interaction is independent of N-cadherin-mediated cellular adhesion.107 Secondly, 
blocking antibodies directed at the FGFR-1-interacting domain of N-cadherin (EC4) 
have been shown to inhibit N-cadherin-mediated migration, but not N-cadherin-
mediated aggregation, of human breast cancer cells.111 Thus, it would appear that N-
cadherin-mediated cell-cell adhesion and N-cadherin-mediated cell migration via 
FGFR-1 are independent and mutually exclusive events. Further studies are warranted 
to identify whether N-cadherin potentiates FGFR-1 signalling in cancers other than 
breast and pancreatic cancer. 
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1.4.3 N-cadherin modulates canonical Wnt signalling 
In addition to stabilising cadherin-mediated cell-cell adhesion, β-catenin plays a central 
role in the canonical Wnt signalling pathway. Canonical Wnt signalling promotes the 
cytoplasmic accumulation and nuclear translocation of β-catenin which activates T cell 
factor/lymphoid enhancer factor (TCF/LEF)-mediated transcription of gene targets 
(reviewed in Murillo-Garzón & Kypta, 2017, Valenta et al., 2012 and Klaus & 
Birchmeier, 2008)112-114 including genes which promote tumour cell invasion and 
metastasis (e.g. MMPs and CD44).115-121 It has been proposed that cadherins and the 
canonical Wnt signalling pathway may compete for the same cellular pool of β-catenin, 
with cadherins sequestering β-catenin from the nucleus, thereby attenuating Wnt 
signalling.122,123 Indeed, enforced expression of N-cadherin in colon carcinoma cells 
resulted in the relocation of nuclear β-catenin to the plasma membrane and attenuated 
LEF-responsive trans-activation.124 Alternatively, studies suggest that the N-cadherin-β-
catenin complex may provide a stable pool of β-catenin which is available for 
TCF/LEF-mediated gene transcription in cancer cells.86,125 To this end, disruption of N-
cadherin-mediated adhesion in leukaemic cells was found to increase TCF/LEF reporter 
activity.126 Thus, given β-catenin is essential in the stabilization of N-cadherin-mediated 
cellular adhesion (discussed earlier), it is feasible that the ability of N-cadherin to 
modulate TCF/LEF-mediated gene transcription may play an important role in 
individual cell migration, at the expense of collective cell migration (Figure 1.2C). 
The ability of N-cadherin to modulate canonical Wnt signalling has been shown 
to play a role in the trans-endothelial migration of cancer cells, a key process in the 
metastatic cascade (reviewed in van Zijl et al., 2011).127 Studies in melanoma cells have 
shown that while β-catenin co-localizes with N-cadherin during the initial stages of 
endothelial cell adhesion, the activation of the tyrosine kinase Src phosphorylates the N-
cadherin cytoplasmic domain, leading to the dissociation of the N-cadherin-β-catenin 
complex.128 β-catenin is then translocated to the nucleus during trans-endothelial 
migration and activates TCF/LEF-mediated gene transcription, resulting in up-
regulation of the diapedesis-promoting adhesion molecule CD44.86,129-131 In line with 
these in vitro findings, N-cadherin knock-down in human melanoma cells has been 
shown to reduce lung nodule formation following intravenous injection in immuno-
compromised mice.88 While N-cadherin-expressing tumour cells have been detected in 
the circulation of patients with various epithelial cancers54,63,71, a role for N-cadherin in 
the trans-endothelial migration of epithelial cancer cells has not yet been demonstrated. 
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1.5 The emerging role of N-cadherin in haematological malignancies 
We have thus far summarised the functional role and clinical implications of aberrant 
N-cadherin expression in the context of solid tumour metastasis. There is now emerging 
evidence suggesting that N-cadherin plays a role in haematological malignancies, 
including leukaemia and multiple myeloma (MM). These cancers account for 
approximately 10% of all cancer cases and are typically characterized by the abnormal 
proliferation of malignant white blood cells within the bone marrow (BM) and the 
presence of tumour cells within the circulation. Specialised compartments, or ‘niches’, 
within the BM microenvironment play critical roles in housing and maintaining pools of 
quiescent haematopoietic stem cells (HSCs), and in regulating HSC self-renewal and 
differentiation.132,133 Notably, N-cadherin is expressed by various cell types associated 
with the HSC niche, including osteoblasts and stromal cells in the endosteal niche, and 
endothelial cells and pericytes in the perivascular niche.30,134-136 In the following 
section, we discuss the potential implications of aberrant N-cadherin expression in 
haematological cancer cells; namely, BM homing and the BM microenvironmental 
protection to chemotherapeutic agents.  
 
1.5.1 Leukaemia 
Leukaemias are thought to arise by the malignant transformation of HSCs into 
leukaemic stem cells (LSCs) which occupy and modify BM HSC niches.137-140 
Adhesive interactions between LSCs and the BM microenvironment activate signalling 
cascades which contribute to LSC self-renewal and survival, and the capacity to evade 
the cytotoxic effects of chemotherapeutic agents.141, 142 Indeed, therapeutic targeting of 
adhesion molecules to disrupt interactions with the niche represents a potential strategy 
to eliminate LSCs.143  
Studies have demonstrated that N-cadherin is expressed in a subpopulation of 
primitive HSCs30, although its precise role within the HSC niche in normal 
haematopoiesis is controversial. To this end, the over-expression of N-cadherin in HSCs 
has been shown to increase HSC lodgement to BM endosteal surfaces in irradiated 
mice, enhance HSC self-renewal following serial BM transplantation and promote HSC 
quiescence in vitro.144 However, other studies have reported that deletion of N-cadherin 
in HSCs or osteoblastic cells has no effect on haematopoiesis or HSC quiescence, self-
renewal or long-term repopulating activity.31,134, 145 
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 While these studies suggest that N-cadherin is not essential for the maintenance 
of the HSC niche, emerging evidence implicates N-cadherin in the function of the LSC 
niche. Studies have reported that N-cadherin is expressed on primitive sub-populations 
of leukaemic cells including patient-derived CD34+ CD38- chronic myeloid leukaemia 
(CML) cells and CD34+ CD38- CD123+ acute myeloid leukaemia (AML) cells, 
suggesting that N-cadherin is a marker of LSCs.125,146,147 Similar to solid tumours, N-
cadherin is thought to facilitate engagement of leukaemic cancer cells with cells of the 
surrounding microenvironment. For example, treatment of primary human CD34+ CML 
cells with the N-cadherin blocking antibody GC-4 significantly reduced their adhesion 
to human BM stromal cells.125 Similarly, GC-4 treatment of a BCR-ABL-positive 
mouse acute lymphoblastic leukaemia (ALL) cell line was found to inhibit their ability 
to adhere to mouse fibroblasts.148 Pre-clinical mouse models also suggest that N-
cadherin may promote BM homing, engraftment and self-renewal of AML cells in 
vivo.149,150 Thus, N-cadherin represents a potential target to inhibit LSC interactions 
with the BM microenvironment. 
 
1.5.1.1 N-cadherin-mediated cell adhesive interactions promote microenvironmental 
protection of leukaemic cells to chemotherapeutic agents  
Adhesive interactions between leukaemic cells and cells of the BM microenvironment 
confers sub-populations of leukaemic cells with resistance to chemotherapy, leading to 
disease relapse.151,152 As such, there is growing interest in targeting molecules involved 
in leukaemic cell-BMSC interactions to enhance leukaemic sensitivity to 
chemotherapy.125,153 The role of N-cadherin in the microenvironmental protection of 
leukaemic cells to chemotherapeutic agents was first demonstrated in studies showing 
that N-cadherin expression was associated with resistance to treatment with a 
farnesyltransferase inhibitor in the murine lymphoblastic leukaemia cell line, B-1, when 
grown in co-culture with fibroblasts. Enforced N-cadherin expression in B-1 cells also 
conferred farnesyltransferase inhibitor-resistance when grown in the presence of 
fibroblasts.148 Notably, these findings are in line with reports showing that N-cadherin is 
up-regulated in solid tumour cancer cells resistant to chemotherapeutic agents154-157 and 
androgen deprivation therapy.46,158 Direct demonstration that N-cadherin-mediated cell-
cell adhesion facilitated microenvironmental protection of leukaemic cells to 
chemotherapy was provided in co-culture experiments with primary human CD34+ 
CML cells and BMSCs. Disruption of CML cell-BMSC adhesion, using an N-cadherin 
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antagonist peptide (containing the HAV sequence) or the N-cadherin function-blocking 
antibody GC-4 increased CML cell sensitivity to the tyrosine kinase inhibitor 
imatinib.125,126 An association between response to chemotherapy and LSC expression 
of N-cadherin has also been reported in AML patients. To this end, patients exhibiting a 
higher proportion of N-cadherin-expressing BM-derived CD34+ CD38- CD123+ LSCs at 
diagnosis were less responsive to induction chemotherapy.146 While the precise 
mechanism by which N-cadherin-mediated adhesion confers drug-resistance in 
leukaemic cells is unclear, studies in solid tumour cells suggest that N-cadherin-
mediated adhesion increases activity of the anti-apoptotic protein Bcl-2, by PI3K-Akt-
mediated inactivation of the pro-apoptotic protein Bad.80,155,159 
 
1.5.2 Multiple myeloma 
Multiple myeloma (MM), preceded by a benign precursor condition called monoclonal 
gammopathy of undetermined significance (MGUS), is a haematological malignancy 
characterised by the uncontrolled proliferation of transformed immunoglobulin-
producing plasma cells (PCs) within the BM. Clinical manifestations of MM include 
osteolytic bone lesions, hypercalcaemia, renal insufficiency and anaemia. While the 
introduction of so-called 'novel' anti-MM agents (e.g. the immunomodulatory drugs 
thalidomide and lenalidomide, and the proteasome inhibitor bortezomib) have 
significantly improved the overall survival prospects of MM patients over the past 10-
15 years, the long-term management of MM patients following disease relapse and 
progression remains a major challenge.160-164 Nevertheless, the identification of MM 
patients who are likely to experience rapid disease relapse is paramount to the success 
of therapeutically managing these patients in order to maximise their survival 
prospects.162 Notably, studies in our laboratory have demonstrated that stratification of 
newly-diagnosed MM patients based on plasma N-cadherin levels identifies a subset of 
individuals (> 6ng/ml plasma N-cadherin) with increased risk of earlier death, 
irrespective of disease stage, tumour burden or poor cytogenetic features.76 Moreover, 
data from our group, and others, suggest that N-cadherin gene and protein expression is 
elevated in CD138+ BM-derived PCs in approximately 50% of newly-diagnosed MM 
patients compared with BM PCs from healthy individuals, and is associated with poor 
prognosis76,81 (Table 1.1). Notably, the expression of the N-cadherin gene, CDH2, is up-
regulated in MM patients harbouring the high-risk t(4;14)(p16;q32) translocation. This 
translocation encompasses 15-20% of all MM patients and is characterised by the 
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dysregulated expression of the histone methyltransferase MMSET.81,165-167 Through yet 
to be defined mechanisms, CDH2 expression is also up-regulated in more than 50% of 
MM patients in the hyperdiploidy-related sub-group.81 
 
1.5.2.1 N-cadherin mediates cell-cell adhesion between MM PCs and the BM 
microenvironment 
Adhesive interactions between MM PCs and the BM microenvironment are critical in 
the permissiveness of the BM to the development of MM disease. These include cell-
cell interactions which support MM PC growth and resistance to chemotherapeutic 
agents, and promote the inhibition of osteoblast differentiation, thereby contributing to 
MM PC-mediated bone loss (reviewed in Noll et al., 2012 and Katz, 2010).168,169 In 
addition to endothelial cell adhesion, in vitro studies have demonstrated that N-cadherin 
mediates the adhesion of human MM PCs to osteoblasts and stromal cells, which 
constitute the endosteal MM niche.81,170 In a functional context, N-cadherin-mediated 
adhesion between MM PCs and pre-osteoblastic cells has been shown to inhibit 
osteoblast differentiation, suggesting that N-cadherin may contribute to MM-related 
bone loss in the clinical setting.81 Mechanistically, studies have demonstrated that N-
cadherin inhibits osteoblast function and impedes bone formation in vivo by negative 
regulation of canonical Wnt signalling in bone cells.171-174 Studies have also shown that 
treatment of human MM PC lines in co-culture with stromal cells or osteoblasts with the 
N-cadherin blocking antibody GC-4 induced a significant expansion of MM PCs in 
vitro.170 Thus, it has been proposed N-cadherin may maintain the proliferative 
quiescence of MM PC in contact with cells of the endosteal MM niche.170 In light of the 
role of N-cadherin in mediating leukaemic cell resistance to chemotherapeutic agents, 
these findings may provide a rationale to investigate whether N-cadherin-mediated 
adhesion potentiates chemotherapeutic resistance in MM. 
 
1.6 The regulation of N-cadherin expression in cancer 
A range of extracellular stimuli implicated in cancer pathogenesis have been shown to 
increase N-cadherin gene and protein expression in cancer cells including transforming 
growth factor β1 (TGF-β1)175-178, ligands for receptor tyrosine kinases (epidermal 
growth factor [EGF]179-181, insulin-like growth factor 1 [IGF-1]182-184 and hepatocyte 
growth factor [HGF]185,186), C-X-C and C-C chemokines (CXCL12187,188, CCL21189,190 
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and CCL18191), cytokines (receptor activator of nuclear factor κB [NF-κB] ligand 
[RANKL]192,193 and interleukin 6 [IL-6]88,194,195), Wnt3a157, ECM proteins196,197 and 
hypoxia.198-201 These stimuli up-regulate N-cadherin expression by activating a number 
of intracellular signalling cascades including, but not limited to, canonical and non-
canonical TGF-β1175,177,202,203, Wnt/β-catenin157,188,201,204, PI3K/Akt205-207, NF-κB193,199, 
Janus kinase 2/signal transducer and activator of transcription 3 
(JAK2/STAT3)88,180,184,195,205 and c-Jun N-terminal kinase (JNK)84,177,197,208,209 
signalling pathways. The expression of N-cadherin has also been shown to be up-
regulated by oncogenic transcription factors, histone-modifying enzymes and 
glycoproteins including SET (activator of JNK signalling)209-211, BTF3 
(JAK/STAT3)212-214, SATB2 (Wnt/β-catenin)215,216, FOXP3 (Wnt/β-catenin)217-219 and 
MUC-4 (JNK signalling).108,220 In turn, these signalling pathways orchestrate the 
activation of classical EMT-associated transcription factors Twist188,178,179,184,193,196,199 
and Slug68,176,195,208,209, which are well-established positive regulators of N-cadherin 
expression in cancer cells. In some cancers, the up-regulation of N-cadherin may also be 
potentiated by the EMT-associated transcription factor Snail, following the activation of 
PI3K/Akt and MAPK signalling.37,185,221 In addition, the dysregulated expression of the 
histone methyltransferase MMSET appears to play a major role in the up-regulation of 
N-cadherin expression in prostate cancer and MM81,166,167 (Figure 1.3). Notably, in vitro 
and in vivo studies have also demonstrated that N-cadherin expression is increased in 
prostate cancer cells following androgen deprivation, and suppressed following 
androgen re-introduction, suggesting N-cadherin may be negatively regulated by 
androgens.46,87,158 Here, we discuss some of the key transcriptional regulators of N-
cadherin gene expression, and the negative regulation of N-cadherin expression by 
microRNAs, in cancer cells. 
 
1.6.1 Twist1 
The basic helix-loop-helix transcription factor Twist1 is well-established as a central 
regulator of EMT and its expression is extensively associated with cancer metastasis.222-
227 In addition to Twist1 positively correlating with N-cadherin expression in clinical 
samples of various cancers50,228,229, over-expression and knock-down studies have 
demonstrated that Twist1 positively regulates N-cadherin expression in vitro in 
melanoma cells and in a number of epithelial cancers.37,50,196,226,230,231 Mechanistically, 
Twist1 has been shown to directly regulate transcription of the N-cadherin gene, CDH2, 
Figure 1.3.  A schematic overview of N-cadherin regulatory mechanisms in cancer. 
A multitude of extracellular stimuli implicated in cancer pathogenesis (shown in purple) 
activate numerous intracellular signalling pathways (green). In turn, these pathways 
converge to up-regulate classical EMT-related transcription factors (orange) which 
increase N-cadherin expression. Whether transcription factors intrinsically associated 
with these signalling pathways (eg. c-Jun, TCF/LEF, p50/p65 and STAT3) up-regulate 
N-cadherin independent of Twist1, Slug and Snail, is not known. It is also unknown 
whether Slug- and Snail-induced N-cadherin expression is independent of Twist1. 
Several microRNAs (maroon) also directly regulate N-cadherin expression in cancer. 
For simplicity, not all extracellular stimuli, transcription regulators, microRNAs (e.g. 
targeting Twist1, Slug or Smads), intracellular signalling pathways (including the 
involvement of the PI3K/Akt module in mediating these pathways) and cross-regulation 
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through binding to an E-box within the first intron of CDH2. Twist1-mediated 
regulation of N-cadherin expression may be dependent on adhesion to ECM proteins, as 
both the nuclear accumulation of Twist1 and subsequent expression of N-cadherin was 
strongly up-regulated in PC-3 prostate cancer cells following adhesion to fibronectin.196 
Thus, tumour cell attachment to ECM proteins may play an important role in Twist1-
driven induction of N-cadherin in cancer cells. In prostate cancer cells, Twist1 also 
indirectly potentiates TGF-β1-mediated N-cadherin up-regulation by activation of the 
metastasis-associated protein clusterin.178,232 
 
1.6.2 Slug 
Slug is a member of the Snail family of transcription factors and putatively behaves as a 
transcriptional repressor.233 However, while it is well established that Slug induces 
EMT by directly repressing E-cadherin gene transcription234,235, over-expression and 
knock-down studies in a variety of epithelial and non-epithelial cancer cells have 
demonstrated that Slug positively regulates N-cadherin expression in vitro.62,236-239 Up-
regulation of Slug is also associated with increased N-cadherin expression in clinical 
samples of bladder and head and neck cancer.62,237 While it is unknown whether Slug 
directly activates CDH2 gene transcription, Slug has been shown to positively regulate 
Twist1 expression236, suggesting that Twist1 may mediate Slug-induced up-regulation 
of N-cadherin expression. Moreover, Twist1 positively regulates Slug expression240, 
implying a Twist1-Slug positive feedback loop may further potentiate the up-regulation 
of N-cadherin in cancer cells. 
 
1.6.3 Smads 
Smads, the intracellular effecter proteins of canonical TGF-β signalling which control 
gene transcription241, are important mediators of TGF-β-driven up-regulation of N-
cadherin expression in cancer. Notably, Smad complexes have been shown to bind to 
the CDH2 promoter and activate CDH2 transcription in lung cancer and immortalised 
pancreatic epithelial cells in vitro.175,242 Knock-down of Smad3 or Smad4, or inhibition 
of Smad2 and Smad3 phosphorylation, has also been shown to prevent the induction of 
CDH2 transcription in response to TGF-β in lung, ovarian and prostate cancer cell lines. 
175,243 Studies suggest that Smads may also indirectly promote N-cadherin expression in 
cancer cells by up-regulating the expression of Twist1, Slug or Snail.242-244  
 




MicroRNAs (miRs) are small (~22 nucleotide long) single-stranded non-coding RNAs 
which mediate post-transcriptional gene silencing and are widely implicated in cancer-
associated EMT (reviewed in Fabbri et al., 2007 and Ceppi & Peter, 2014).245,246 To 
date, studies have identified several miRs that are down-regulated in epithelial cancer 
tissues, when compared with corresponding normal epithelium, and which suppress N-
cadherin expression and metastasis. These include miR-218, miR-194, miR-199a, miR-
199b, miR-145 and miR-124 which directly target CDH2 transcripts and down-regulate 
N-cadherin expression in various solid tumours.52,59,74,247-254 The expression of a number 
of these miRs is also inversely associated with N-cadherin levels in human cancer tissue 
samples52,74,247,253,254 (Figure 1.3). 
 Studies in cancer cell lines have also identified a number of miRs which 
indirectly down-regulate N-cadherin expression by targeting Twist1 (miR-106b, miR-
720)230,255, Slug (miR-140)256 and Smad gene transcripts (miR-125b, miR-34a and miR-
136).257-259 These miRs are down-regulated in cancer tissues, compared with normal 
tissues, and suppress cancer cell invasiveness.230,255-261 Additionally, studies using 
clinical colorectal cancer specimens identified two miRs, miR-135b and miR-210, 
which indirectly up-regulate N-cadherin expression by targeting the FOXN3 gene, a 
transcriptional repressor of CDH2. Expression of these miRs, in conjunction with down-
regulation of miR-218, was associated with elevated N-cadherin levels and metastasis in 
colorectal cancer.247 Recent studies have also shown that miR-181a positively regulates 
N-cadherin in prostate cancer cells, potentially by targeting PTEN, a PI3K/Akt pathway 
inhibitor and tumour suppressor.262,263 
 
1.7 N-cadherin as a therapeutic target in cancer 
As N-cadherin is widely implicated in cancer metastasis, the utility of N-cadherin 
antagonists as therapeutic drugs is being investigated in the oncology setting. Notably, 
N-cadherin-targeting agents have been shown to inhibit cell adhesion and to modulate 
cell signalling. Interestingly, studies have also shown that N-cadherin-targeting agents 
affect both tumour cells and tumour-associated vasculature. Here, we describe the 
current repertoire of N-cadherin antagonists that have displayed efficacy as anti-cancer 
agents in vivo. 
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1.7.1 Monoclonal antibodies 
Several monoclonal antibodies directed against N-cadherin have been investigated for 
their ability to block N-cadherin-dependent tumour migration and invasion in vitro and 
metastasis in vivo. The mouse monoclonal antibody, designated GC-4, binds to the EC1 
domain of N-cadherin monomers and subsequently blocks N-cadherin-mediated 
adhesion.30,81,264,265 GC-4 has been shown to suppress N-cadherin-mediated Akt 
signalling56,159, and inhibit the migration and invasion of melanoma, bladder, ovarian 
and breast cancer cells in vitro.56,78,86,92 In vivo, pre-treatment of AML cells with GC-4 
has been shown to inhibit BM homing of circulating tumour cells.149 Thus, treatment 
with GC-4 may by therapeutically relevant in the context of limiting the metastatic 
dissemination of tumour cells in melanoma and haematological malignancies, where N-
cadherin plays a role in trans-endothelial migration and BM homing of circulating 
tumour cells.81,86,149 Additionally, GC-4-mediated blocking of N-cadherin engagement 
between human CD34+ CML cells and stromal cells increased tumour cell sensitivity to 
imatinib, demonstrating a potential therapeutic strategy to overcome tyrosine kinase 
inhibitor resistance.126 Two additional monoclonal antibodies, 1H7 (targeting N-
cadherin EC1-3) and 2A9 (targeting N-cadherin EC4), have shown efficacy in a 
subcutaneous xenograft prostate cancer mouse model, whereby both antibodies reduced 
the growth of established tumours and inhibited localised muscle invasion and distant 
lymph node metastasis.87 
 
1.7.2 ADH-1 
The lateral clustering of N-cadherin monomers is essential in the stabilization and 
maturation of nascent N-cadherin-mediated adhesive junctions between neighbouring 
cells.14,16 Peptides containing the classical cadherin HAV motif are likely to complete 
with the cis adhesive interface of N-cadherin on EC1, thereby inhibiting the lateral 
clustering of N-cadherin monomers.266 On the basis that a HAV motif located on 
FGFR-1 is required for FGF-2 binding107, it is feasible that ADH-1 may also inhibit 
FGFR signalling. The cyclization of first-generation linear peptides harbouring the 
HAV sequence led to the development of a more stable cyclic pentapetide called ADH-
1 (N-Ac-CHAVC-NH2) which similarly inhibited N-cadherin-dependent function.267 In 
vitro, ADH-1 has been shown to induce apoptosis in a range of tumour cell types, and 
inhibits tumour cell migration at sub-cytotoxic concentrations, with cell sensitivity 
proportional to relative N-cadherin expression.268-270 The efficacy of ADH-1 to inhibit 
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primary tumour growth has been demonstrated in a number of pre-clinical mouse 
models including pancreatic, breast, colon, ovarian and lung cancer.268,271 Notably, 
ADH-1 has also been identified as a vascular disrupting agent, suggesting the 
compound may have effects on both tumour cells and tumour-associated 
vasculature.271,272 In phase I clinical trials, ADH-1 was shown to have an acceptable 
toxicity profile with no maximum tolerated dose achieved. ADH-1 treatment was 
associated with disease control in approximately 25% of patients with advanced 
chemotherapy-refractory solid tumours, independent of tumour N-cadherin expression 
status.273,274 
The therapeutic efficacy of ADH-1 as an anti-cancer agent has been most 
extensively evaluated in the melanoma setting. Pre-clinical studies suggest that ADH-1 
synergistically enhances melanoma tumour response to melphalan.275,276 These studies 
showed that ADH-1 enhances the permeability of tumour vasculature and increases 
melphalan delivery to the tumour microenvironment, as evidenced by increased 
formation of melphalan-DNA adducts in tumours. However, the combinatorial effects 
of ADH-1 and melphalan were not replicated in phase I/II clinical trials.277,278 In 
contrast to other tumour settings, studies have also suggested that ADH-1 may stimulate 
tumour growth in some mouse models of melanoma.275,276 These effects were associated 
with activation of pro-growth and survival intracellular signalling pathways including 
Akt signalling and the down-stream mTOR signalling pathway in vitro and in vivo.276 
These data suggest that ADH-1 may act as an N-cadherin agonist in certain tumour 
contexts. However, to date, ADH-1-mediated activation of tumour cell proliferation and 
signalling has not been reported in the clinical setting. 
 
 
1.8 Concluding remarks and future perspectives 
The up-regulation or 'de novo' expression of N-cadherin has significant negative 
implications in metastasis-related cancer relapse and progression, as well as overall 
survival of cancer patients. In addition to its prognostic significance in cancer, N-
cadherin actively promotes the metastatic capacity of tumour cells. Here, we have 
described three distinct mechanisms by which N-cadherin endows tumour cells with 
increased migratory capacity: facilitation of collective cell migration, augmentation of 
FGFR-1 signalling and modulation of canonical Wnt signalling. Unfortunately, our 
understanding of how N-cadherin influences cancer cell metastasis, and tumorigenesis 
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in general, remains incomplete. Studies in cardiomyocytes, stromal cells and epithelial 
cancer-like cells have ascribed focal adhesion-like properties to N-cadherin including 
mechano-transduction and traction-force transmission.279-282 Indeed, whether a 'traction 
and propulsion'-type system, via homotypic N-cadherin mediated cell-cell contacts, is 
utilised by cancer cells to facilitate migration is intriguing and warrants further 
investigation. Moreover, there is an emerging body of evidence demonstrating that N-
cadherin is expressed and is functionally relevant in the context of numerous 
haematological malignancies including lymphoblastic and myelogenous leukaemias, 
and MM. Notably, studies suggest that N-cadherin facilitates engagement of LSCs with 
the tumour microenvironment and promotes chemotherapeutic resistance of leukaemic 
cells. On the basis of observations in epithelial cancers, N-cadherin may mediate drug 
resistance in leukaemic cells, at least in part, by activation of the pro-survival protein 
Bcl-287,155,159, or modulation of Sonic Hedgehog signalling283, widely implicated in 
cancer stem cell function and maintenance.284 Interestingly, N-cadherin expression is 
induced in solid tumour cells resistant to standard chemotherapeutic agents including 
tyrosine kinase inhibitors.154-157 However, it remains to be determined whether N-
cadherin functionally contributes to microenvironmental cell adhesion mediated-drug 
resistance in these cancers. 
 Given the established role of N-cadherin in cancer, N-cadherin is continually 
being investigated as a therapeutic target. To date, peptides and mouse monoclonal 
antibodies have demonstrated some efficacy in the pre-clinical setting, by inhibiting 
cancer metastasis, enhancing cancer cell sensitivity to chemotherapeutic agents and 
delaying castration resistance in prostate cancer. However, the challenge remains to 
develop N-cadherin antagonists which are effective anti-cancer agents in the clinical 
setting. The humanization of N-cadherin blocking antibodies such as GC-4 may 
represent one such approach to utilize N-cadherin as a therapeutic target. Moreover, the 
development of next-generation N-cadherin-targeting small molecules with enhanced 
stability over existing peptide inhibitors show promise as potent inhibitors of N-
cadherin function.285-287 It remains to be seen whether these compounds have efficacy as 
anti-cancer agents in solid tumours and in haematological malignancies. Undoubtedly, 
further exploration of N-cadherin as a therapeutic target to inhibit metastasis and 
overcome chemotherapeutic resistance is warranted.   
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Elevated expression of the cell adhesion molecule N-cadherin (CDH2) is associated 
with poor prognosis in newly-diagnosed multiple myeloma (MM) patients. In this study, 
we investigated whether targeting of N-cadherin represents a potential treatment for the 
~50% of MM patients with elevated N-cadherin. Initially, we stably knocked-down N-
cadherin in the mouse MM plasma cell (PC) line 5TGM1 to assess the functional role of 
N-cadherin in MM pathogenesis. When compared with 5TGM1-scramble-shRNA cells, 
5TGM1-Cdh2-shRNA cells had significantly reduced adhesion to bone marrow 
endothelial cells. However, N-cadherin knock-down did not affect 5TGM1 cell 
proliferation or adhesion to bone marrow stromal cells. In the C57BL/KaLwRij murine 
MM model, mice intravenously inoculated with 5TGM1-Cdh2-shRNA cells showed 
significantly decreased tumour burden after four weeks, compared with animals bearing 
5TGM1-scramble-shRNA cells. Finally, the N-cadherin antagonist ADH-1 had no 
effect on tumour burden in the established disease setting, whereas up-front ADH-1 
treatment resulted in significantly reduced tumour burden after four weeks. Our findings 
demonstrate that N-cadherin may play a key role in the extravasation of circulating MM 
PCs promoting bone marrow homing. Moreover, these studies suggest that N-cadherin 
may represent a viable therapeutic target to prevent the dissemination of MM PCs and 
delay MM disease progression.            




Multiple myeloma (MM) is an incurable haematological malignancy characterized by 
the clonal proliferation of immunoglobulin-producing plasma cells (PCs) within the 
bone marrow (BM).1 Despite recent advances in therapeutics and improvements in 
overall survival rates, the prognosis of patients with intermediate to high-risk MM 
remains relatively poor.2 During MM disease progression, MM PCs egress from the 
localized BM microenvironment, enter the circulation and disseminate to distal 
medullary sites.3 MM PC extravasation and BM homing is a multi-step process 
requiring attachment to the BM endothelial lumen, trans-endothelial migration and 
colonisation within the new stromal microenvironment. These processes are mediated 
by stromal cell-derived chemokines, which promote MM PC migration, as well as 
dynamic adhesive interactions.4-6 MM PCs express several adhesion molecules which 
mediate the physical interactions between PCs and the cellular (endothelial and stromal 
cells) and acellular (extracellular matrix proteins) components of the BM 
microenvironment. Previous studies have implicated the adhesion molecules CD44, 
VLA-4 and PSGL-1 in the attachment of MM PCs to BM endothelial cells (BMECs).7-9 
Studies have also demonstrated that functional blocking of CD44 and PSGL-1 inhibits 
MM PC extravasation and BM homing in vivo.8,9 Moreover, interactions between 
adhesion molecules expressed by MM PCs and their cognate adhesion partners activate 
numerous signal transduction cascades and positive feed-back loops which promote 
MM PC growth, survival, migration and resistance to chemotherapeutic agents.10-12 
Given that malignant transformation of normal PCs is often associated with the 
dysregulated expression of adhesion molecules13,14, the targeting of adhesion molecules 
represents an attractive therapeutic modality for MM. 
 N-cadherin (encoded by the gene CDH2) is a calcium-binding, single pass 
transmembrane glycoprotein expressed by a variety of cell types including neuronal, 
smooth muscle and endothelial cells.15-19 N-cadherin is a homophilic cell adhesion 
molecule that plays an important role in embryogenesis, morphogenesis and cancer 
pathogenesis.20 N-cadherin consists of 5 extracellular domains and mediates cell-cell 
binding through the reciprocal insertion of a Trp2 side chain located near the N-
terminus of the first extracellular domain (EC1) into the hydrophobic pocket of the 
apposed partner EC1 domain. Lateral clustering of N-cadherin through EC1 and the 
second extracellular domain (EC2) further strengthens the adhesive interaction.19,21-24 
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The cadherin cytoplasmic domain is functionally linked to the actin cytoskeleton via β-
catenin, α-catenin and p120 catenin, which also stabilizes the adhesive contacts.25 
Additionally, N-cadherin is implicated in the activation of several signal transduction 
pathways including MAPK-ERK (via cross-talk with FGF receptor) and PI3K/Akt, and 
signalling via Rho family GTPases, which regulates cell survival, proliferation, 
migration and differentiation.26-29 Sequestration of β-catenin to the plasma membrane by 
N-cadherin may also modulate β-catenin/TCF-dependent transcription of canonical 
Wnt-signalling gene targets.26,30 In the context of cancer, studies have shown that N-
cadherin mediates binding between tumour cells and stromal cells28,31,32, osteoblasts33 
and endothelial cells.34,35 Studies have also shown that N-cadherin promotes the 
survival, migration, invasion and metastatic capacity of solid tumour cell lines.28,34,36,37 
N-cadherin expression is up-regulated during tumour cell epithelial-to-mesenchymal 
transition (EMT) which involves a loss of cell polarity and an increase in dynamic 
cellular interactions, and consequently promotes tumour cell migration and 
dissemination.28,35,38-40. Indeed, aberrant expression of N-cadherin is strongly associated 
with highly aggressive forms of epithelial malignancies including breast, prostate, 
bladder and pancreatic cancer.41-45 Notably, the disulphide-linked N-cadherin antagonist 
ADH-1 (N-Ac-CHAVC-NH2) has been shown to inhibit tumour growth in pre-clinical 
models of pancreatic cancer and, when used in combination with melphalan, limits 
melanoma tumour growth.19,46,47 Moreover, phase I and II clinical trials with ADH-1 
have demonstrated disease control, and improved initial responses to melphalan, in 
some patients with advanced solid tumours.48-51 
 Our recent studies52, and those of others33, have shown that N-cadherin gene 
expression is up-regulated in PCs in approximately 50% of newly-diagnosed MM 
patients. In addition, we have recently demonstrated that circulating N-cadherin levels, 
which correlate with membrane N-cadherin expression in MM PCs, are up-regulated in 
approximately 30% of newly diagnosed MM patients. Moreover, these patients have 
decreased progression-free and overall survival compared with patients with normal 
circulating N-cadherin levels demonstrating that N-cadherin is a negative prognostic 
indicator in patients with MM.52 Previous studies have implicated N-cadherin in BM 
homing of MM PCs and in MM PC-osteoblast interactions.33 In this study, we 
investigated the effect of N-cadherin knock-down on MM PC behaviour in vitro using 
the murine MM PC line 5TGM1. Furthermore, utilising the C57BL/KaLwRij murine 
model of MM, we also assessed whether targeting of N-cadherin by knock-down or 
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2.3.1 Mouse tissue and PC isolation 
C57BL/KaLwRij mice, originally kindly provided by Andrew Spencer (Monash 
University, Clayton, Australia) were bred and housed at the SA Pathology Animal Care 
Facility (Adelaide, Australia). All procedures were performed with approval of the SA 
Pathology and University of Adelaide Animal Ethics Committees. Brain tissue from 
C57BL/KaLwRij mice was snap frozen in liquid nitrogen and homogenised in TRIzol® 
(Life Technologies, Carlsbad, CA). Murine BM PCs and BM stromal cells (BMSCs) 
were isolated from C57BL/KaLwRij mice as previously described.53,54 Briefly, mouse 
femora and tibiae were excised, the bone marrow was flushed and the bones were 
crushed prior to isolation of MSC cultures.53 The BM mononuclear fraction was isolated 
by Ficoll density gradient separation and the cells were blocked with 110µg/mL murine 
gamma globulin (Jackson Laboratories, Bar Harbor, ME, USA) and stained with rat 
anti-mouse CD138 (R & D Systems, Minneapolis, MN) followed by goat anti-rat IgG 
PE (Southern Biotech, Birmingham, AL). CD138+ BM PCs were then isolated by flow 
cytometry (FACSAria II, BD Biosciences, San Jose, CA) and total RNA was isolated 
from sorted cells using an RNAqueous Micro kit (Life Technologies). 
 
2.3.2 Cell culture 
All cell culture reagents were sourced from Sigma-Aldrich (St Louis, MO, USA), unless 
otherwise stated. All media were supplemented with 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 10mM HEPES buffer, 
unless otherwise specified. The mouse MM PC line 5TGM1 was maintained in Iscove's 
modified Dulbecco's medium (IMDM) with 20% foetal calf serum (FCS; Thermo Fisher 
Scientific, Waltham, MA, USA) and supplements. The human BM endothelial cell 
(BMEC) line TrHBMEC55 was maintained in M199 medium with 20% FCS and 
supplemented with 0.1% sodium bicarbonate, 1x MEM Non-Essential Amino Acids, 
100U/ml penicillin, 100ug/ml streptomycin, 1mM sodium pyruvate and 10mM HEPES 
buffer, 50µg/ml endothelial cell growth factor (BD Biosciences) and 100U/ml heparin. 
C57BL/KaLwRij BMSCs were maintained in alpha-modified Eagle’s medium (α-
MEM) with 10% FCS, 100mM L-ascorbate-2-phosphate and supplements. 
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2.3.3 Generation of a 5TGM1 N-cadherin (Cdh2) shRNA cell line 
The pFIV-H1-mCherry vector was created by excising the GFP cassette from pFIV-H1-
GFP (System Biosciences, Mountain View, CA) using XbaI and SalI and replacing it 
with the mCherry cassette from pMSCV-mCherry. To generate stable knock-down cell 
lines, an RNA duplex targeting mouse Cdh2 (AAGGATGTGCACGAAGGACAG)56 
was cloned into pFIV-H1-mCherry. A scrambled sequence 
(AAGCCACGGCCATAGAAGGCA) was used as a control. Following lentiviral 
infection of 5TGM1-luc cells (expressing a dual GFP and luciferase reporter 
construct)54,57, GFP and mCherry-expressing cells were sorted by FACS using a 
Beckman Coulter Epics AltraHyperSort (Beckman Coulter, Miami, FL, USA) and 
single cell clones were generated. A pool of 3 clonal 5TGM1-Cdh2-shRNA lines was 
used for subsequent in vitro and in vivo assays. 
 
2.3.4 Quantitative PCR 
Total RNA was isolated using TRIzol® and cDNA was synthesised using Superscript® 
III First-Strand Synthesis System (Life Technologies). Quantitative real-time PCR 
(qPCR) was performed using a Rotor-Gene (QIAGEN, Valencia, CA, USA) using 
primers for Cdh2 (Fwd 5'-ATCACTACTATTGCCGTTTTGG-3'; Rev 5'-
CTCCGGCTCTTGAGGTAACA-3') and Actb (Fwd 5'-
GATCATTGCTCCTCCTGAGC-3'; Rev 5'-GTCATAGTCCGCCTAGAAGCAT-3'). 
 
2.3.5 Western blotting 
Whole cell lysates were prepared and polyacrylamide gel electrophoresis was 
performed as described previously.54 Following transfer, the polyvinylidinedifluoride 
(PVDF) membrane was incubated in blocking buffer (2.5% ECL Blocking Agent [GE 
Healthcare, Little Chalfont, Buckinghamshire] in 0.1% Tween 20 Tris-buffered saline) 
for 2 hours at room temperature. The PVDF membrane was then probed overnight at 
4°C with a monoclonal rabbit anti-mouse N-cadherin antibody (Millipore; Billerica, 
MA, USA) diluted 1:10,000 in blocking buffer. Primary antibody binding was detected 
by incubating membranes with an alkaline phosphatase (AP)-conjugated anti-rabbit IgG 
(Millipore) diluted 1:2500 in blocking buffer for 1 hour at room temperature. Proteins 
were visualised with ECL detection reagent (GE Healthcare) on a Typhoon FLA 7000 
(GE Healthcare).  
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 To ensure equal loading of total protein, the membrane was stripped using 
Western Blot Recycling kit (Alpha Diagnostic International Inc., San Antonio, TX, 
USA) and probed for 1 hour at room temperature with rat anti-α-tubulin (Abcam; 
Cambridge, UK) at 200ng/ml in blocking buffer. The membrane was then incubated for 
1 hour at room temperature with AP-conjugated anti-rat IgG (Millipore; diluted 1:5000) 
and proteins visualised with ECL detection reagent. N-cadherin levels were quantitated 
and normalised to α-tubulin levels using ImageQuant TL Software (GE Healthcare).  
 
2.3.6 Proliferation assays 
For WST-1 assays, 5TGM1 cells were plated at 1x105 cells/ml in triplicate in phenol 
red-free IMDM containing 20% FCS and supplements using a 96-well plate. Relative 
cell numbers were assessed over 3 days using WST-1 (Roche, Basel, Switzerland) as 
per manufacturer's instructions.  
 To assess cell numbers by bioluminescence imaging (BLI), 5TGM1 cells were 
plated at 5x104/ml in triplicate in IMDM using black clear-bottomed 96-well plates 
(Corning Life Science, New York, USA). For proliferation assays in co-culture, BMSCs 
were irradiated at 30 Gy and seeded at 1.5x105/ml in black clear-bottomed 96-well 
plates 24 hours prior to the addition of the 5TGM1 cells. After 3 days, firefly D-
luciferin (Biosynth AG, Staad, Switzerland) was added to wells with a final 
concentration of 150ng/ml and incubated for 20 mins at 37°C. Bioluminescence 
(photons/sec) was measured and analysed using the Xenogen IVIS 100 (Caliper Life 
Sciences, Hopkinton, MA, USA) and Living Image software (PerkinElmer, Waltham, 
MA). Absolute cell numbers were calculated using a standard curve. 
5TGM1-scramble-shRNA cells and 5TGM1-Cdh2-shRNA cells displayed 
equivalent levels of basal mitochondrial dehydrogenase activity (WST-1 assay) and 
bioluminescence, allowing for direct comparison between the cell lines (data not 
shown). 
 
2.3.7 Adhesion assays 
Adhesion under static conditions was performed as previously described.57 For adhesion 
to cell monolayers, non-irradiated BMSCs or BMECs were plated at 1x105/ml 24 hours 
prior to adhesion assay. 5TGM1 cells were added at 1x106/ml in triplicate and incubated 
at 37°C. After 10 minutes, non-adherent 5TGM1 cells were gently removed by 
aspiration followed by 3 washes with IMDM with 20% FCS and supplements and cell 
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number was quantitated by BLI as described above. For adhesion to N-cadherin-Fc, 96-
well plates were coated with 10µg/ml recombinant human N-cadherin-Fc (R&D 
Systems, Northeast Minneapolis, MN, USA) or human IgG-Fc fragment (Rockland 
Immunochemicals, Limerick, PA, USA) for 2 hours at 37°C. After blocking wells with 
1% BSA in IMDM for 2 hours at 37°C, 5TGM1 cells were added at 1x106/ml in 
triplicate and incubated at 37°C. After 2 hours, non-adherent 5TGM1 cells were gently 
removed by aspiration and 1 wash with IMDM with 20% FCS and supplements and 
adherent cells were quantitated by BLI. The percentage of 5TGM1 cells adherent to cell 
monolayers or N-cadherin-Fc was calculated relative to total cell input, following 
subtraction of the untreated or IgG-Fc controls, respectively. 
 Adhesion under shear stress was performed using a parallel plate flow chamber 
assay (GlycoTech, Gaithersburg, MD, USA).58 Non-irradiated BMECs were seeded at 
6x104/cm2 (5x105 cells in total) in 35mm dishes (Corning) 24 hours prior to the 
adhesion assay. BMECs were stimulated with 5ng/ml TNF-α for 4 hours prior to the 
assay. Using a syringe pump (New Era Pump Systems, Farmingdale, NY, USA), a total 
of 6x106 5TGM1 cells in IMDM with 2% FCS and supplements were pre-warmed to 
37°C and were perfused across BMECs at 2 dynes/cm2 (1.25ml/min using a 10mm 
gasket window width) to mimic physiologic shear forces within the vasculature.59,60 
After flushing away non-adherent cells with IMDM + 2% FCS with supplements, the 
average number of adherent 5TGM1 cells was enumerated over 7 fields of view. 
5TGM1 cells were visualized using an inverted microscope and digital video recorder 
(Olympus, Tokyo, Japan). 
 
2.3.8 Trans-well and trans-endothelial migration assays 
Migration assays were performed using trans-wells (8 µm polycarbonate membrane; 
Costar) in a 24-well plate with a FCS concentration gradient (0% and 20% in upper and 
lower chambers, respectively), as previously described.57 For trans-well migration 
assays, 5TGM1 cells (1x105 per trans-well) were seeded in triplicate trans-wells in 
IMDM with supplements and cell migration towards IMDM with 20% FCS and 
supplements was assessed after 24 hours. For trans-endothelial migration assays, 1x104 
BMECs were plated per trans-well and were allowed to adhere for 24 hours. 5TGM1 
cells (5x105 per trans-well) were then added to triplicate trans-wells and cell migration 
to the lower chamber was assessed after 8 hours. The number of migrated cells was 
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enumerated using an inverted microscope and digital camera (Olympus) and ImageJ 
software (http://imagej.nih.gov/ij/). 
 
2.3.9 Gelatine zymography 
To assess matrix metalloproteinase 9 (MMP9) activity, 5TGM1 cells were cultured at 
2x105/ml in a 6-well plate and conditioned media was collected after 3 days. 
Conditioned media (20µl) was run on a gelatine-sodium dodecyl sulphate-
polyacrylamide gel (30% acrylamide and 1% gelatine) as previously described.61 The 
gel was incubated overnight in MMP9 activation buffer (1.25% Triton X-100, 10mM 
Tris-HCl, 5mM CaCl2, 1µM ZnCl2) at 37°C. The gel was then stained with 0.25% 
Coomassie Blue in de-stain solution (50% (v/v) methanol and 10% (v/v) acetic acid in 
water) for 2 hours and de-stained for 2 hours. Clear zones were imaged on a Typhoon 
FLA 7000. 
 
2.3.10 Animal studies 
C57BL/KaLwRij mice (6-8 weeks old) were inoculated with 5x105 5TGM1-scramble-
shRNA cells or 5TGM1-Cdh2-shRNA cells in 100µl phosphate-buffered saline (PBS) 
via tail vein injection as previously described.54,62 After 2, 3 and 4 weeks, mice were 
intraperitoneally administered 150mg/kg firefly D-luciferin (diluted in PBS; 100µl 
volume), bioluminescence was measured after 10 mins using the Xenogen IVIS 100 
system and total body MM tumour burden was assessed using Living Image software. 
Total body MM tumour burden, as assessed by BLI at 4 weeks, closely correlates with 
serum paraprotein levels as an independent measure of MM tumour burden (n = 34 
mice; P < 0.0001, R2 = 0.7874; supplementary Fig. 1). 
 For N-cadherin inhibition studies with the N-cadherin antagonist ADH-119, 6–8-
week-old C57BL/KaLwRij mice were inoculated with 5x105 parental 5TGM1-luc cells 
in 100µl phosphate-buffered saline (PBS) via tail vein injection. Mice were 
intraperitoneally injected once daily with either the N-cadherin antagonist ADH-1 (N-
Ac-CHAVC-NH2) (100mg/kg/day in PBS; CanPeptide, Pointe-Claire, Canada) or PBS 
vehicle alone, commencing immediately prior to 5TGM1 cell injection (up-front 
treatment group) or 1 week after 5TGM1 cell injection (delayed treatment group) for the 
duration of the experiment. Tumour burden was assessed 2, 3 and 4 weeks following 
tumour inoculation using BLI. 
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2.3.11 Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6. In vitro assays were 
analysed using a paired t test or two-way ANOVA. Tumour burden was analysed using 
a two-way ANOVA with Bonferroni's multiple comparisons test. The correlation 
between total body MM tumour burden, as assessed by BLI and serum paraprotein 
levels, was analysed by Pearson correlation. 




2.4.1 N-cadherin expression in 5TGM1 cell lines 
The expression of the N-cadherin gene, Cdh2, in 5TGM1 cells was assessed by qPCR. 
While Cdh2 was not expressed in normal murine BM PCs, Cdh2 expression in 5TGM1 
cells was approximately 5-fold higher than in mouse positive control cells (brain tissue 
and BMSCs) (Figure 2.1A). Expression of CDH2 was also detected in human BMECs 
(data not shown). C57BL/KaLwRij mouse-derived BMSC and human BMECs also 
exhibited considerable expression of N-cadherin protein (Figure 2.1B). Following stable 
5TGM1 Cdh2-shRNA knock-down, expression of N-cadherin protein was reduced by 
60%, as assessed by Western blot, when compared with 5TGM1-scramble-shRNA 
control cells (Figure 2.1B).  
 
2.4.2 5TGM1 cell proliferation and adhesion to BMSCs is unaffected by N-
cadherin knock-down 
Basal proliferation of 5TGM1 cells following N-cadherin shRNA-mediated knock-
down was unaffected, relative to 5TGM1-scramble-shRNA cells, over a 3 day time 
course as shown using a WST-1 assay (scramble-shRNA: 1.55 ± 0.14 A450 [mean ± 
SD]; Cdh2-shRNA: 1.51 ± 0.14; after 3 days; P = 0.99) (Figure 2.2A). Similarly, there 
was no difference between 5TGM1-scramble-shRNA and 5TGM1-Cdh2-shRNA cell 
numbers after 3 days of culture, as assessed by BLI (scramble-shRNA: 60.86 ± 11.00 
[x103] cells/well; Cdh2-shRNA: 50.82 ± 8.66; P = 0.22) (Figure 2.2B). Given that 
C57BL/KaLwRij mouse-derived BMSCs express abundant N-cadherin (Figure 2.1A,B) 
and that MM PC interactions with stromal cells are important in cell survival and drug 
resistance in MM63,64, we assessed the effect of N-cadherin knock-down on 5TGM1 cell 
proliferation in co-culture with BMSCs and on adhesion to confluent BMSC 
monolayers. We found no difference in 5TGM1 cell numbers, as assessed by BLI, 
between 5TGM1-scramble-shRNA and 5TGM1-Cdh2-shRNA cells after 3 days of co-
culture with BMSCs (scramble-shRNA: 41.84 ± 6.33 [x103] cells/well; Cdh2-shRNA 
32.92 ± 2.50; P = 0.20) (Figure 2.2C). In addition, there was no difference in the 
adhesion of 5TGM1-scramble-shRNA cells and 5TGM1-Cdh2-shRNA cells to BMSC 
monolayers (scramble-shRNA: 46.9 ± 1.7% adherence [mean ± SD]; Cdh2-shRNA: 
44.7 ± 2.3%; P = 0.13) (Figure 2.3A). 
 
Figure 2.1.  N-cadherin expression in C57BL/KaLwRij mouse tissues and 5TGM1 
cell lines. 5TGM1 cells express high levels of Cdh2 compared with positive control 
C57BL/KaLwRij mouse-derived brain tissue and BMSCs, and negative control 
C57BL/KaLwRij PCs, as shown by qPCR. Data was normalised to Actb expression. 
Graph depicts mean ± SD of 2 independent experiments (A). C57BL/KaLwRij mouse 
BMSCs and human BMECs express N-cadherin protein as shown by Western blot. 
Levels of N-cadherin protein is reduced by 60% in 5TGM1-Cdh2-shRNA cells 










































Figure 2.2.  N-cadherin does not affect the proliferation of 5TGM1 cells in vitro. 
Basal proliferation of 5TGM1-Cdh2-shRNA cells is no different from that of 5TGM1-
scramble-shRNA cells after 3 days as assessed by WST-1 assay (A) and BLI (B). 
Graphs depict mean ± SEM of 3 and 5 independent experiments, respectively. shRNA-
mediated N-cadherin knockdown has no effect on proliferation of 5TGM1 cells in co-
culture with C57BL/KaLwRij mouse-derived BMSCs as assessed by bioluminescence 
imaging after 3 days. Graph depicts mean ± SEM of 4 independent experiments (C). 
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Figure 2.3.  N-cadherin expression modulates the adhesive capacity of 5TGM1 cells 
to BMECs in vitro. Adhesion of 5TGM1-Cdh2-shRNA cells to monolayers of 
C57BL/KaLwRij BMSCs is no different from that of 5TGM1-scramble-shRNA cells 
after 10 minutes. Graph depicts mean ± range of 2 independent experiments (A). 
Adhesion of 5TGM1-Cdh2-shRNA cells to immobilised N-cadherin-Fc (10µg/ml) after 
2 hours is significantly inhibited compared with 5TGM1-scramble-shRNA cells. Graph 
depicts mean ± range of 2 independent experiments (B). 5TGM1-Cdh2-shRNA cells 
adhere significantly less to monolayers of BMECs compared with 5TGM1-scramble-
shRNA cells after 10 minutes in a static adhesion assay (C) or under 2 dynes/cm2 of 
shear stress (D). Graphs depict mean ± SEM of 4 and 3 independent experiments, 
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2.4.3 N-cadherin knock-down reduces 5TGM1 cell adhesion to BMECs 
A crucial step in the extravasation and BM homing of circulating MM PCs is their 
adhesion to BMECs.65 As BMECs express abundant N-cadherin (Figure 2.1B) and N-
cadherin has been implicated in the adhesion of tumour cells to endothelial cells28,34, the 
role of N-cadherin in the adhesion of 5TGM1 cells to BMECs was assessed. Initially, 
we confirmed N-cadherin-mediated binding in 5TGM1 cells by assessing adhesion to 
immobilised N-cadherin-Fc. Compared with 5TGM1-scramble-shRNA cells, 5TGM1-
Cdh2-shRNA cells displayed a reduced capacity to adhere to N-cadherin-Fc (scramble-
shRNA: 27.2 ± 3.5% adherence [mean ± range]; Cdh2-shRNA: 17.8 ± 3.1%; P < 0.05) 
(Figure 2.3B). 
Subsequently, we assessed 5TGM1 cell adhesion to BMECs under static 
conditions and under shear stress, representative of physiological flow in blood vessels. 
Compared with 5TGM1-scramble-shRNA cells, 5TGM1-Cdh2-shRNA cell adhesion to 
BMECs was significantly reduced (scramble-shRNA: 16.61 ± 0.61% adherence [mean 
± SEM]; Cdh2-shRNA:  9.85 ± 1.95%; P < 0.05) (Figure 2.3C). Using a parallel plate 
flow chamber, we assessed the ability of 5TGM1 cells to adhere to confluent 
monolayers of BMECs under 2 dynes/cm2 of shear stress. Compared with 5TGM1-
scramble-shRNA cells, 5TGM1-Cdh2-shRNA cells displayed a reduced capacity to 
adhere to BMECs under shear stress (scramble-shRNA: 26.81 ± 3.99 cells/field of view 
[mean ± SEM]; Cdh2-shRNA: 13.69 ± 3.28; P < 0.01) (Figure 2.3D). 
 
2.4.4 Trans-endothelial migration of 5TGM1 cells is unaffected by N-cadherin 
knock-down 
Following adhesion to BM endothelium, MM PCs penetrate the endothelial basement 
membrane and extravasate into the BM microenvironment.65 We assessed the functional 
role of N-cadherin in 5TGM1 cell migration using a FCS concentration gradient as a 
chemoattractant. We found no difference in basal migration of 5TGM1-scramble-
shRNA cells and 5TGM1-Cdh2-shRNA cells across a transwell membrane, after 24 
hours (scramble-shRNA: 252.3 ± 21.2 cells/well [mean ± SEM]; Cdh2-shRNA: 321.3 ± 
84.1 cells/well; P = 0.56) (Figure 2.4A). Furthermore, the ability of 5TGM1-Cdh2-
shRNA cells to migrate through a monolayer of BMECs was unchanged relative to 
5TGM1-scramble-shRNA cells (scramble-shRNA: 830.7 ± 134.4 cells/well [mean ± 
range]; Cdh2-shRNA: 717 ± 111 cells/well; P = 0.72) (Figure 2.4B).  
Figure 2.4.  N-cadherin does not affect the migration of 5TGM1 cells in vitro. 
Migration of 5TGM1 cells through trans-wells or through BMECs is unaffected by N-
cadherin shRNA. 5TGM1 cells (1x105) were seeded into the upper chamber of trans-
wells and migration to the bottom chamber was assessed after 24 hours. Graph depicts 
mean ± SEM of 3 independent experiments (A). 5TGM1 cells (5x105) were seeded onto 
a confluent monolayer of BMECs established on trans-well membranes (upper 
chamber) and trans-endothelial migration to the bottom chamber was assessed after 8 
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MM PC extravasation is dependent on the production of proteolytic enzymes 
such as matrix metalloprotease 9 (MMP9) to degrade the endothelial basement 
membrane 66. We found no difference in the MMP9 activity of 5TGM1 cells following 
N-cadherin knock-down compared to control 5TGM1 cells (data not shown). 
 
2.4.5 Targeting of N-cadherin reduces total body tumour burden in a 
C57BL/KalwRij murine model of MM 
To investigate whether therapeutic targeting of N-cadherin may represent a novel 
treatment modality for MM patients with high N-cadherin expression, we utilised the 
5TGM1-C57BL/KaLwRij murine model of MM. In this model, following intravenous 
injection, circulating 5TGM1 tumour cells home to the BM and establish at multiple 
sites throughout the skeleton. Initially, we investigated the effect of N-cadherin knock-
down in 5TGM1 cells on MM development in vivo. Total body tumour burden in mice 
inoculated with 5TGM1-Cdh2-shRNA cells was reduced by 73.1%, compared with 
mice inoculated with 5TGM1-scramble-shRNA cells (scramble-shRNA: 1.99x106 ± 
0.46x106 photons per second [photons/s]; Cdh2-shRNA: 0.54x106 ± 0.15x106 
photons/s; P < 0.0001), after 4 weeks (n = 5 mice/group; Figure 2.5A). 
 In order to investigate the effectiveness of the N-cadherin inhibition in 
suppressing MM establishment and disease progression in vivo, the effects of the N-
cadherin antagonist ADH-1 were assessed in C57BL/KaLwRij mice bearing parental 
5TGM1-luc cells, which express abundant N-cadherin. C57BL/KaLwRij mice were 
treated with ADH-1 (100mg/kg/day) or PBS vehicle control commencing immediately 
prior to inoculation with 5TGM1-luc cells (up-front treatment group) or one week after 
parental 5TGM1-luc cell inoculation (delayed treatment group). ADH-1 did not cause 
adverse effects, as assessed by weight loss or change in physical appearance. The total 
body tumour burden in the ADH-1 up-front treatment group (2.09x106 ± 0.43x106 
photons/s) was reduced by 68.6% compared with mice treated with PBS vehicle alone 
(6.67x106 ± 0.21x106 photons/s) as assessed by BLI after 4 weeks (n = 10-11 
mice/group; P < 0.01) (Figure 2.5B). In contrast, there was no reduction in total body 
tumour burden in the delayed ADH-1 treatment group (1.59x107 ± 0.43x107 photons/s) 
compared with mice treated with PBS vehicle alone (1.46x107 ± 0.13x107 photons/s) 
after 4 weeks (n = 6-7 mice/group) (Figure 2.5C).  
 
Figure 2.5.  Targeting of N-cadherin reduces total body MM tumour burden in 
C57BL/KaLwRij mice after 4 weeks. C57BL/KalwRij mice bearing 5TGM1-Cdh2-
shRNA cells had significantly reduced overall tumour burden compared with 5TGM1-
scramble-shRNA cell-bearing C57BL/KalwRij mice after four weeks, as shown by BLI. 
Graph depicts mean ± SEM. n = 5 mice/group (A). Daily treatment of C57BL/KalwRij 
mice with 100mg/kg/day ADH-1 commencing pre-5TGM1 cell injection significantly 
reduced overall tumour burden after 4 weeks compared with C57BL/KalwRij mice 
treated with PBS vehicle alone, as measured by BLI. Graph depicts mean ± SEM. n = 
10 and 11 PBS-treated and ADH-1-treated mice, respectively (B). Daily treatment of 
C57BL/KaLwRij mice with 100mg/kg/day ADH-1 commencing 1 week post-5TGM1 
cell injection did not reduce overall tumour burden after 4 weeks compared with 
C57BL/KaLwRij mice treated with PBS vehicle alone, as measured by BLI. Graph 
depicts mean ± SEM. n = 6 and 7 PBS-treated and ADH-1-treated mice, respectively 
(C). ** P < 0.01 **** P < 0.0001 (two-way ANOVA with Bonferroni's multiple 
comparisons test). BLI images of one representative animal from each group over the 4 
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Approximately 30% of newly diagnosed MM patients display elevated levels of 
circulating N-cadherin, which correlate with membrane N-cadherin expression in MM 
PCs. Notably, these patients have significantly worse progression-free and overall 
survival compared with patients with normal circulating N-cadherin levels, 
demonstrating that elevated N-cadherin confers a poor prognosis in MM.52 Previous 
studies have also shown that N-cadherin plays a functional role in MM PC biology and 
behaviour such as BM homing, osteoblast interactions and, in certain contexts, 
proliferation.33,67 In this study, our findings suggest that N-cadherin plays an important 
role in the pathogenesis of MM in vivo by mediating MM PC adhesion to BMECs, a 
crucial step in the extravasation of circulating MM PCs and subsequent establishment 
within the BM microenvironment. Notably, this is the first pre-clinical study to target 
N-cadherin as a potential therapeutic modality in MM. The C57BL/KaLwRij murine 
model of MM was utilised as it replicates many of the clinical and histopathological 
features characteristic of human MM disease.68,69 The N-cadherin-expressing murine 
5TGM1 MM PC line is highly aggressive following intravenous inoculation into 
C57BL/KaLwRij mice resulting in extensive tumour burden in the spleen and 
throughout the skeleton after four weeks.54,70 Importantly, knock-down of N-cadherin in 
5TGM1 cells and up-front administration of the N-cadherin antagonist ADH-1 
significantly decreased total body MM tumour burden after four weeks compared with 
control animals. 
 Following intravenous inoculation into C57BL/KaLwRij mice, 5TGM1 cells 
extravasate, home to, and establish within BM microenvironment leading to the 
formation of multiple tumour foci throughout the axial and appendicular skeleton within 
four weeks.54 In this study, knock-down of N-cadherin in 5TGM1 cells resulted in a 
significant reduction in overall tumour burden in C57BL/KaLwRij mice demonstrating 
the functional role of N-cadherin in MM development in vivo. Pre-clinical studies have 
previously shown that targeting N-cadherin using the antagonist ADH-1 alone, or in 
combination with other chemotherapeutics, significantly inhibited the growth of 
pancreatic tumours and melanoma, respectively.46,47 ADH-1 is a disulfide-linked cyclic 
pentapeptide harbouring the His-Ala-Val (HAV) motif, found in the EC1 domain of 
type I classical cadherins, including N-cadherin.19 Previous studies have demonstrated 
that synthetic linear and cyclic peptides containing the HAV motif are potent N-
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cadherin antagonists, inhibiting N-cadherin-dependent neurite outgrowth and myoblast 
fusion, retarding Schwann cell and smooth muscle cell migration and inducing 
endothelial cell apoptosis in vitro.15,16,71-73 We investigated the effect of ADH-1 on MM 
pathogenesis using the C57BL/KaLwRij murine model. Notably, daily administration of 
5TGM1 cell-inoculated C57BL/KaLwRij mice with ADH-1 significantly reduced 
overall tumour burden demonstrating that N-cadherin function in MM development can 
be pharmaceutically inhibited in vivo. By commencing ADH-1 treatment of tumour-
bearing C57BL/KaLwRij mice before and (one week) after 5TGM1 cell inoculation, we 
were able to assess the functional role of N-cadherin in BM homing of circulating MM 
PCs (ADH-1 up-front treatment) and intramedullary growth (delayed ADH-1 treatment) 
in vivo. In contrast to up-front ADH-1 treatment, delayed ADH-1 administration did not 
reduce total body tumour burden in C57BL/KaLwRij mice suggesting that N-cadherin 
is particularly important in the BM homing of MM PCs. Notably, our findings are 
consistent with previous observations in which N-cadherin knock-down in NCI-H929 
MM PCs reduced their capacity to home to the BM following intravenous inoculation 
into Rag-2-/-γc-/- mice.33 Moreover, this is in line with evidence demonstrating the 
efficacy of N-cadherin inhibition in limiting metastasis in pre-clinical solid tumour 
models.34,36 
 We assessed the functional role of N-cadherin in 5TGM1 cells using a series of 
in vitro assays addressing individual aspects of MM PC behaviour, which contribute to 
MM development in vivo. Previous over-expression and knock-down studies have 
demonstrated that the proliferation of tumour and non-tumour cell lines can be either 
inhibited or promoted by N-cadherin in a cell context-specific manner.34,74,75 In our 
study, N-cadherin knock-down did not affect the proliferation of 5TGM1 cells under 
basal growth conditions or in co-culture with N-cadherin-expressing BMSCs in vitro, 
suggesting that N-cadherin-mediated homotypic binding (between 5TGM1 cells) and 
heterotypic binding (between 5TGM1 and BMSCs) does not appear to play a crucial 
role in 5TGM1 cell proliferation. These results are consistent with previous findings 
which showed that N-cadherin knock-down had no effect on basal proliferation of the 
human MM PC line NCI-H929.33 Moreover, there was no difference in the proliferation 
of N-cadherin-positive and negative human MM PC lines when cultured on 
immobilized N-cadherin-Fc.33 In contrast to these results, Sadler et al. found that the N-
cadherin blocking antibody GC-4 increased the proliferation of N-cadherin-expressing 
human MM cell lines when co-cultured with BMSCs or osteoblasts.67 However, the 
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interpretation of these results is complicated by the fact that while GC-4 blocks cell-cell 
binding67, it has also been shown to stimulate the adhesion and spreading of tumour 
cells76, suggesting that the antibody may behave as an agonist. To this end, while GC-4 
may promote cell proliferation, our in vitro data supports previous data suggesting that 
N-cadherin knock-down does not affect the proliferation of MM cell lines either basally 
or in the presence of BMSCs. 
 Stromal cells constitute the majority of the non-hematopoietic cellular 
compartment within the BM microenvironment and are essential in providing pro-
growth and survival cues to MM PCs.63,64,77 Studies using an N-cadherin blocking 
antibody have previously shown that N-cadherin mediates the adhesion of breast cancer 
and melanoma cell lines to stromal cells and dermal fibroblasts, respectively.28,31 In 
addition, studies using the N-cadherin antagonist ADH-1 have shown a role for N-
cadherin in the adhesion of CML progenitor cells to BMSCs.78 In contrast, our study 
shows that N-cadherin knock-down did not affect the ability of 5TGM1 cells to adhere 
to BMSCs. This finding is discordant with previous studies which reported that N-
cadherin knock-down or blocking with antibody decreased the adhesion of human MM 
PC lines to murine fibroblast cells.33 However, while our studies were performed in 
medium containing several divalent cations, the aforementioned study conducted 
adhesion assays in the presence of calcium only, that is, in the absence of other divalent 
cations that are required for integrin-mediated adhesion.79-81 Our findings therefore 
suggest that other adhesion interactions, such as VLA-4-VCAM-1/fibronectin and LFA-
1-ICAM-1, are potentially more important than N-cadherin-mediated binding in 
5TGM1 cell adhesion to BMSCs. 
 The BM-homing cascade of MM PCs involves adhesion to the BM endothelium, 
trans-endothelial migration and establishment within the local BM microenvironment.65 
Studies have previously established the importance of N-cadherin in mediating 
haematopoietic and tumour cell interactions with endothelial cells. For example, an N-
cadherin blocking antibody prevented the adhesion of neutrophil granulocytes to 
endothelial cells.82 Additionally, enforced expression of N-cadherin in MCF-7 breast 
cancer cells promoted adhesion to human umbilical vein endothelial cells (HUVECs), 
while antibody-mediated N-cadherin blocking impeded the adhesion of melanoma cells 
to HUVECs.28,34 Furthermore, previous studies have shown that N-cadherin 
accumulates at the initial heterotypic contact sites between melanoma cells and 
endothelial cells, suggesting a role in adhesion.18,35,83,84 In the current study, we found 
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that N-cadherin knock-down significantly reduced the adhesion of 5TGM1 cells to 
monolayers of BMECs under static conditions and under shear stress, representative of 
physiological stress encountered within the vasculature. Given that N-cadherin knock-
down reduced the ability of 5TGM1 cells to adhere to endothelial cells, it may impede 
the ability of 5TGM1 cells to undergo trans-endothelial migration. N-cadherin knock-
down or blocking with antibody in melanoma cell lines has previously been shown to 
decrease trans-endothelial migration without affecting adhesion to endothelial cells, 
suggesting a specific role of N-cadherin in diapedesis.35,84 However, consistent with 
previous studies using NCI-H929 MM PCs33, N-cadherin knock-down did not affect 
trans-endothelial migration of 5TGM1 cells in this study. Taken together, these data 
suggest that N-cadherin knockdown may decrease tumour homing in vivo by inhibiting 
MM cell adhesion to endothelial cells, and therefore arrest of the tumour cells in the 
vasculature, without affecting the rate of the subsequent diapedesis.  
 Our findings demonstrate that N-cadherin is an important mediator of MM PC 
adhesive interactions with the BM endothelium, a crucial step in the BM homing 
cascade. We propose a mechanism whereby functional inhibition of N-cadherin 
prevents the extravasation of circulating MM PCs, which subsequently inhibits homing 
and colonization within the BM microenvironment. From a therapeutic perspective, our 
findings suggest that targeting of N-cadherin with ADH-1 may be of particular benefit 
in MM patients with high N-cadherin expression and, hence, high-risk disease. Further 
studies are warranted to examine the effectiveness of ADH-1 as a maintenance therapy 
in order to inhibit the ability of MM PCs to disseminate to multiple BM sites. Our 
results also encourage the examination of orally available ADH-1 peptidomimetics19 for 
their ability to suppress MM disease. To this end, therapeutic targeting of N-cadherin 
may be a novel approach in delaying disease progression and relapse and improving 
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Supplementary Figure 2.1.  Positive correlation between total body MM tumour 
burden assessed by BLI and serum paraprotein levels after 4 weeks. Serum 
paraprotein levels are presented as a percentage of total serum protein. n = 34 MM 
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N-cadherin is a homophilic cell-cell adhesion molecule which plays a critical role in 
maintaining vascular stability and modulating endothelial barrier permeability. Previous 
studies have demonstrated that the N-cadherin antagonist peptide ADH-1 enhances 
chemotherapeutic drug delivery to the tumour microenvironment by increasing vascular 
permeability to macromolecules, thereby enhancing tumour response. In the current 
study, we evaluated a synthetic small molecule peptidomimetic of ADH-1, LCRF-0006, 
as a novel vascular disrupting agent. We demonstrate that LCRF-0006 displays rapid, 
transient and reversible effects on endothelial cell junctions and increases vascular 
permeability in vitro and in vivo. Using a well-established C57Bl/KaLwRij/5TGM1 
mouse model of multiple myeloma (MM) disease, LCRF-0006 synergised with the anti-
MM agent bortezomib, significantly inhibiting MM tumour progression and leading to 
regression of disease in 100% of mice (co-efficient of drug interaction < 0.7). 
Moreover, LCRF-0006 and bortezomib synergistically induced 5TGM1 MM plasma 
cell apoptosis in vitro (co-efficient of drug interaction < 0.7). Our findings suggest the 
potential clinical utility of LCRF-0006 in a combinatorial approach to significantly 
increase bortezomib efficacy in MM. 




The structural integrity and permeability of the vascular endothelial barrier plays an 
essential role in the supply of nutrients and the maintenance of fluid balance in tissues.1 
Endothelial barrier stability is tightly controlled and maintained through adhesive 
interactions between neighbouring endothelial cells (ECs), as well as between ECs and 
adjacent mural cells (pericytes and smooth muscle cells).2,3 In addition to molecules that 
mediate tight junctions between ECs (eg, occludin and claudins), the adhesive 
interactions in blood vessels involve N-cadherin and VE-cadherin, which mediate 
calcium-dependent, adherens junction-type cell-cell adhesion and inhibit EC 
proliferation and apoptosis by the activation of intracellular signalling cascades.3-8 
While VE-cadherin is the major cadherin expressed at established EC-EC junctions, N-
cadherin is diffusely expressed on the EC surface and is thought to facilitate adhesion in 
nascent EC-EC junctions.9-12 In addition, studies have proposed that N-cadherin may 
co-ordinate endothelial junction maturation by controlling VE-cadherin expression.13 N-
cadherin also plays a major role in the recruitment and adhesion of mural cells to ECs 
on the abluminal surface of blood vessels, which facilitates the remodelling, maturation 
and stabilisation of vascular networks.5,6,14-16 Notably, recent studies have shown that 
perturbation of N-cadherin function can also disrupt established EC-EC and EC-mural 
cell junctions, thereby destabilising vascular integrity.17,18 
Tumour-associated vasculature, essential to cancer cell growth, survival and 
metastasis, is widely recognised and investigated as a potential anti-cancer therapeutic 
target.19,20 In comparison to normal vasculature, tumour-associated vasculature is 
relatively immature and structurally abnormal, characterised by gaps between adjacent 
ECs and loosely-attached or absent pericytes, resulting in a weakened endothelial 
barrier.21-27 These characteristics are also thought to endow tumour-associated 
vasculature with greater sensitivity to vascular-disrupting agents, compared with normal 
vasculature.28,29 The importance of N-cadherin in establishing and maintaining vascular 
stability suggests that inhibition of N-cadherin function is a potential mechanism to 
disrupt tumour vasculature. In support of this, perturbation of N-cadherin function has 
been shown to increase vascular permeability to macromolecules in vitro and in 
vivo.17,18 Indeed, treatment of confluent human umbilical vein-derived EC monolayers 
with the cyclic pentapeptide N-cadherin inhibitor ADH-1 increased permeability to 
FITC-conjugated dextran in vitro.17 Additionally, ADH-1 treatment in a rat melanoma 
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xenograft model increased the permeability of the tumour vasculature to Evans blue dye 
and increased delivery of the chemotherapeutic melphalan to the tumour 
microenvironment.17 In support of these findings, a Phase I/II clinical trial found that 
intravenous ADH-1 treatment, in combination with isolated limb intravenous infusion 
of melphalan improved initial response rates in patients with advanced melanoma, when 
compared with melphalan alone. Notably, 60% of patients receiving the combination 
therapy achieved a partial response or greater, compared with 40% of patients receiving 
melphalan alone. However, the combination did not improve time to disease 
progression, compared with melphalan alone.30,31 While preliminary, these data suggest 
that therapeutic targeting of N-cadherin may increase chemotherapeutic drug delivery to 
the tumour microenvironment and enhance tumour response. 
Synthetic small molecule mimetics of peptide drugs may offer increased 
therapeutic efficacy in comparison to their peptide counterparts, due to enhanced 
proteolytic stability, bio-availability and potency.32,33 LCRF-0006 (compound number 
35 in patent US 7,446,120 B234) was originally identified as a potential ADH-1 mimetic 
in a screen of compounds with three-dimensional structures that were similar to the 
HAV sequence-containing region of ADH-1 (Figure 3.1A,B). LCRF-0006 was 
identified as a non-peptidyl, small molecular weight molecule with a simple chemical 
structure which significantly inhibited neurite outgrowth in N-cadherin over-expressing, 
but not control, NIH/3T3 cells in vitro, suggesting LCRF-0006 inhibits N-cadherin-
dependent processes.34 In the current study, we hypothesised that LCRF-0006 would 
function as a vascular disrupting anti-cancer agent in the haematological malignancy 
multiple myeloma (MM) which is characterised by the uncontrolled proliferation of 
clonal antibody-producing plasma cells within the bone marrow (BM). To this end, we 
evaluated the efficacy of LCRF-0006 as a vascular disrupting agent in vitro and in vivo, 
and as an anti-cancer agent using a well-established pre-clinical mouse model of MM. 
LCRF-0006 was evaluated as a monotherapy and in combination with the proteasome-







Figure 3.1.  The structure of the cyclic pentapeptide ADH-1 (A) and the ADH-1 
peptidomimetic LCRF-0006 (B).  
BA ADH-1 LCRF-0006




3.3.1 Cell culture 
Cell culture reagents were sourced from Sigma-Aldrich (St Louis, MO, USA), unless 
otherwise specified. All media were supplemented with 2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 10mM HEPES buffer, 
unless otherwise stated. The mouse MM plasma cell line 5TGM1 (expressing a dual 
GFP and luciferase reporter construct35,36) was maintained in Iscove's modified 
Dulbecco's medium (IMDM) with 20% foetal calf serum (FCS; Thermo Fisher 
Scientific, Waltham, MA, USA) and supplements (2mM L-glutamine, 100U/ml 
penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] buffer). The human MM 
plasma cell line RPMI-8226 was maintained in Roswell Park Memorial Institute 1640 
(RPMI-1640) with 10% FCS and supplements. The human BM EC line TrHBMEC 
(BMEC)37 was maintained in M199 medium with 20% FCS and supplements (BMEC 
medium), as previously described.38 All cell lines were maintained at 37°C in a 
humidified atmosphere with 5% CO2.  
 
3.3.2 Drugs 
For in vitro experiments, the N-cadherin antagonist LCRF-0006, kindly provided by 
Crocus Laboratories, Montreal, Canada, was solubilised in DMSO (Sigma-Aldrich). For 
in vivo experiments, LCRF-0006 was solubilised in saline containing 40% 2-
hydroxypropyl-β-cyclodextrin (2-HP-β-CD; Sigma). Bortezomib (Janssen-Cilag Pty 
Ltd, New Brunswick, NJ, USA) was reconstituted in 0.028% DMSO for in vitro studies 
and 1.33% DMSO for in vivo studies. 
 
3.3.3 Cell apoptosis assays 
To assess the effect of LCRF-0006 on 5TGM1 cell viability in vitro, 5TGM1 cells were 
cultured at 1x105 cells/ml with LCRF-0006, or vehicle alone, in IMDM with 20% FCS 
and additives in 12-well plates (Corning Life Science, New York, USA). After 3 days, 
1x105 cells/test were washed in IMDM with 20% FCS and additives, then washed and 
resuspended in 20µl annexin V binding buffer (Hank's balanced salt solution with 1% 
HEPES and 5mM CaCl2) containing 0.075µg/ml annexin V-PE (BioLegend; San Diego, 
CA, USA) and 10% (v/v) 7-AAD (Beckman Coulter; Brea, CA, USA) and were stained 
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for 20 minutes in the dark at 4°C. Cells were then diluted with ice-cold 200µl annexin V 
binding buffer and immediately analysed by flow cytometry using an LSRFortessa™ X-
20 flow cytometer (BD; Franklin Lakes, NJ, USA). For single-stained positive controls, 
5TGM1 cells were treated with DMSO (early apoptosis control) or 80% ethanol (dead 
cell control) for 10 minutes. For drug synergy assays, 5TGM1 cells were cultured, as 
described above, in combinations of various concentrations of LCRF-0006 and 
bortezomib. After 24 hours, 1x105 cells from each condition were stained and analysed, 
as described above. Drug synergy was defined as a co-efficient of drug interaction 
(CDI) value of less than 0.7, where CDI was the actual viability of 5TGM1 cells treated 
with the drug combination (AB) divided by their predicted viability (calculated as the 
product of 5TGM1 cell viabilities treated with each drug alone [A*B]). 
To assess the effect of LCRF-0006 on BMEC viability in vitro, BMECs were 
seeded at 1.2x105 cells/well (2.4x105 cells/ml) in BMEC medium in 24-well plates 
(Corning Life Science) and cultured for 24 hours. Confluent BMEC monolayers were 
then cultured with LCRF-0006, or vehicle alone, in M199 medium with 15% FCS and 
supplements (as previously described38). After 24 hours, BMECs were trypsinised and 
1x105 cells/test were washed in M199 medium with 15% FCS and supplements, and 
prepared and analysed for cell viability, as described above.  
 
3.3.4 Endothelial tube disruption assays 
Endothelial tubes were pre-formed on growth factor-reduced Matrigel® matrix in a 96-
well plate by seeding 3.5x104 BMECs in a 50:50 mix of BMEC medium and 
conditioned media from the human MM cell line RPMI-8226 as a stimulant, as 
described previously.39 To investigate the effect of LCRF-0006 on endothelial tube 
integrity, immature (5-hour-old) or established (24-hour-old) endothelial tubes were 
then treated with up 200µg/ml LCRF-0006. Tubes were then imaged over a 24 hour 
period using an Olympus CKX41 inverted microscope and DP21 imaging system 
(Tokyo Japan) and analysed using cellSens Entry 1.11 software (Olympus). 
 
3.3.5 Endothelial monolayer retraction and recovery assay 
BMECs were seeded into gelatinized 96-well plates (5x104 cells/well) and grown to 
confluence over 24 hours. BMECs were then treated with LCRF-0006 in IMDM with 
2% FCS and additives for 1 hour and imaged, as described above. After gently washing 
twice in IMDM with 2% FCS and additives, BMECs were allowed to recover for 1 hour 
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in M199 with 20% FCS and BMEC supplements and again imaged. BMEC monolayer 
confluency was assessed using cellSens Entry 1.11 software. 
 
3.3.6 Endothelial monolayer permeability assay 
BMECs (5x104 cells/well) were seeded onto gelatinized 0.4µm 6.5mm trans-wells 
(Corning Life Science) and grown to confluence over 24 hours. BMECs were then 
treated with LCRF-0006 in IMDM with 2% FCS and additives for 1 hour and gently 
washed twice in serum-free IMDM with additives. To measure endothelial monolayer 
permeability, 1 mg/mL 70 kDa FITC-dextran (Sigma) in phenol red-free IMDM with 
2% FCS and additives was added to the trans-wells and fluorescence in the bottom 
chamber (containing phenol red-free IMDM with 2% FCS and additives) was assessed 
after 1 hour using a FLUOstar® Omega microplate reader (BMG LABTECH; 
Ortenberg, Germany). 
 
3.3.7 Animal studies 
C57Bl/KaLwRij mice (aged 6-8 weeks) were used for all in vivo studies. For MM 
tumour studies, mice were inoculated with 5x105 5TGM1 cells in 100µl phosphate-
buffered saline (PBS) by intravenous injection (i.v.) via the tail vein. Total body tumour 
burden was assessed at days 14, 21 and 28 by bioluminescence imaging (BLI) using a 
Xenogen IVIS 200 imaging system (Perkin Elmer, Waltham, MA, USA), as previously 
described.38 
All animals used for therapy studies were randomised by age, sex and, where 
appropriate, tumour burden. For monotherapy studies, mice were administered LCRF-
0006 (100mg/kg/day) or vehicle alone i.p. (110-150µl volume), commencing 15 
minutes prior to 5TGM1 cell injection or at day 14 following establishment of disease 
until the conclusion of the experiment. For the combination studies, mice with 
established MM disease were administered LCRF-0006 (100mg/kg) or vehicle alone 
i.p. on day 14, followed by 6 cycles of LCRF-0006 and bortezomib combination 
therapy (or relevant vehicle controls) over the remaining 14 days of the experiment. 
Each treatment cycle consisted of LCRF-0006 (100mg/kg) or 2-HP-β-CD vehicle alone 
i.p. followed by low-dose bortezomib (0.5mg/kg)40 or 1.33% DMSO vehicle alone i.p. 1 
hour later. At day 28, cardiac blood was collected into tubes containing 50µl 0.5M 
EDTA (pH 8.0) and complete blood counts were performed using a HEMAVET®950 
automated blood analyzer (Drew Scientific; Miami Lakes, FL). Drug synergy was 
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defined as a co-efficient of drug interaction (CDI) value of less than 0.7, where CDI was 
the actual proportion of tumour remaining in C57Bl/KaLwRij mice treated with the 
drug combination (AB) relative to mice treated with vehicles alone (as assessed by 
BLI), divided by the predicted proportion of tumour remaining (calculated as the 
product of proportion of tumour remaining in C57Bl/KaLwRij treated with each drug 
alone [A*B]). 
 In vivo vascular permeability was assessed using an amended version of 
previously published protocols.41-43 Mice were injected once with 100mg/kg LCRF-
0006 or vehicle alone (as described above). After 1 hour, mice were injected with 
250mg/kg 70 kDa FITC-dextran i.v. via the tail vein and humanely killed 30 minutes 
later. Eyes were immediately enucleated and fixed for 2 hours in 4% PFA. The retinal 
tissues were then isolated44, dissected into maltese-cross formation and flat-mounted 
onto glass slides using Fluoroshield™ mounting medium (Sigma). Extravasated FITC-
dextran was immediately assessed by epi-fluorescence microscopy (Olympus).  
All animal procedures were performed in accordance with guidelines approved by 
the South Australian Health and Medical Research Institute (SAHMRI) Animal Ethics 
Committee (SAM165).   
 
3.3.8 Detection of circulating tumour cells 
Freshly collected blood was transferred to round-bottom polystyrene tubes and red 
blood cells were lysed by three rounds of 10 min incubation in 7.5ml red blood cell lysis 
buffer (0.15M NH4Cl 10mM KHCO3 1.1mM di-sodium EDTA in Milli-Q water) at 
room temperature. Samples were centrifuged for 5 minutes at 1400 rpm, washed once in 
10 ml ice-cold PFE buffer (2% FCS 2mM EDTA in PBS), resuspended in 0.5ml PFE 
buffer and were immediately analysed by flow cytometry using a FACSCanto™ II flow 
cytometer (BD). For gating purposes, a control sample (from a tumour-naïve mouse) 
was spiked with in vitro-cultured 5TGM1 cells. 
 
3.3.9 Cell composition analysis of compact bone 
Compact bone was isolated from the long bones (i.e. femora and tibiae) of both hind 
limbs from humanely killed mice and prepared for analysis of mesenchymal stromal 
cell (MSC) and osteoblast (OB) numbers, as previously described.35 Samples were run 
on a BD LSRFortessa™ X-20 flow cytometer using BD FACSDiva™ software v8.0 
(BD) and analysed using FlowJo V.10.0.8 software (FlowJo, LLC; Ashland, Oregon). 
CHAPTER 3: LCRF-0006 synergistically enhances MM tumour response to bortezomib 
81 
 
Non-haematopoietic cell populations were defined as: Lin-CD45-CD31+ (ECs), Lin-
CD45-CD31-Sca-1+CD51- (MSCs), Lin-CD45-CD31-Sca-1+CD51+ (osteoprogenitors; 
OPs) and Lin-CD45-CD31-Sca-1-CD51+ (OBs).  
 
3.3.10 Statistical analyses 
For in vitro studies, statistical significance was calculated using a one-way ANOVA 
with Dunnett's multiple comparisons test, or two-way ANOVA with Sidak's multiple 
comparisons test. For in vivo studies, statistical significance was calculated using a 
Mann-Whitney U test, Kruskal-Wallis test with Dunn's multiple comparisons test, one-
way ANOVA with Holm-Sidak’s multiple comparisons test or two-way ANOVA with 
Bonferroni's multiple comparisons test. Tumour burden data were log-transformed prior 
to conducting statistical analyses. All statistical analyses were performed using 








3.4.1 LCRF-0006 disrupts EC junctions and increases monolayer permeability at 
sub-cytotoxic doses in vitro 
Previous studies have shown the ability of N-cadherin antagonists to rapidly 
compromise the integrity of confluent EC monolayers, resulting in increased vascular 
permeability in vitro.17,45 In order to assess whether LCRF-0006 can disrupt EC 
monolayers, we treated confluent BMEC monolayers with LCRF-0006 in vitro. 
Initially, we confirmed that LCRF-0006 did not affect the survival of BMECs in vitro, 
using Annexin V (early apoptosis) and 7-AAD (dead cell) staining. The treatment of 
confluent BMEC monolayers with LCRF-0006 for 24 hours had no significant effect on 
BMEC viability in comparison to vehicle-treated monolayers, as assessed by the 
AnnexinVneg 7-AADneg cell population, at concentrations up to 200µg/ml 
(Supplementary Figure 3.1). However, LCRF-0006 induced a dose-dependent 
dissociation of EC-EC contacts, resulting in increased EC rounding and monolayer 
retraction, and decreased monolayer confluency after 1 hour of treatment at 
concentrations of 50µg/ml and greater, when compared with vehicle-treatment (P < 
0.0001; Figure 3.2A,B). Notably, these effects were reversible, as monolayers treated 
with up to 100µg/ml LCRF-0006 completely reformed within 1 hour of removal of 
LCRF-0006 (Figure 3.2A,B). Previous studies have shown that EC retraction, rounding 
and gap formation is associated with increased vascular permeability to macromolecules 
in vitro.46-49 To this end, we assessed the effects of LCRF-0006-mediated BMEC 
monolayer disruption on macromolecular permeability in vitro, using a 70 kDa FITC-
dextran trans-well flow-through assay. The pre-treatment of confluent BMEC 
monolayers with LCRF-0006 for 1 hour significantly increased BMEC monolayer 
permeability to 70 kDa FITC-dextran in a dose-dependent manner, when compared with 
vehicle-treatment (P < 0.05) (Figure 3.2C). 
 
3.4.2 LCRF-0006 disrupts endothelial tube integrity at sub-cytotoxic doses in 
vitro 
We then assessed the effect of LCRF-0006 on pre-formed three-dimensional endothelial 
tubes grown on a basement membrane-like Matrigel® matrix in vitro. Initially, we 
assessed the effect of LCRF-0006 on immature (5-hour-old) endothelial tubes. Vehicle-
treated tubes matured normally into networks of thick tubes with smooth morphology 
Figure 3.2.  LCRF-0006 disrupts BMEC monolayers and increases their 
permeability to 70 kDa FITC-dextran in vitro. Confluent BMEC monolayers in 96-
well plates were treated with LCRF-0006, or vehicle alone, for 1 hour and then imaged. 
After removing LCRF-0006, monolayers were gently washed, allowed to recover for 1 
hour and imaged again. Images shown are representative of 3 independent experiments. 
Scale bars depict 100µm (A). BMEC monolayer confluency quantitated after treatment 
and recovery. Graph depicts mean ± SEM of 3 independent experiments (B). **** P < 
0.0001 compared with monolayers treated with vehicle alone (0µg/ml) #### P < 0.0001 
compared with monolayers after 1 hour of treatment (two-way ANOVA with Sidak's 
multiple comparisons test). Confluent BMEC monolayers established on 0.4µM trans-
well membranes were treated with LCRF-0006, or vehicle alone, for 1 hour. 
Monolayers were then gently washed, 70 kDa FITC-dextran (1 mg/mL) was added to 
the upper chamber of trans-wells and FITC-dextran flow-through was assessed 1 hour 
later by measuring fluorescence in the bottom chamber of triplicate trans-wells. Graph 
depicts mean ± SEM of 3 independent experiments (C). * P < 0.05 compared with 
monolayers treated with vehicle alone (0µg/ml) (one-way ANOVA with Dunnett's 
multiple comparisons test). 
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over 24 hours (Supplementary Figure 3.2A,B). In contrast, concentrations of 100µg/ml 
LCRF-0006 and greater compromised tube maturation, with EC rounding and 
detachment from tubes observed, resulting in a significant reduction in tube thickness 
after 24 hrs (P < 0.0001) (Figure 3.3A and Supplementary Figure 3.2A,B). However, 
addition of LCRF-0006 to immature tubes did not reduce the total length of EC tubes 
after 24 hrs (data not shown). Notably, the initial effects of LCRF-0006 treatment were 
rapid, with BMEC retraction and rounding seen as early as 30 minutes after LCRF-0006 
addition (data not shown), consistent with EC gap formation.46,50,51 LCRF-0006 was 
then added to established (24-hour-old) networks of endothelial tubes. Similar to the 
effects on immature tubes, treatment with 100µg/ml LCRF-0006 and greater for 24 
hours resulted in a loss of tube smoothness and a significant reduction of tube thickness 
(P < 0.0001) (Figure 3.3B and Supplementary Figure 3.3A,B), without affecting tube 
length (data not shown). 
 
3.4.3 LCRF-0006 is well tolerated and increases blood vessel permeability in vivo 
As LCRF-0006 disrupted endothelial integrity and increased permeability in vitro, we 
then postulated that LCRF-0006 may have effects on vascular permeability in vivo, 
consistent with previous findings using N-cadherin antagonists.14,17 Prior to conducting 
vascular permeability experiments, we assessed whether LCRF-0006 had any toxicities 
in C57Bl/KaLwRij mice. Mice treated with 100mg/kg/day LCRF-0006 for 28 days 
tolerated the dosing regimen well with no effects on weight (Supplementary Figure 
3.4A) or other adverse effects observed, in comparison with vehicle-treated animals. In 
addition, complete blood counts in C57Bl/KaLwRij mice were unaffected by 28 days of 
LCRF-0006 treatment, in comparison with vehicle-treated, or un-treated, mice 
(Supplementary Table 3.1). Given that N-cadherin plays a role in OB differentiation52-
55, we also assessed whether LCRF-0006 affected the proportion of MSCs, OPs and 
OBs within the long bones of LCRF-0006-treated C57Bl/KaLwRij mice. The 
proportion of MSCs, OPs and OBs within the Lin-CD45-CD31- fraction of compact 
bone isolated from the long bones was unaffected by 28 days of LCRF-0006 treatment, 
when compared with that of vehicle-treated animals (Supplementary Figure 3.4B-D). In 
addition, LCRF-0006 did not affect the proportion of CD31+ ECs within the Lin-CD45- 
fraction of compact bone or BM, relative to that of vehicle-treated controls 
(Supplementary Figure 3.4E,F). In line with these findings, histological analysis 
Figure 3.3.  LCRF-0006 disrupts immature and established endothelial tubes in 
vitro. BMECs were cultured on growth factor-reduced Matrigel® matrix in a 96-well 
plate and endothelial tube formation was induced using a 50:50 mix of BMEC culture 
medium and RPMI-8226 conditioned medium. Immature (5-hour-old) (A) or 
established (24-hour-old) (B) tubes were treated with LCRF-0006 for 24 hours, imaged 
and mean tube thickness was quantitated. Images shown are representative of 2 
independent experiments. Scale bars depict 250µm. Graphs depict mean ± range of 2 
independent experiments. * P < 0.05 ** P < 0.01 *** P < 0.001 **** P < 0.0001 
compared with tubes treated with vehicle alone (0µg/ml) (one-way ANOVA with 
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revealed LCRF-0006 had no overt effects on blood vessel number or vascular 
morphology (data not shown). 
Fluorescence angiography of the retina is an established technique used to rapidly 
investigate vascular perfusion and permeability in response to cytokines and other 
agents in rodent models.41,42 To this end, we performed whole-mount retinal 
fluorescence angiography to assess the effect of LCRF-0006 on FITC-dextran 
extravasation in vivo. C57Bl/KaLwRij mice were infused with 70 kDa FITC-dextran 1 
hour after a single treatment with 100mg/kg LCRF-0006 or vehicle alone and, 30 
minutes later, whole mounts of the retinas were prepared for fluorescence imaging. 
Sites of retinal peri-vascular hyper-fluorescence, indicative of blood vessel leakiness, 
were only observed in mice pre-treated with LCRF-0006 (3/4 LCRF-0006-treated mice 
vs. 0/4 vehicle-treated mice) (Figure 3.4A-D).  
 
3.4.4 LCRF-0006 and low-dose bortezomib combination therapy synergistically 
induces tumour regression in mice with established MM disease 
Previous studies have reported the efficacy of ADH-1 to inhibit tumour establishment 
and growth in a range of pre-clinical mouse models including pancreatic cancer, lung 
cancer and MM.38,56,57 In addition to disrupting tumour-associated vasculature17,57, 
ADH-1 has been shown to induce apoptosis in several N-cadherin-expressing cancer 
cell types in vitro56,58,59 suggesting that N-cadherin antagonism may suppress tumour 
progression by targeting both tumour cells and the associated vasculature. To this end, 
we investigated the efficacy of LCRF-0006 as an anti-cancer agent in a pre-clinical 
mouse model of MM. Initially, we assessed the effect of LCRF-0006 treatment on the 
viability of the N-cadherin-expressing mouse myeloma cell line 5TGM1 in vitro. 
LCRF-0006 treatment significantly induced 5TGM1 cell apoptosis at concentrations of 
25µg/ml and greater after 72 hours (P < 0.01; IC50= 53.03µg/ml) (Figure 3.5A). 
However, daily treatment of 5TGM1 tumour-bearing C57Bl/KaLwRij mice with 
100mg/kg LCRF-0006 had no effect on tumour burden, as assessed by BLI, compared 
with vehicle-treated controls (Figure 3.5B). In addition, LCRF-0006 had no significant 
effect on the proportion of circulating tumour cells within the leukocyte fraction of 
peripheral blood at day 28 (Supplementary Figure 3.5A). Similar to MM tumour-naïve 
mice, LCRF-0006 did not affect the proportion of CD31+ ECs within the Lin-CD45- 
fraction of compact bone or BM in mice with established disease, relative to vehicle-
treated controls (Supplementary Figure 3.5B,C). 
Figure 3.4.  LCRF-0006 increases vascular permeability to 70 kDa FITC-dextran 
in vivo. C57BL/KaLwRij mice were injected with 250mg/kg 70 kDa FITC-dextran i.v., 
1 hour  after a single injection of 100mg/kg LCRF-0006 or vehicle (2-HP-β-CD [CD]) 
alone i.p., and humanely killed 30 minutes later. After fixation of eyes, the retinal 
tissues were isolated, flat-mounted and immediately assessed for fluorescence using epi-
fluorescence microscopy. Representative epi-fluorescence images of vehicle-treated 
mice (A,B) and LCRF-0006-treated mice (C,D) are shown. Sites of peri-vascular 












Figure 3.5.  LCRF-0006 monotherapy induces 5TGM1 MM PC apoptosis in vitro 
but does not inhibit tumour progression in vivo. The viability of 5TGM1 cells 
following in vitro culture in the presence of LCRF-0006 for 72 hours was assessed by 
flow cytometry following annexin V and 7-AAD staining. Graph depicts mean ± SEM 
of 3 independent experiments (A). * P < 0.05 ** P < 0.01 *** P < 0.001 compared with 
5TGM1 cells treated with vehicle alone (0µg/ml) (one-way ANOVA with Dunnett's 
multiple comparisons test). C57BL/KaLwRij mice with established MM (day 14 post-
5TGM1 cell injection) were treated with LCRF-0006 (100mg/kg/day) or vehicle (CD) 
alone i.p. for 14 days. Tumour burden was assessed at day 14, 21 and 28 by BLI. Graph 
depicts mean ± SEM. n = 12 mice/treatment group (B). Data are not statistically 
significant (two-way ANOVA). 
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Previous studies have additionally demonstrated that ADH-1 administration 
increases the delivery of chemotherapeutic drugs and Evans blue dye to tumour sites 
suggesting that N-cadherin antagonism increases vascular permeability.17 In light of the 
increased vascular permeability observed with LCRF-0006 treatment in vitro and in 
vivo, we speculated that LCRF-0006 may enhance the delivery of anti-cancer drugs to 
tumour sites in vivo, thereby increasing drug efficacy. To this end, MM tumour-bearing 
C57Bl/KaLwRij mice were administered 3 cycles of combination therapy per week for 
2 weeks, whereby 1 cycle consisted of LCRF-0006 (100mg/kg) followed by a low dose 
of the anti-MM agent bortezomib (0.5mg/kg) 1 hour later (Figure 3.6A). The 
combination therapy regimen was well tolerated by mice with no adverse welfare 
effects. Notably, low-dose bortezomib and the combination of LCRF-0006 and low-
dose bortezomib did not affect the proportion of MSCs, OPs and OBs within the Lin-
CD45-CD31- fraction of compact bone isolated from the long bones, when compared 
with vehicle-treated animals (data not shown). Strikingly, while neither low-dose 
bortezomib nor LCRF-0006 alone significantly affected tumour burden, mice which 
received the combination of LCRF-0006 and low-dose bortezomib had significantly 
lower tumour burden at days 21 and 28 compared with mice treated with bortezomib 
alone, LCRF-0006 alone or vehicles only (all P < 0.001) (Figure 3.6B-C). Notably, the 
combination therapy also resulted in regression of tumour burden in 5/5 mice at day 28, 
with 2/5 mice administered the combination therapy having no BLI-detectable tumour 
at the conclusion of the study. Analysis of peripheral blood collected at day 28 revealed 
that mice administered the combination therapy had significantly fewer residual 
circulating tumour cells than mice treated with vehicles alone, LCRF-0006 alone or 
low-dose bortezomib alone (all P < 0.0001) (Figure 3.6D). CDI revealed synergism in 
the anti-MM effects of LCRF-0006 and low-dose bortezomib (at days 21 and 28) 
(Figure 3.6E). 
 
3.4.5 LCRF-0006 and bortezomib synergistically induce 5TGM1 cell apoptosis in 
vitro 
While we speculate that the synergistic effects observed in vivo may in large part be 
mediated by LCRF-0006-enhanced tumour delivery of bortezomib, previous studies 
have also demonstrated the ability of ADH-1 to enhance tumour response to 
chemotherapeutic agents independently of increasing drug delivery to tumours.17 To this 
end, we investigated the effect of LCRF-0006 in combination with bortezomib on 
Figure 3.6.  The combination of LCRF-0006 and low-dose bortezomib 
synergistically increases MM tumour response in vivo. Schematic representation of 
treatment regimen (A). C57BL/KaLwRij mice with established MM (day 14 post-
5TGM1 cell injection) were treated with LCRF-0006 (100mg/kg) and low-dose 
bortezomib (0.5mg/kg) (LCRF-0006 + bortezomib), LCRF-0006 and DMSO vehicle 
(LCRF-0006), CD vehicle and low-dose bortezomib (bortezomib) or CD and DMSO 
vehicles (vehicles) i.p., as per treatment regimen. Tumour burden was assessed at day 
14, 21 and 28 by BLI. Graph depicts mean ± SEM. n = 5-6 mice/treatment group (B). 
*** P < 0.001 **** P < 0.0001 compared with mice treated with LCRF-0006, low-dose 
bortezomib or vehicles (two-way ANOVA with Bonferroni's multiple comparisons 
test). Images depict tumour burden in individual mice at day 28, as assessed by BLI (C). 
Peripheral blood was collected from mice at day 28 and the proportion of circulating 
tumour cells within the leukocyte fraction was assessed by flow cytometry. Graph 
depicts mean ± SEM. n = 5-6 mice/treatment group (D). ** P < 0.01 **** P < 0.001 
(one-way ANOVA with Holm-Sidak’s multiple comparisons test). The co-efficient of 
drug interaction (CDI) was calculated using BLI data at day 21 and 28, and the 
proportion of circulating tumour cells (CTCs) within the leukocyte fraction of 
peripheral blood at day 28, to assess drug synergy. CDI < 0.7 (shown in shaded text) 
indicates drug synergy (E).  
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induction of 5TGM1 cell apoptosis in vitro, as assessed by Annexin V and 7-AAD 
staining. Initially, we determined the doses of LCRF-0006 (25-150µg/ml) and 
bortezomib (1-7nM) which individually had minimal to moderate pro-apoptotic effects 
on 5TGM1 cells, after 24 hrs (Figure 3.7A,B). Significantly, we found that LCRF-0006 
and bortezomib had synergistic effects on 5TGM1 cell apoptosis, with LCRF-0006 
concentrations of 50µg/ml and above enhancing the sensitivity of 5TGM1 cells to 
bortezomib, after 24 hrs (CDI < 0.7) (Figure 3.7C,D). 
Figure 3.7.  LCRF-0006 synergistically increases bortezomib-induced 5TGM1 MM 
PC apoptosis in vitro. The viability of 5TGM1 cells following in vitro culture in the 
presence of increasing concentrations of LCRF-0006 (A) or bortezomib (B) for 24 
hours was assessed by flow cytometry following annexin V and 7-AAD staining. 
Graphs depict mean ± SEM of 3 independent experiments. * P < 0.05 ** P < 0.01 *** P 
< 0.001 compared with 5TGM1 cells treated with vehicle alone (0µg/ml) (one-way 
ANOVA with Dunnett's multiple comparisons test). Graphical representation of 
5TGM1 cell viability following in vitro culture in the presence of bortezomib and 
increasing concentrations of LCRF-0006 simultaneously for 24 hours (as assessed by 
flow cytometry following Annexin V and 7-AAD staining), relative to 5TGM1 cells 
treated with vehicle alone (C). Data is representative of 3 independent experiments. The 
co-efficient of drug interaction (CDI) was calculated using the relative viability of 
5TGM1 cells after 24 hours to assess drug synergy. CDI < 0.7 (shown in shaded text) 











































1 3 5 7 
25 0.97 0.91 0.80 0.74 
50 0.95 0.68 0.38 0.32 
100 0.92 0.23 0.18 0.19 















































































Tumour-associated vasculature is structurally abnormal, characterised by gaps between 
adjacent ECs and loosely attached or absent mural cells.22,28,60 These structural 
abnormalities, in addition to the disorganised, tortuous nature of tumour-associated 
vasculature, and the defective lymphatic drainage in tumours, result in abnormal 
pressure gradients and heterogeneous perfusion which can limit drug delivery to the 
tumour.19,60,61 Paradoxically, however, the compromised EC barrier of tumour-
associated vasculature is thought to mediate the passive and selective extravasation of 
macromolecules (> 40 kDa) into interstitial tumour spaces.23-27,62,63 Furthermore, the 
paucity of lymphatic drainage is considered to increase the retention of macromolecular 
drugs at the tumour site.63,64 Collectively, this phenomenon is known as the enhanced 
permeability and retention (EPR) effect.62,63 One hypothesised approach to increase the 
efficiency of tumour delivery of macromolecular drugs, or drug complexes, is by 
augmentation of the EPR effect.62,63,65 Pre-clinical studies have demonstrated that 
factors such as angiotensin II and nitric oxide can rapidly increase macromolecular 
extravasation in tumours by increasing tumour blood flow, thereby improving tumour 
delivery of, and response to, macromolecular drugs and drug complexes.66-70 Indeed, a 
nitric oxide delivery system which augments the EPR effect was recently shown to 
increase the anti-cancer efficacy of nanoparticle albumin-bound paclitaxel (Abraxane®) 
in several pre-clinical cancer models, including a colon cancer model possessing 
inherently high vascular permeability and a melanoma model characterised by 
inherently low vascular permeability.68,71 Notably, recent studies have demonstrated the 
efficacy of the N-cadherin antagonist ADH-1 to increase EC permeability in vitro, and 
rapidly enhance tumour blood vessel permeability to macromolecules in vivo, as 
demonstrated by the accumulation of albumin conjugated-Evans blue dye in melanoma 
tumours of mice treated with ADH-1. Moreover, ADH-1 improved melanoma tumour 
uptake of, and response to, the chemotherapeutic agent melphalan, which displays high 
affinity for plasma proteins.17,72 Taken together, these studies suggest that N-cadherin 
antagonists may increase the delivery of plasma protein-bound drugs to tumours by 
increasing the permeability of tumour-associated vasculature, thereby improving tumour 
response to chemotherapy.17 
 The primary objective of the current study was to evaluate the efficacy of a 
small molecule peptidomimetic of ADH-1, LCRF-0006, as a novel vascular disrupting 
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agent and to assess its ability to increase the effectiveness of the anti-MM agent 
bortezomib73,74 in a pre-clinical model of MM. We have demonstrated that LCRF-0006 
is a vascular disrupting agent which increases blood vessel permeability to 
macromolecules, as evidenced by LCRF-0006-mediated extravasation of 70 kDa FITC-
dextran in retinal tissues. Mechanistically, our in vitro studies using BMECs suggest 
that LCRF-0006 enhances vascular permeability by directly inducing the retraction of 
endothelial monolayers, thereby facilitating para-cellular macromolecule transport. It is 
well established that N-cadherin mediates the recruitment and adhesion of mural cells to 
the abluminal surface of ECs, which stabilises blood vessel integrity and modulates 
barrier function.5,6,14,15,18 Indeed, recent studies using three-dimensional bio-engineered 
microvessels suggest that abrogation of N-cadherin-mediated mural cell attachment to 
endothelial cells also enhances endothelial barrier permeability to macromolecules.18 As 
retinal microvessels have a relatively high pericyte coverage75, it is possible that LCRF-
0006 may also compromise endothelial barrier function by disrupting EC-mural cell 
interactions. 
 The observation that disrupted BMEC monolayers recovered in vitro following 
removal of LCRF-0006 suggests that the effects of LCRF-0006 on ECs are transient and 
reversible, in line with the proposed role of N-cadherin in endothelial barrier 
closure.76,77 Moreover, the disruptive effects of LCRF-0006 are not a consequence of 
EC apoptosis which may eventuate in vessel collapse. This is consistent with our 
findings that LCRF-0006 did not affect the EC composition of long bones or the overall 
vascular architecture of the bone marrow, either in the normal or malignant setting. 
Thus, the effects of LCRF-0006 differ from those of vascular disrupting agents such as 
microtubule-depolymerizing agents which induce necrosis of tumour-associated 
vasculature.28,51,78 Importantly, we also observed that the initial effects of LCRF-0006 
on EC retraction and rounding were more rapid in immature endothelial tubes than 
established tubes. As tumour-associated vasculature is considered to be relatively 
immature, in comparison to normal blood vessels28,29, these findings suggest that 
tumour-associated vasculature may have increased sensitivity to LCRF-0006-mediated 
disruption, compared with normal blood vessels. 
The anti-MM agent bortezomib, used as induction therapy, maintenance therapy, 
and in the relapse setting73,74,79,80, is a small, dipeptide boronic acid which becomes 
highly bound to plasma proteins upon clinical administration.81 On the basis of previous 
reports that ADH-1 increased melanoma tumour delivery of, and response to, 
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melphalan, which similarly has high plasma protein affinity17,72, we speculated that 
LCRF-0006 may enhance MM tumour delivery of bortezomib. Although LCRF-0006 
did not display single-agent anti-tumour efficacy in the C57Bl/KaLwRij/5TGM1 MM 
model, LCRF-0006 in combination with a sub-therapeutic dose of bortezomib induced a 
synergistic response in mice with established tumours, with tumour regression achieved 
in all animals. Importantly, the combination therapy was well tolerated with no adverse 
effects observed on animal welfare.  
While we speculate that the synergistic effects may, at least in part, be mediated 
by enhanced tumour delivery of bortezomib facilitated by LCRF-0006, potentially by 
augmentation of the EPR effect, N-cadherin antagonists may directly enhance tumour 
response to chemotherapeutic agents. For example, ADH-1 has previously been shown 
to significantly increase melanoma tumour response to the chemotherapeutic agent 
temozolamide in vivo, without altering tumour up-take of the drug.17 Consistent with 
these findings, our in vitro drug combination assays provide evidence that LCRF-0006 
and bortezomib can synergistically induce apoptosis in 5TGM1 cells, which may further 
contribute to the synergism observed in vivo. One potential mechanism by which 
LCRF-0006 and bortezomib may synergistically induce MM tumour cell apoptosis is by 
differential inhibition of the Bcl-2-family pro-survival proteins Bcl-2 and Mcl-1, shown 
to mediate MM tumour cell survival.82-85 Proteasome inhibition by bortezomib is 
thought to induce MM tumour cell apoptosis by increasing the expression of NOXA 
which neutralizes and degrades Mcl-1.86-89 In contrast, N-cadherin engagement has been 
shown to activate Bcl-2 by enhancing PI3K/Akt-mediated phosphorylation of the pro-
apoptosis protein Bad.90-92 Thus, LCRF-0006 may potentially inhibit the 
phosphorylation of Bad, resulting in inactivation of Bcl-2. Recent studies have also 
shown that N-cadherin potentiates prostate cancer cell resistance to metformin by 
activation of NF-кB signalling, which could be inhibited by perturbation of N-cadherin 
function.93 In light of this, LCRF-0006 may decrease activation of NF-кB signalling in 
5TGM1 cells, a pathway implicated in chemotherapeutic resistance of human MM 
cells94-97, thereby increasing sensitivity to bortezomib.  
In addition, it is also possible that LCRF-0006 may disrupt the physical 
engagement of MM cells with the BM microenvironmental niche, known to play critical 
roles in MM cell growth, proliferation and resistance to chemotherapeutic agents.98-101 
N-cadherin is expressed by numerous cell types within the BM milieu, including MSCs 
and OBs, and mediates MM tumour cell adhesion to OBs.52,53,102,103 Moreover, N-
CHAPTER 3: LCRF-0006 synergistically enhances MM tumour response to bortezomib 
90 
 
cadherin expression in MM tumour cells is a negative regulator of OB differentiation, 
which may potentiate tumour growth by maintaining the MSC pool.52,104 Our analyses 
revealed that LCRF-0006 treatment did not affect the relative proportion of MSCs, OPs 
and OBs within the long bones of MM tumour-bearing or tumour-naïve 
C57Bl/KaLwRij mice, which is consistent with our observed lack of single-agent 
LCRF-0006 efficacy to inhibit MM tumour growth in vivo. However, given the ability 
of N-cadherin antagonists to overcome BM stromal cell-mediated leukaemic cell 
resistance to chemotherapeutic agents105,106, we cannot exclude the possibility that 
LCRF-0006 treatment may disrupt MM tumour cell interactions with the supportive BM 
niche in vivo, thereby increasing tumour cell sensitivity to bortezomib. Importantly, 
while bortezomib has known bone anabolic effects in the clinical setting107,108, low-dose 
bortezomib did not affect the relative cellular composition of compact bone tissue. 
Thus, it is unlikely that low-dose bortezomib indirectly alters 5TGM1 cell response to 
LCRF-0006 therapy by modifying the endosteal BM niche.      
Despite significant progress in the development of novel therapeutic agents and 
effective combination strategies over the past decade, MM is still largely considered to 
be incurable with most patients relapsing and ultimately succumbing to the disease.79 
Notably, there is increasing evidence, both in vitro and in pre-clinical animal models, 
that N-cadherin antagonism represents a potential approach to increase the efficacy of 
chemotherapeutic agents.17,72,105,106 However, these findings have not been fully 
replicated in Phase I/II clinical trials to date.30,31 Given synthetic small molecule 
peptidomimetics may offer increased therapeutic efficacy over their peptide 
counterparts32,33, the use of an ADH-1 peptidomimetic is a rational proposition to 
potentially improve clinical efficacy. In the current study, we report that the small 
molecule ADH-1 mimetic LCRF-0006 is a novel vascular disrupting agent which 
increases vascular permeability in vitro and in vivo. Our findings demonstrate the 
potential clinical utility of LCRF-0006 in a combinatorial approach to significantly 
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Supplementary Figure 3.1.  LCRF-0006 does not affect the viability of BMECs 
after 24 hours in vitro. Confluent BMEC monolayers grown in vitro in 24-well plates 
were treated with LCRF-0006, or vehicle alone, for 24 hours. BMECs were then 
trypsinised and cell viability was assessed by flow cytometry using annexin V and 7-
AAD staining. Graph depicts mean ± SEM of 3 independent experiments. Data are not 














































Supplementary Figure 3.2.  Time-course of the effect of LCRF-0006 on immature 
(5-hour-old) endothelial tubes. BMECs were cultured on growth factor-reduced 
Matrigel® matrix supplemented with RPMI-8226 conditioned medium. Tubes were 
allowed to form for 5 hours and were then treated with LCRF-0006 and imaged after 0, 
5 and 24 hours (hrs). Images are representative of 2 independent experiments. Scale 





























Supplementary Figure 3.3.  Time-course of the effect of LCRF-0006 on established 
(24-hour-old) endothelial tubes. BMECs were cultured on growth factor-reduced 
Matrigel® matrix supplemented with RPMI-8226 conditioned medium. Tubes were 
allowed to form for 24 hours and were then treated with LCRF-0006 and imaged after 
0, 5 and 24 hours (hrs).  Images are representative of 2 independent experiments. Scale 





























Supplementary Figure 3.4.  Assessment of LCRF-0006 effects on non-tumour-
bearing C57Bl/KaLwRij mice. C57Bl/KaLwRij mice were treated with 100mg/kg 
LCRF-0006, or vehicle (CD) alone, by i.p. injection daily for 28 days. Animal weights 
are shown. Graph depicts mean ± SEM. n = 8 mice/treatment group (A). Data are not 
statistically significant (two-way ANOVA). After 28 days, the long bones were isolated 
and the proportion of MSCs (Sca-1+CD51-) (B), OPs (Sca-1+CD51+) (C) and OBs (Sca-
1-CD51+) (D) within the Lin-CD45-CD31- fraction of compact bone (CB) was 
quantified. The EC (CD31+) composition of the non-haematopoietic (Lin-CD45-) 
fraction of CB (E) and bone marrow (BM) (F) was also quantified. Graphs depict mean 
± SEM. n = 8 mice/treatment group. Data are not statistically significant (Mann-




































































































































































Supplementary Figure 3.5.  Assessment of LCRF-0006 effects in tumour-bearing 
C57Bl/KaLwRij mice. C57BL/KaLwRij mice with established MM (day 14 post-
5TGM1 cell injection) were treated with LCRF-0006 (100mg/kg/day) or vehicle (CD) 
alone i.p. for 14 days. The proportion of circulating tumour cells within the leukocyte 
fraction of peripheral blood collected from mice at day 28 was assessed by flow 
cytometry. Graph depicts mean ± SEM. n = 12 mice/treatment group (A). The EC 
(CD31+) composition of the non-haematopoietic (Lin-CD45-) fraction of compact bone 
(CB) from the long bones (B), and bone marrow (BM) (C), was quantified. Graphs 
depict mean ± SEM. n = 5-9 mice/treatment group. Data are not statistically significant 


































































































Supplementary Table 3.1  Complete blood counts of C57Bl/KaLwRij mice1
following 28-day 100mg/kg/day LCRF-0006 treatment                                                                                           
WBCs (K/µl) 5.92 ± 0.35 4.99 ± 0.57 5.49 ± 0.61 n.s.
Neutrophils (K/µl) 1.05 ± 0.18 0.68 ± 0.11 1.02 ± 0.18 n.s.
Lymphocytes (K/µl) 4.54 ± 0.18 4.05 ± 0.44 4.15 ± 0.37 n.s.
Monocytes (K/µl) 0.25 ± 0.04 0.18 ± 0.03 0.17 ± 0.04 n.s.
Eosinophils (K/µl) 0.07 ± 0.03 0.06 ± 0.02 0.11 ± 0.04 n.s.
Basophils (K/µl) 0.02 ± 0.01 0.02 ± 0.01 0.04 ± 0.01 n.s.
RBCs (M/µl) 7.59 ± 0.20 7.97 ± 0.10 7.83±0.13 n.s.
Hemoglobin (g/dl) 9.13 ± 0.14 9.55 ± 0.09 9.53 ± 0.14 n.s.
Hematocrit (%) 37.96 ± 0.99 39. 2± 0.39 39.0 ± 0.63 n.s.
MCV (fl) 50.08 ± 0.29 49.2 ± 0.17 49.8 ± 0.21 n.s.
MCH (pg) 12.05 ± 0.19 12.0 ± 0.13 12.2 ± 0.14 n.s.
MCHC  (g/dl) 24.09 ± 0.44 24.4 ± 0.21 24.4 ± 0.33 n.s.
RDW (%) 16.41 ± 0.22 15.9 ± 0.20 16.9 ± 0.65 n.s.
Platelets (M/µl) 0.74 ± 0.06 1.05 ± 0.07 0.99 ± 0.09 n.s.
MPV (fl) 4.79 ± 0.16 4.95 ± 0.06 5.10 ± 0.15 n.s.
1 11-12 weeks of age at the �me of cardiac bleed
2 mean ± SEM
3 Kruskal-Wallis test (with Dunn's mul�ple comparisons test)
WBCs (white blood cells), RBCs (red blood cells), MCV (mean corpuscular volume), MCH 
(mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentra�on), 
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(5m & 3f)
n =8               
(4m & 4f)
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Multiple myeloma (MM) is a largely incurable haematological malignancy 
characterised by the abnormal proliferation of immunoglobulin-producing plasma cells 
(PCs) within the bone marrow (BM). We have previously shown that expression of the 
homophilic cell-cell adhesion molecule N-cadherin (CDH2) is up-regulated in MM PCs 
in approximately 50% of newly-diagnosed MM patients and is associated with inferior 
patient prognosis. To date, the key drivers of aberrant N-cadherin expression in MM 
PCs are not fully understood. While 10-15% of CDH2-expressing MM cases are 
associated with the chromosomal translocation t(4;14)+, suggesting expression may be 
driven by the dysregulated oncogenes MMSET or FGFR3, an additional 35-40% of 
newly-diagnosed patients also express CDH2 despite having t(4;14)- status. Here, we 
combined bioinformatic analyses of publicly available microarray data from newly-
diagnosed MM patients with in vitro studies in human MM cell lines to confirm that 
MMSET is a key driver of CDH2 expression in t(4;14)+ MM. Additionally, we 
performed in silico analyses incorporating microarray data from over 900 MM patients 
to identify potential novel regulators of CDH2 in t(4:14)- MM. These analyses revealed 
more than 200 genes which were significantly correlated with CDH2 in t(4:14)- MM. 
These included the putative transcriptional regulator BTBD3, which positively 
correlated with CDH2 levels, and upstream modulators of the JAK/STAT3 signalling 
cascade (IL6ST, BTF3 and SGPL1). Furthermore, these analyses identified 8 miRNAs, 
including miR-190, which inversely associated with CDH2 expression and therefore 
may negatively regulate CDH2 levels in t(4:14)- MM. BTBD3 was selected for further 
investigation as a candidate driver of CDH2 expression as almost all t(4:14)- CDH2high 
MM patients expressed BTBD3, and that BTBD3 was strongly up-regulated in BM MM 
PCs, compared with normal BM PCs. While our BTBD3 over-expression and knock-
down studies suggest that BTBD3 is unlikely to be a key driver of CDH2 expression in 
t(4:14)- MM, this work provides insight into potential N-cadherin regulatory 
mechanisms in t(4;14)- MM and reveals a number of regulatory candidates which 
warrant future investigation. Given that the up-regulation of BTBD3 expression is 
associated with a trend towards poorer overall survival in t(4:14)- MM patients, the 
potential role of BTBD3 in MM pathogenesis also warrants investigation.   




Multiple myeloma (MM) is the second-most common haematological malignancy after 
non-Hodgkin lymphoma, with approximately 1,700 new cases diagnosed in Australia 
each year.1 MM is characterised by the uncontrolled proliferation of immunoglobulin-
producing plasma cells (PCs) within the bone marrow (BM) leading to clinical 
manifestations such as osteolytic bone lesions, hypercalcaemia, renal insufficiency and 
anaemia. Chromosomal abnormalities including hyperdiploidy (eg. gain of chromosome 
3, 7, 9, 11, 15, 17 and 19) and translocations involving the immunoglobulin heavy chain 
(IGH) switch region on chromosome 14 encompass the primary initiating events of MM 
disease, leading to the aberrant up-regulation and activation of oncogenes such as 
MMSET (encoding the histone-modifying enzyme MMSET [also known as NSD2 and 
WHSC1]), the transcription factors MAF and MAFB, and D-group cyclins. Together 
with the acquisition of additional genetic lesions, these mutations lead to dysregulated 
cell signalling and result in aberrant PC growth, survival and behavioural 
characteristics, thereby driving MM pathogenesis and disease progression.2,3 
 N-cadherin (CDH2) is a calcium-dependent, adherens junction-type homophilic 
cell-cell adhesion and signalling molecule expressed by numerous cell types (e.g. 
neuronal cells, osteoblasts, endothelial cells and myocytes) which contributes to a 
variety of cellular processes including polarity establishment, migration and survival.4-13 
In epithelial cancers, the up-regulation or de novo expression of N-cadherin is widely 
associated with tumour invasiveness and metastasis and inferior patient prognosis.14-24 
In addition, there is an emerging body of evidence that N-cadherin is aberrantly 
expressed in haematological malignancies, particularly playing a role in tumour cell 
dissemination and chemotherapeutic resistance.25-33 In MM, N-cadherin gene and 
protein expression in CD138+ BM PCs is up-regulated in approximately 50% of newly-
diagnosed patients.25,26 Studies have also shown that CDH2 up-regulation in BM MM 
PCs and increased circulating N-cadherin levels (which correlate with CDH2 expression 
in BM MM PCs) at clinical diagnosis are significantly associated with inferior MM 
patient prognosis.25 N-cadherin is strongly implicated in the BM-homing capacity of 
circulating MM PCs, thereby facilitating dissemination.26 N-cadherin may also 
contribute to MM-associated bone disease by facilitating MM PC-mediated inhibition 
of osteoblast differentiation.26 However, while the deleterious implications of elevated 
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N-cadherin expression in MM are increasingly apparent, the key drivers of aberrant N-
cadherin expression in MM PCs are not fully understood. 
 Microarray analyses have previously demonstrated that CDH2 is highly 
expressed in approximately 90% of MM patients harbouring the chromosomal 
translocation t(4;14)(p16;q32), a genetic lesion observed in 10-15% of newly-diagnosed 
patients with intermediate to high-risk disease.26,34-36 This translocation involves a 
breakpoint in the IGH switch region and a breakpoint region between the genes MMSET 
and FGFR3 on chromosome 4, resulting in MMSET and FGFR3 being placed under the 
influence of strong IGH gene enhancers.37 MMSET is universally over-expressed in 
t(4;14)+ MM patients, whereas FGFR3 over-expression is lost in approximately 30% of 
cases. Notably, t(4;14)+ status in MM is an adverse prognostic factor, independent of 
FGFR3 expression, suggesting MMSET dysregulation is likely to be a primary mediator 
of oncogenesis in this sub-group of patients.35 MMSET encodes for the histone 
methyltransferase, MMSET, which is associated with a global H3K36me2/K27me3 
switch resulting in a more open chromatin structure favouring gene activation and 
promoting tumourigenesis.38-40 Indeed, targeted disruption of the translocated MMSET 
allele in the t(4;14)+ human MM cell line (HMCL) KMS-11 has been shown to inhibit 
MM PC clonogenicity in vitro and tumorigenicity in vivo.40,41 Notably, studies have also 
demonstrated that MMSET silencing reduces the expression of several adhesion 
molecule-encoding genes in KMS-11 cells including CDH2 41, suggesting MMSET may 
be a primary driver of N-cadherin expression in t(4;14)+ MM. 
 In addition to t(4;14)+ MM patients, CDH2 is also up-regulated in approximately 
40% of newly-diagnosed t(4;14)- patients.26 In particular, a distinct population of 
CDH2-overexpressing MM patients is observed in the hyperdiploidy sub-group.26 
Owing to the heterogeneity and lack of known genetic initiators of hyperdiploidy-
associated MM disease3, little is known regarding the potential mechanism(s) 
responsible for elevated CDH2 expression in these patients. Interestingly, CDH2 is also 
up-regulated at low frequency in other t(4;14)- MM subgroups harbouring a variety of 
primary genetic lesions.26 In addition to validating the dysregulated expression of 
MMSET as a key driver of up-regulated CDH2 in MM, the aim of the study was to 
reveal potential regulators of CDH2 expression in t(4;14)- MM by the identification of 
genes which significantly correlate with CDH2 expression in t(4;14)- MM patients, 
using publicly available microarray data. In silico analysis was also performed to 
identify potential microRNAs (miRNAs) which may additionally regulate N-cadherin 
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levels in t(4;14)- MM. In addition, we investigated the role of a putative transcriptional 
regulator emanating from our correlative studies, BTB/POZ domain-containing protein 


































4.3.1 In silico analysis of microarray datasets 
For analysis of gene expression in CD138-purified BM PCs from newly-diagnosed MM 
or monoclonal gammopathy of undetermined significance (MGUS) patients, or normal 
controls, 5 independent microarray datasets were used: E-MTAB-363 (MM, n = 155; 
MGUS, n = 5; normal, n = 5)42, E-GEOD-19784 (MM, n = 368)43, E-GEOD-26863 
(MM, n = 304)44, E-MTAB-317 (MM, n = 227)45 and GSE4581 (MM, n = 414)46. For 
gene expression analysis in the HMCL KMS-11 following MMSET silencing, 3 
microarray datasets were used: GSE2914847, GSE5007240 and GSE2474639. For 
GSE4581, MAS5-normalised data were downloaded from Gene Expression Omnibus 
(GEO; NCBI) and log2 normalised prior to analysis. For all other datasets, CEL files 
from Affymetrix Human Genome U133 Plus 2.0 cDNA microarrays were downloaded 
from GEO or ArrayExpress (EMBL-EBI), and were processed using RMA as 
previously described.48-50 Analysis of overall survival in MM patients stratified on the 
basis of CD138+ BM PC gene expression at diagnosis was performed using the 
GSE4581 dataset. For analysis of miRNA expression in t(4;14)- MM patients, RMA-
processed Human Gene 1.0 ST Array (Affymetrix) mRNA expression data and TaqMan 
miRNA expression data from CD138+ BM PCs in newly-diagnosed MM patients 
(GSE16558) (n = 60) was analysed, as previously described 51. Patients were classified 
as MMSETlow, MMSEThigh/FGFR3low and MMSEThigh/FGFR3high using specific cut-offs 
for MMSET/NSD2 (209053_s_at) and FGFR3 (204379_s_at) for each dataset, as shown 
in Supplementary Figure 4.1A-F. Patients were defined as CDH2high or CDH2low and 
BTBD3high or BTBD3low based on the median expression of CDH2 (203440_at) and 
BTBD3 (202946_s_at) for the entire MM patient cohort, respectively. Patients were 
defined as miR-190high or miR-190low using a cut-off of zero. Gene set enrichment 
analysis (GSEA) was performed using the MSigDB Hallmark gene sets and Curated 
gene sets collections.52 Predicted miRNA targets were retrieved from three independent 
databases (TargetScan, version 7.1 (June 2016), http://targetscan.org53; PicTar (March 
2007), http://pictar.mdc-berlin.de54; miRdb (May 2016), http://mirdb.org55). 
 
4.3.2 Cell culture 
Cell culture reagents were sourced from Sigma-Aldrich (St Louis, MO, USA), unless 
otherwise specified. The HMCLs MOLP-8, EJM, KMM-1, ANBL6, JJN3, KMS-26, 
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JIM-1, NCI-H929 and OPM-2 were a kind gift from Prof. Andrew Spencer (Monash 
University, Melbourne, VIC). The B-cell lines NALM-6 and Balm were kindly 
provided by Emeritus Prof. Leonie Ashman (University of Newcastle, Newcastle, 
NSW). The transformed B-cell line ARH-77 and HMCLs KMS-11, LP-1, RPMI-8226 
and U266 were obtained from the American Type Culture Collection. EJM cells were 
maintained in Iscove's Modified Dulbecco's Medium (IMDM) with 10% foetal calf 
serum (FCS) (Thermo Fisher Scientific, Waltham, MA, USA) and supplements (2mM 
L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1mM sodium pyruvate and 
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] buffer) at 37°C in 
a humidified atmosphere with 5% CO2. All other lines were maintained in Roswell Park 
Memorial Institute 1640 (RPMI-1640) medium with 10% FCS and supplements. 
 
4.3.3 Flow cytometry 
For analysis of N-cadherin expression, HMCLs cells were incubated in blocking buffer 
(2mM EDTA 2% FCS PBS) for 30mins on ice. Cells were then stained with mouse 
monoclonal anti-N-cadherin antibody (clone GC-4; 30µg/ml; Sigma-Aldrich), or mouse 
IgG1 isotype control (clone 1B556; a kind gift from Dr Graham Mayrhofer, The 
University of Adelaide, Adelaide, SA), for 45mins on ice in blocking buffer. After 
washing in Hank's Balanced Salt Solution with 5% FCS, cells were incubated with PE-
conjugated goat anti-mouse IgG (0.2µg/1x106 cells; SouthernBiotech; Birmingham, AL, 
USA) for 45 minutes on ice in blocking buffer. Cells were again washed, resuspended 
in 1% w/v neutral-buffered formalin 2% w/v sucrose 1% sodium azide PBS and 
analysed using a FACSCanto™ II flow cytometer (BD; Franklin Lakes, NJ, USA). For 
cell purification, cells were sorted using a FACSAria™ Fusion flow cytometer (BD). 
 
4.3.4 Quantitative PCR  
All reagents were sourced from Thermo Fisher Scientific, unless otherwise specified. 
Total RNA was isolated from HMCLs using TRIzol® Reagent. For detection of 
MMSET, BTBD3, CDH2 and ACTB mRNA, cDNA was synthesized using SuperScript® 
IV reverse transcriptase. MMSET primers were designed to detect full-length MMSET 
(MMSET II) transcripts (Forward (Fwd) 5'-AGAGGATACAGGACCCTACA-3', 
Reverse (Rev) 5'-GTGTTTCGTCTGCACTTTCG-3'). For detection of total BTBD3 
transcript levels, BTBD3-targeting primers for quantitative real-time PCR (qPCR) were 
designed to detect all 6 BTBD3 mRNA transcript variants (Fwd 5'-
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GCTGCTTTTCTCGCTATGCT-3', Rev 5'-AGGAGCACACAGGCATTCTT-3'). 
CDH2 primers were designed to detect total CDH2 mRNA transcripts (Fwd 5'-
GGCAGTAAAATTGAGCCTGAAG-3', Rev 5'-AGTTTTCTGGCAAGTTGATTGG-
3'). qPCR was performed using the RT2 SYBR® Green qPCR Mastermix (Qiagen, 
Hilden, Germany). For miRNA analysis, miRNAs were converted to cDNA using the 
TaqMan® MicroRNA Reverse Transcription Kit and expression assessed using the 
TaqMan® Universal Master Mix II, according to the manufacturer’s instructions. Pre-
designed TaqMan® primers were used to detect hsa-miR-190a-5p (miR-190) (Assay ID 
000489; UGAUAUGUUUGAUAUAUUAGGU) and U6 snRNA (Assay ID 001973). 
Gene and miRNA expression was calculated relative to ACTB and U6 snRNA, 
respectively, using the 2-ΔCt method.57 
 
4.3.5 Western blotting 
Nuclear protein lysates from HMCLs were prepared using the Nuclear Complex Co-IP 
Kit (Active Motif, Carlsbad, CA, USA) and polyacrylamide gel electrophoresis was 
performed as described previously.58 Following transfer, the PVDF membrane was 
incubated in blocking buffer (2.5% membrane blocking agent (GE Healthcare; Little 
Chalfont, UK) in 0.1% Tween 20 Tris-buffered saline) for 2 hours at room temperature. 
The membrane was then probed overnight at 4°C with a polyclonal rabbit anti-
human/mouse BTBD3 antibody (8µg/ml; Sigma, Cat. No. HPA042048) diluted in 
blocking buffer. After washing, the membrane was incubated with alkaline 
phosphatase-conjugated donkey anti-rabbit IgG (0.4µg/ml; Merck Millipore, 
Burlington, MA, USA) diluted in blocking buffer for 1 hour at room temperature. 
Proteins were visualized with ECL detection reagent (GE Healthcare) on a Gel Doc™ 
XR+ Imaging System (Bio-Rad; Hercules, CA, USA). The membrane was then stripped 
using Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific), re-blocked 
and probed for 1 hour at room temperature with rabbit anti-histone H3 (Cell Signaling 
Technology, Danvers, MA; 1:2500) as a nuclear protein-loading control. After washing, 
the membrane was incubated for 1 hour at room temperature with alkaline phosphatase-
conjugated donkey anti-rabbit IgG and protein was visualised, as described above. 
 
4.3.6 Over-expression of MMSET and BTBD3 in HMCLs 
The pRetroX-MMSET-DsRed vector harbouring full-length MMSET cDNA or 
pRetroX-DsRed empty vector (kind gifts from Prof. Jonathan Licht, University of 
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Florida Health Cancer Center, Gainsville, FL, USA)38, were transfected into HEK-293T 
cells. Supernatant containing viral particles was subsequently used to infect the HMCL 
RPMI-8226, as previously described.59 Following expansion, cells over-expressing the 
DsRed constructs were purified by flow cytometry.  
 BTBD3 transcript variants 1 and 6 were amplified from cDNA derived from the 
t(4;14)- HMCL KMS-26 (primer sets; Fwd 5'-
ACACGGATCCACCATGGTAGATGACAAGGAAAA-3' and Rev 5'- 
AAGTGAATTCTCAAGCATAGAATATAAGTT-3' (transcript variant 1); Fwd 5'- 
TGTGGGATCCACCATGTTTTACGGAGAACTTGC-3' and Rev 5'- 
AAGTGAATTCTCAAGCATAGAATATAAGTT-3' (transcript variant 6)) and initially 
cloned into pGEM®-T Vector System I (Promega; Madison, WI, USA), as per 
manufacturer's instructions. Each BTBD3 transcript was subsequently cloned into the 
pLeGO-iCer2 lentiviral vector60 (gift from Boris Fehse, Addgene plasmid # 27346) 
using the EcoRI and BamHI restriction sites, and sequence-verified by Sanger 
sequencing. Constructs were then transfected into HEK293T cells using the psPAX2 
(gift from Didier Trono, Addgene plasmid #12260) and pVSV-G (Clontech 
Laboratories, Inc.; Mountain View, CA, USA) packaging vectors and the viral 
supernatants were used to infect RPMI-8226 and U266 HMCLs. Following expansion, 
cerulean-positive cells were purified by flow cytometry. 
 
4.3.7 siRNA-mediated BTBD3 knock-down in HMCLs 
All reagents were sourced from Thermo Fisher Scientific, unless otherwise specified. 
Immediately prior to siRNA transfection at day 0, HMCLs were washed and 
resuspended in Opti-MEM™ at 2.5x105/ml in 25cm2 tissue culture flasks. Silencer® 
Select Negative Control No. 1 siRNA (Cat. 4390843)  and pre-designed BTBD3-
targeting siRNAs (Assay ID s22631, siRNA#1; Assay ID s22632, siRNA#2; Assay ID 
s22633, siRNA#3) were pre-incubated in Opti-MEM™ at 150nM with 15µl/mL 
Lipofectamine® RNAiMAX reagent for 15 minutes at room temperature. For no siRNA 
controls, siRNA was replaced with nuclease-free water. siRNA-lipid complexes (or no 
siRNA mock complexes) were then added drop-wise to HMCLs for a final 
concentration of 25nM siRNA and 2.5µl/mL Lipofectamine® RNAiMAX reagent and 
flasks were gently rocked to mix. After 6 hours at 37°C, cells were diluted 2-fold with 
antibiotic-free RPMI-1640 containing 10% FCS and supplements, as described above, 
and cultured for 2 days. At day 2, cells were washed and resuspended in Opti-MEM™ 
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and siRNA transfection was repeated, as described above. At day 4, cells were 
harvested for RNA isolation. 
 
4.3.8 Statistical analyses 
For analysis of genes which correlate with CDH2 expression in t(4;14)- MM patients, 
Spearman correlation analyses were performed using 4 microarray datasets (E-MTAB-
363, E-GEOD-19784, E-GEOD-26863 and E-MTAB-317), using the Benjamini-
Hochburg false discovery rate (FDR) correction for multiple testing. Differential 
expression of gene probesets between groups in microarray experiments was 
determined using linear models for microarray data analysis (LIMMA;61) in 
MultiExperiment Viewer (MeV;62). Survival curves were compared using the log-rank 
(Mantel-Cox) test with hazard ratios calculated using the Mantel-Haenszel calculation. 
All other analyses were performed using an ordinary one-way ANOVA with Dunnett's 
multiple comparisons test, performed using GraphPad Prism® v7.02 software 
(GraphPad Software, Inc.; La Jolla, CA, USA). 




4.4.1 The histone methyltransferase MMSET is a key driver of CDH2 expression 
in t(4;14)+ MM 
Previous studies have identified that CDH2 expression is up-regulated in a high 
proportion of newly-diagnosed t(4;14)+ MM patients.26,34 Similarly, using qPCR and 
flow cytometry, we have found that t(4;14)+ HMCLs highly express N-cadherin mRNA 
(Figure 4.1A) and protein (Figure 4.1B), when compared with t(4;14)- MM and B-cell 
lines. Indeed, the mean expression of CDH2 is significantly higher in t(4;14)+ HMCLs 
relative to t(4;14)- HMCLs and B-cell lines (data not shown). t(4;14)+ MM is 
characterised by a reciprocal chromosomal translocations that leads to constitutive 
expression of both MMSET and FGFR3, although FGFR3 expression is lost in 
approximately 30% of these patients.35 In order to ascertain whether MMSET or FGFR3 
is the likely driver of CDH2 expression in t(4;14)+ MM, we analysed CDH2 expression 
in publicly available microarray data on CD138+ BM PCs from newly-diagnosed MM 
patients (GSE4581, E-MTAB-363, E-GEOD 19784, E-MTAB-317 and E-GEOD-
26863), characterised as MMSEThigh or MMSETlow, and further characterised on the 
basis of FGFR3 expression (as shown in Supplementary Figure 4.1A-E). Our analysis 
revealed that over 82% of MMSEThigh MM patients express high CDH2 levels (above 
the median for the entire MM cohort) (GSE4581: 66 CDH2high of 74 MMSEThigh 
patients, 89.2%; E-MTAB-363: 17/19, 89.5%; E-GEOD-19784: 33/35, 94.3%; E-
MTAB-317: 30/33, 90.9%; E-GEOD-26863: 28/32, 82.3%), irrespective of their 
FGFR3 expression (Figure 4.1C). These data imply that MMSET, and not FGFR3, is 
responsible for increased CDH2 expression in t(4;14)+ MM patients (Supplementary 
Figure 4.2A).  
 To directly investigate whether MMSET regulates CDH2 in t(4;14)+ MM, we 
then performed in silico analysis of publicly available microarray data in which MMSET 
was genetically modified in the t(4;14)+ HMCL KMS-11. We found that CDH2 
expression was markedly lower in KMS-11 cells following targeted knockout of the 
translocated MMSET allele alone (MMSET TKO) (GSE29148 and E-GEOD-50072) 
(Figure 4.2A,B), consistent with previous findings.41 Over-expression of full-length 
MMSET in MMSET-TKO KMS-11 cells also rescued CDH2 expression (E-GEOD-
50072 and GSE24746) (Figure 4.2B,C). Notably, over-expressing MMSET containing a 
histone-binding domain mutation (MMSET Y1118A) failed to rescue CDH2 expression 
Figure 4.1.  CDH2 expression is up-regulated in t(4;14)+ HMCLs and MMSEThigh 
MM patients. CDH2 expression (normalised to ACTB expression) in a panel of 
HMCLs, stratified based on t(4;14) status, and B-cell lines, as assessed by qPCR. Graph 
depicts mean ± SEM of 3 independent experiments (A). N-cadherin protein expression 
in representative t(4;14)- and t(4;14)+ HMCLs, as assessed by flow cytometry. Black 
line represents N-cadherin expression and shaded area represents isotype control (B). In 
silico analyses of publicly available microarray datasets demonstrating CDH2 
expression in CD138+ BM PCs isolated from newly-diagnosed MM patients, segregated 
into MMSETlow, MMSEThigh/FGFR3low or MMSEThigh/FGFR3high subsets (GSE4581, E-
MTAB-363, E-GEOD-19784, E-MTAB-317 and E-GEOD-26863). Graphs depict 
median with inter-quartile range. * P < 0.05 ** P < 0.01 *** P < 0.001 **** P < 0.0001 
compared with MMSETlow MM patients (LIMMA) (C). 









































































































































































































































































































































Figure 4.2.  CDH2 expression is positively regulated by MMSET in HMCLs. In 
silico analyses of publicly available microarray datasets demonstrating CDH2 
expression in KMS-11 cells following targeted knockout of the translocated MMSET 
allele (TKO) (GSE29148, A; E-GEOD-50072, B) and add-back of full-length MMSET 
(E-GEOD-50072, B; GSE24746, C), or MMSET Y1118A mutant (GSE24746, C), in 
TKO KMS-11 cells. Graphs depict mean ± SEM of 3 independent experiments. * P < 
0.05 *** P < 0.001 **** P < 0.0001 compared with parental KMS-11 cells (A,B), or 
TKO KMS-11 cells (C) (one-way ANOVA with Dunnett's multiple comparisons test). 
MMSET and CDH2 expression (normalised to ACTB expression) in RPMI-8226-EV, 
RPMI-8226-MMSET and RPMI-8226-MMSET Y1118A cells, as assessed by qPCR. 
Graphs depict mean ± SEM of 3 independent experiments (D). **P < 0.01 **** P < 
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in MMSET-TKO KMS-11 cells (GSE24746) (Figure 4.2C). To verify these findings, 
we utilised a t(4;14)- HMCL, RPMI-8226, to independently generate cell lines which 
over-expressed wild-type or Y1118A mutant MMSET. In concordance with our in 
silico analyses, up-regulation of CDH2 was observed in RPMI-8226 cells over-
expressing full-length MMSET (RPMI-8226-MMSET), but not MMSET Y1118A 
mutant (RPMI-8226-MMSET Y1118A), relative to empty-vector control RPMI-8226 
cells (RPMI-8226-EV) (Figure 4.2D). Taken together, these results demonstrate that 
MMSET is a key driver of CDH2 expression in MM and suggest that the ability of 
MMSET to up-regulate CDH2 expression in MM PCs is dependent on its functional 
histone-modifying domain. 
 
4.4.2 Identification of genes which significantly correlate with CDH2 in t(4;14)- 
MM 
While t(4;14)+ MM accounts for 15% of newly-diagnosed patients with up-regulated 
CDH2 expression in MM PCs, our analysis suggests that a further 41-46% of 
MMSETlow patients express high CDH2 levels (GSE4581: 141 CDH2high of 340 
MMSETlow patients, 41.5%; E-MTAB-363: 60/136, 44.1%; E-GEOD-19784: 131/293, 
44.7%; E-MTAB-317: 83/192, 43.2%; E-GEOD-26863: 124/270, 45.9%) (Figure 4.1C), 
in line with previous findings.26 In order to identify potential regulators of CDH2 
expression in t(4;14)- MM, we identified genes that correlated with CDH2 expression in 
BM MM PCs from MMSETlow MM patients in 4 of the microarray datasets included 
above (E-MTAB-363, E-GEOD-19784, E-MTAB-317 and E-GEOD-26863). GSE4581 
was excluded from this analysis as raw, unprocessed data was not available for this 
dataset. In total, we identified 186 genes which significantly positively correlated (Table 
4.1), and 32 genes which significantly inversely correlated (Table 4.2), with CDH2 
expression in all 4 datasets. Genes which positively correlated with CDH2 expression 
included transcriptional regulators (BTF3, E2F5, BTBD3, GFI1 and FLI1), protein 
kinases (PAK1 and PRKD2), growth factors (BMP4), modifiers of chromatin structure 
(FBXO22 and HMGA1) and ribosomal proteins (RPS17, RPL13A and RPL37). Notably, 
GSEA revealed an enrichment for genes associated with a hyperdiploidy-related MM 
gene signature amongst the genes which positively correlated with CDH2 expression 
(Supplementary Table 4.1). Genes which inversely correlated with CDH2 expression 
included transcriptional regulators (IRF2BP2 and TCFL5) and the kinase inhibitor 
CDKN1C (CDKN1C). GSEA also identified an enrichment for genes that are down-



















XRCC4 205071_x_at 0.328 7.53E-04 0.478 7.71E-05 0.353 1.08E-06 0.492 8.91E-14 0.413
MGAT4C 207447_s_at 0.342 4.35E-04 0.515 8.34E-06 0.412 1.25E-09 0.359 6.39E-07 0.407
FER 206412_at 0.315 1.41E-03 0.538 1.92E-07 0.381 4.82E-08 0.387 4.89E-08 0.405
C21orf91 226109_at 0.437 2.18E-06 0.453 2.41E-04 0.310 3.55E-05 0.410 5.27E-09 0.402
MORC1 220850_at 0.303 2.21E-03 0.486 5.16E-05 0.398 8.17E-09 0.390 3.64E-08 0.394
SCYL2 224961_at 0.403 2.66E-05 0.398 2.91E-03 0.402 5.77E-09 0.374 1.57E-07 0.394
TNFSF10 202688_at 0.391 4.36E-05 0.413 1.26E-03 0.366 3.32E-07 0.389 4.26E-08 0.390
EPHB1 230425_at 0.432 2.88E-06 0.293 4.36E-02 0.423 2.89E-10 0.405 8.25E-09 0.388
CDC42SE2 1552612_at 0.342 4.30E-04 0.466 1.37E-04 0.325 1.14E-05 0.385 6.12E-08 0.380
BTBD3 202946_s_at 0.359 1.87E-04 0.436 5.66E-04 0.371 1.73E-07 0.336 4.05E-06 0.375
ELOVL7 227180_at 0.315 1.40E-03 0.403 2.31E-03 0.382 5.74E-08 0.401 1.26E-08 0.375
DLC1 210762_s_at 0.337 5.49E-04 0.368 7.06E-03 0.388 2.77E-08 0.380 9.36E-08 0.368
LOC346887 235205_at 0.481 5.95E-10 0.313 2.84E-02 0.281 2.41E-04 0.396 2.07E-08 0.368
COL4A6 213992_at 0.250 1.36E-02 0.462 1.59E-04 0.370 1.65E-07 0.379 9.68E-08 0.365
PAK1 226507_at 0.424 4.99E-06 0.292 4.44E-02 0.341 3.29E-06 0.403 1.01E-08 0.365
IDH3A 202070_s_at 0.443 1.27E-06 0.289 4.79E-02 0.344 2.60E-06 0.365 3.65E-07 0.360
ELOVL4 219532_at 0.295 3.03E-03 0.449 2.77E-04 0.414 1.05E-09 0.280 2.11E-04 0.359
COL4A5 213110_s_at 0.260 9.90E-03 0.408 1.85E-03 0.407 2.23E-09 0.362 4.69E-07 0.359
SPEF2 1552716_at 0.362 1.65E-04 0.365 7.61E-03 0.329 6.74E-06 0.374 1.51E-07 0.358
CCRL2 211434_s_at 0.264 8.81E-03 0.426 8.51E-04 0.357 7.43E-07 0.376 1.34E-07 0.356
PML 235508_at 0.425 4.66E-06 0.382 4.75E-03 0.310 3.16E-05 0.296 7.03E-05 0.353
MMP16 223614_at 0.243 1.67E-02 0.447 2.55E-04 0.395 8.17E-09 0.322 1.10E-05 0.352
MAB21L1 206163_at 0.311 1.63E-03 0.490 4.52E-05 0.318 1.86E-05 0.283 1.68E-04 0.351
ISL2 232352_at 0.329 7.46E-04 0.368 7.08E-03 0.309 3.92E-05 0.397 1.73E-08 0.351
RSL24D1 217915_s_at 0.377 7.99E-05 0.441 4.37E-04 0.287 1.69E-04 0.275 2.79E-04 0.345
GTPBP8 223486_at 0.388 4.97E-05 0.344 1.35E-02 0.330 7.77E-06 0.316 1.70E-05 0.344
PCDH9 219737_s_at 0.323 1.01E-03 0.403 2.31E-03 0.363 4.34E-07 0.279 2.14E-04 0.342
UBA7 1294_at 0.399 3.29E-05 0.320 2.40E-02 0.350 1.44E-06 0.293 8.51E-05 0.341
NCAM1 212843_at 0.365 1.45E-04 0.335 1.72E-02 0.274 3.91E-04 0.387 5.16E-08 0.340
SNAPC5 1554093_a_at 0.300 2.46E-03 0.412 1.51E-03 0.354 9.82E-07 0.289 1.15E-04 0.339
USE1 219348_at 0.369 1.22E-04 0.364 7.99E-03 0.283 2.09E-04 0.330 6.01E-06 0.337
NT5C3 223298_s_at 0.374 9.62E-05 0.436 5.60E-04 0.286 1.73E-04 0.246 1.50E-03 0.336
RPL37 224767_at 0.287 4.21E-03 0.344 1.35E-02 0.296 8.76E-05 0.415 3.83E-09 0.335
TRAT1 217147_s_at 0.295 2.97E-03 0.370 6.62E-03 0.371 1.73E-07 0.295 7.47E-05 0.333
GTF2F2 209595_at 0.298 2.70E-03 0.386 3.96E-03 0.225 5.03E-03 0.417 3.44E-09 0.332
SCAMP5 212699_at 0.292 3.39E-03 0.317 2.63E-02 0.398 8.17E-09 0.314 2.04E-05 0.330
GBA3 222943_at 0.361 1.69E-04 0.326 2.12E-02 0.334 5.45E-06 0.294 8.24E-05 0.329
CD200 209582_s_at 0.224 2.90E-02 0.499 1.92E-05 0.303 5.95E-05 0.290 1.10E-04 0.329
CNTN5 207452_s_at 0.281 5.16E-03 0.331 1.78E-02 0.358 5.00E-07 0.343 2.38E-06 0.328
RPL13A 200715_x_at 0.270 6.96E-03 0.378 5.41E-03 0.293 1.05E-04 0.369 2.60E-07 0.328
EIF2A 223015_at 0.267 7.91E-03 0.427 8.11E-04 0.283 2.07E-04 0.332 5.45E-06 0.327
CMPK2 226702_at 0.390 4.55E-05 0.347 1.24E-02 0.308 3.95E-05 0.262 6.14E-04 0.327
E-GEOD-19784 E-GEOD-26863
Table 4.1: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents
E-MTAB-317 E-MTAB-363
RSAD2 242625_at 0.381 7.05E-05 0.356 9.49E-03 0.311 3.26E-05 0.255 9.23E-04 0.326
SAAL1 225614_at 0.389 4.63E-05 0.356 9.30E-03 0.309 3.83E-05 0.248 1.35E-03 0.326
C3orf17 225281_at 0.289 3.86E-03 0.372 5.85E-03 0.308 4.05E-05 0.334 4.68E-06 0.326
ISG20 204698_at 0.364 1.51E-04 0.351 1.11E-02 0.316 1.99E-05 0.271 3.69E-04 0.325
ICAM3 204949_at 0.297 2.81E-03 0.389 3.74E-03 0.323 1.34E-05 0.291 1.02E-04 0.325
CHSY3 242100_at 0.345 3.95E-04 0.322 2.28E-02 0.234 3.18E-03 0.387 5.23E-08 0.322
IDH2 210046_s_at 0.365 1.46E-04 0.314 2.74E-02 0.337 4.25E-06 0.264 5.45E-04 0.320
COPS2 202467_s_at 0.313 1.49E-03 0.394 3.24E-03 0.322 1.33E-05 0.252 1.09E-03 0.320
CCNDBP1 223084_s_at 0.308 1.85E-03 0.383 4.44E-03 0.308 3.95E-05 0.279 2.28E-04 0.320
RPL35A 238026_at 0.332 6.63E-04 0.318 2.54E-02 0.268 5.45E-04 0.356 7.77E-07 0.319
TMEM161B 236227_at 0.338 5.26E-04 0.339 1.54E-02 0.221 6.13E-03 0.375 1.51E-07 0.318
TTC9C 226175_at 0.363 1.58E-04 0.353 1.01E-02 0.258 9.89E-04 0.298 6.35E-05 0.318
ARHGAP25 204882_at 0.302 2.32E-03 0.374 5.85E-03 0.232 3.70E-03 0.363 4.51E-07 0.318
GFI1 206589_at 0.391 4.36E-05 0.293 4.39E-02 0.257 1.00E-03 0.330 6.13E-06 0.317
UBE2Q2 224747_at 0.335 5.96E-04 0.309 3.09E-02 0.310 3.55E-05 0.315 1.92E-05 0.317
SMOC1 222783_s_at 0.297 2.75E-03 0.339 1.46E-02 0.296 9.12E-05 0.336 3.91E-06 0.317
PALM2-AKAP2 202760_s_at 0.283 4.86E-03 0.303 3.53E-02 0.293 1.05E-04 0.382 7.19E-08 0.315
SQRDL 217995_at 0.335 5.92E-04 0.303 3.54E-02 0.294 9.77E-05 0.326 8.64E-06 0.315
ST8SIA4 206925_at 0.287 4.24E-03 0.387 3.85E-03 0.282 2.07E-04 0.301 5.13E-05 0.314
MOSC2 227417_at 0.320 1.10E-03 0.320 2.44E-02 0.296 9.05E-05 0.319 1.40E-05 0.314
GALT 203179_at 0.381 7.05E-05 0.317 2.58E-02 0.293 9.77E-05 0.259 7.58E-04 0.313
HOMER1 226651_at 0.300 2.52E-03 0.368 7.03E-03 0.274 3.97E-04 0.308 3.13E-05 0.312
ATP5L 207573_x_at 0.352 2.71E-04 0.335 1.68E-02 0.230 4.00E-03 0.328 7.28E-06 0.311
ZDHHC24 227549_x_at 0.278 5.66E-03 0.353 1.01E-02 0.294 9.98E-05 0.318 1.49E-05 0.311
CDV3 213554_s_at 0.232 2.27E-02 0.385 4.11E-03 0.275 3.69E-04 0.349 1.44E-06 0.310
C2orf89 227867_at 0.397 3.33E-05 0.321 2.38E-02 0.318 1.95E-05 0.199 1.48E-02 0.309
GMPR 204187_at 0.384 6.08E-05 0.330 1.90E-02 0.202 1.38E-02 0.317 1.56E-05 0.308
BTLA 236226_at 0.238 1.92E-02 0.365 7.68E-03 0.310 3.55E-05 0.319 1.38E-05 0.308
ST3GAL5 203217_s_at 0.271 7.03E-03 0.343 1.30E-02 0.260 8.90E-04 0.357 7.21E-07 0.308
PCMTD1 244706_at 0.335 5.92E-04 0.361 8.72E-03 0.291 1.22E-04 0.241 2.03E-03 0.307
COX7C 213846_at 0.281 5.17E-03 0.342 1.42E-02 0.244 2.05E-03 0.357 7.18E-07 0.306
IFNGR1 211676_s_at 0.243 1.64E-02 0.433 6.51E-04 0.281 2.40E-04 0.267 4.78E-04 0.306
RPS19 202649_x_at 0.294 2.98E-03 0.378 5.41E-03 0.274 3.87E-04 0.273 3.12E-04 0.305
MRPS27 212145_at 0.271 7.13E-03 0.327 2.07E-02 0.286 1.72E-04 0.331 5.69E-06 0.304
C11orf1 231530_s_at 0.290 3.84E-03 0.345 1.31E-02 0.247 1.72E-03 0.333 5.19E-06 0.304
THG1L 219122_s_at 0.311 1.67E-03 0.321 2.33E-02 0.243 2.17E-03 0.337 3.56E-06 0.303
KIAA1217 1554438_at 0.342 4.35E-04 0.304 3.48E-02 0.258 9.54E-04 0.306 3.49E-05 0.302
GNB2L1 200651_at 0.252 1.27E-02 0.346 1.27E-02 0.250 1.52E-03 0.361 5.18E-07 0.302
LOC728052 1558795_at 0.261 9.66E-03 0.381 4.98E-03 0.286 1.69E-04 0.280 2.10E-04 0.302
IVD 203682_s_at 0.338 5.26E-04 0.376 5.76E-03 0.231 3.93E-03 0.263 5.96E-04 0.302
TAF9 202168_at 0.282 4.91E-03 0.429 7.59E-04 0.273 4.21E-04 0.222 5.24E-03 0.301
SCN8A 1561820_at 0.270 7.26E-03 0.341 1.47E-02 0.345 1.83E-06 0.248 1.35E-03 0.301




















Table 4.1: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents 
(con�nued)
E-MTAB-317 E-MTAB-363
RPL36 219762_s_at 0.299 2.58E-03 0.376 5.78E-03 0.238 2.65E-03 0.291 1.02E-04 0.301
UBXN1 201871_s_at 0.315 1.40E-03 0.338 1.58E-02 0.238 2.78E-03 0.311 2.53E-05 0.301
EIF3K 212716_s_at 0.271 7.13E-03 0.348 1.23E-02 0.260 8.89E-04 0.322 1.14E-05 0.300
C19orf42 224717_s_at 0.308 1.85E-03 0.305 3.39E-02 0.237 2.91E-03 0.350 1.32E-06 0.300
GPR177 228949_at 0.294 3.19E-03 0.312 2.90E-02 0.253 1.30E-03 0.337 3.72E-06 0.299
C19orf53 217926_at 0.279 5.51E-03 0.395 3.17E-03 0.252 1.39E-03 0.269 4.13E-04 0.299
COX5A 203663_s_at 0.301 2.32E-03 0.314 2.79E-02 0.300 7.04E-05 0.279 2.22E-04 0.298
SPATA5L1 218933_at 0.321 1.06E-03 0.344 1.34E-02 0.293 1.08E-04 0.232 3.19E-03 0.298
BMP4 211518_s_at 0.293 3.27E-03 0.323 2.25E-02 0.252 1.37E-03 0.320 1.27E-05 0.297
PFKFB2 226733_at 0.342 4.35E-04 0.334 1.75E-02 0.296 9.10E-05 0.216 6.87E-03 0.297
RPL27A 203034_s_at 0.227 2.65E-02 0.346 1.30E-02 0.229 4.17E-03 0.384 6.63E-08 0.296
RPL4 200089_s_at 0.259 1.03E-02 0.364 7.47E-03 0.302 6.08E-05 0.260 7.01E-04 0.296
NOL6 222554_s_at 0.299 2.55E-03 0.383 3.92E-03 0.215 7.89E-03 0.284 1.55E-04 0.296
PDLIM2 219165_at 0.300 2.52E-03 0.293 4.36E-02 0.303 5.95E-05 0.286 1.34E-04 0.296
ERCC1 203720_s_at 0.287 4.21E-03 0.348 1.23E-02 0.239 2.62E-03 0.306 3.46E-05 0.295
LENG1 232018_at 0.273 6.48E-03 0.341 1.47E-02 0.258 9.71E-04 0.306 3.46E-05 0.295
RAB8B 226633_at 0.214 3.67E-02 0.356 9.53E-03 0.300 6.64E-05 0.307 3.17E-05 0.294
ZNF622 225152_at 0.358 2.04E-04 0.289 4.83E-02 0.238 2.72E-03 0.293 8.42E-05 0.294
RBM7 218379_at 0.335 5.92E-04 0.361 8.60E-03 0.225 4.99E-03 0.256 8.91E-04 0.294
RP3-398D13.1 1556366_s_at 0.260 9.85E-03 0.357 9.04E-03 0.318 1.75E-05 0.241 1.94E-03 0.294
NCRNA00219 225698_at 0.256 1.12E-02 0.333 1.78E-02 0.226 4.93E-03 0.361 5.08E-07 0.294
PIP5K1B 205632_s_at 0.253 1.24E-02 0.298 3.99E-02 0.249 1.56E-03 0.375 1.51E-07 0.294
CD48 204118_at 0.277 5.72E-03 0.391 3.57E-03 0.235 3.15E-03 0.267 4.75E-04 0.293
C19orf43 223003_at 0.275 6.26E-03 0.315 2.69E-02 0.213 8.57E-03 0.367 2.95E-07 0.292
RPL18 200022_at 0.240 1.83E-02 0.375 5.85E-03 0.254 1.16E-03 0.294 8.23E-05 0.291
CADM1 209031_at 0.322 1.06E-03 0.299 3.94E-02 0.291 1.28E-04 0.249 1.30E-03 0.290
GYG1 201554_x_at 0.296 2.93E-03 0.287 4.98E-02 0.252 1.33E-03 0.320 1.31E-05 0.289
NPM1 221691_x_at 0.314 1.44E-03 0.372 6.19E-03 0.240 2.33E-03 0.228 3.85E-03 0.289
STOM 201061_s_at 0.394 3.81E-05 0.295 4.19E-02 0.290 1.32E-04 0.175 3.74E-02 0.289
LOC399804 216387_x_at 0.333 6.48E-04 0.389 3.74E-03 0.192 1.99E-02 0.239 2.18E-03 0.288
PRKD2 38269_at 0.255 1.14E-02 0.303 3.52E-02 0.264 7.00E-04 0.326 8.27E-06 0.287
FLI1 210786_s_at 0.261 9.63E-03 0.315 2.70E-02 0.247 1.75E-03 0.325 9.28E-06 0.287
MTX3 226528_at 0.278 5.46E-03 0.308 3.15E-02 0.241 2.39E-03 0.317 1.57E-05 0.286
FBXO22 225737_s_at 0.299 2.61E-03 0.308 3.13E-02 0.245 1.96E-03 0.288 1.18E-04 0.285
BAI3 205638_at 0.305 2.05E-03 0.309 3.09E-02 0.268 5.59E-04 0.258 8.04E-04 0.285
GPM6A 209469_at 0.316 1.39E-03 0.294 4.33E-02 0.300 6.63E-05 0.224 4.76E-03 0.283
C1R 212067_s_at 0.217 3.43E-02 0.299 3.85E-02 0.344 2.54E-06 0.272 3.50E-04 0.283
FAU 200019_s_at 0.289 3.92E-03 0.339 1.53E-02 0.254 1.13E-03 0.247 1.42E-03 0.283
RPS17 201665_x_at 0.216 3.48E-02 0.355 9.90E-03 0.306 4.52E-05 0.251 1.15E-03 0.282
EAF2 219551_at 0.206 4.54E-02 0.349 1.16E-02 0.253 1.29E-03 0.319 1.40E-05 0.282
HIST1H2AC 215071_s_at 0.298 2.73E-03 0.340 1.51E-02 0.305 4.54E-05 0.183 2.81E-02 0.281
EIF3G 208887_at 0.296 2.92E-03 0.287 4.97E-02 0.258 9.70E-04 0.282 1.81E-04 0.281




















Table 4.1: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents 
(con�nued)
E-MTAB-317 E-MTAB-363
IFIT1 203153_at 0.354 2.33E-04 0.320 2.40E-02 0.240 2.42E-03 0.206 1.08E-02 0.280
C4orf14 223157_at 0.306 2.03E-03 0.314 2.77E-02 0.228 4.48E-03 0.273 3.28E-04 0.280
BTF3 211939_x_at 0.280 5.22E-03 0.344 1.30E-02 0.241 2.30E-03 0.250 1.26E-03 0.279
FHAD1 1564635_a_at 0.208 4.30E-02 0.314 2.66E-02 0.329 8.41E-06 0.263 5.80E-04 0.279
NOP10 217962_at 0.304 2.13E-03 0.335 1.71E-02 0.285 1.82E-04 0.189 2.20E-02 0.278
RPS17P5 216348_at 0.251 1.30E-02 0.292 4.52E-02 0.320 1.71E-05 0.250 1.23E-03 0.278
SOCS2 203372_s_at 0.241 1.75E-02 0.308 3.15E-02 0.276 3.18E-04 0.281 1.97E-04 0.277
TRPM3 216452_at 0.244 1.62E-02 0.294 4.28E-02 0.249 1.57E-03 0.318 1.52E-05 0.276
TMEM85 223857_x_at 0.266 8.38E-03 0.303 3.43E-02 0.282 2.26E-04 0.253 1.07E-03 0.276
RPS13 200018_at 0.247 1.47E-02 0.323 2.25E-02 0.254 1.14E-03 0.278 2.28E-04 0.276
PLSCR1 202430_s_at 0.344 3.95E-04 0.289 4.80E-02 0.239 2.49E-03 0.227 4.01E-03 0.275
POLR1D 224857_s_at 0.262 9.41E-03 0.309 3.09E-02 0.261 8.53E-04 0.266 5.05E-04 0.274
RARS 201330_at 0.328 7.76E-04 0.294 4.28E-02 0.228 4.52E-03 0.247 1.48E-03 0.274
CLNS1A 209143_s_at 0.313 1.49E-03 0.377 5.52E-03 0.207 1.12E-02 0.192 1.99E-02 0.272
EID1 208669_s_at 0.265 8.64E-03 0.292 4.51E-02 0.295 9.40E-05 0.237 2.46E-03 0.272
ZC3H12C 231899_at 0.322 1.05E-03 0.330 1.84E-02 0.230 3.94E-03 0.204 1.17E-02 0.272
RELL2 1564031_a_at 0.211 4.01E-02 0.293 4.36E-02 0.287 1.51E-04 0.293 8.51E-05 0.271
CCDC85A 235228_at 0.271 6.95E-03 0.305 3.39E-02 0.298 8.05E-05 0.207 1.04E-02 0.270
SSR3 217790_s_at 0.250 1.34E-02 0.308 3.09E-02 0.272 4.44E-04 0.248 1.36E-03 0.269
C6orf48 220755_s_at 0.247 1.45E-02 0.310 2.96E-02 0.229 4.17E-03 0.284 1.55E-04 0.268
MFNG 204153_s_at 0.237 1.97E-02 0.397 2.97E-03 0.264 6.88E-04 0.168 4.81E-02 0.267
RPS11 200031_s_at 0.216 3.43E-02 0.324 2.13E-02 0.205 1.19E-02 0.321 1.25E-05 0.266
EEF1D 203113_s_at 0.239 1.84E-02 0.306 3.35E-02 0.212 8.77E-03 0.308 3.12E-05 0.266
UBLCP1 227413_at 0.315 1.44E-03 0.287 4.94E-02 0.225 5.17E-03 0.236 2.57E-03 0.266
FBL 211623_s_at 0.297 2.74E-03 0.337 1.61E-02 0.233 3.50E-03 0.190 2.12E-02 0.264
PDCD2L 224467_s_at 0.306 2.02E-03 0.323 2.27E-02 0.205 1.20E-02 0.222 5.28E-03 0.264
KAT5 214258_x_at 0.252 1.26E-02 0.329 1.98E-02 0.244 2.07E-03 0.220 5.58E-03 0.261
HMGA1 206074_s_at 0.263 9.02E-03 0.361 8.72E-03 0.231 3.87E-03 0.186 2.49E-02 0.260
RPL35 200002_at 0.226 2.67E-02 0.290 4.66E-02 0.203 1.33E-02 0.317 1.58E-05 0.259
RPL31 221593_s_at 0.339 4.99E-04 0.314 2.78E-02 0.207 1.10E-02 0.175 3.81E-02 0.258
GAS5 224741_x_at 0.228 2.55E-02 0.360 8.96E-03 0.198 1.63E-02 0.248 1.38E-03 0.258
FAM96A 224779_s_at 0.243 1.66E-02 0.306 3.30E-02 0.290 1.32E-04 0.190 2.09E-02 0.257
SIX4 229796_at 0.295 2.92E-03 0.329 1.98E-02 0.193 1.99E-02 0.212 8.46E-03 0.257
CSNK1A1 243338_at 0.249 1.37E-02 0.313 2.77E-02 0.289 1.29E-04 0.170 4.44E-02 0.255
NKX6-2 235832_at 0.268 7.68E-03 0.295 4.24E-02 0.201 1.43E-02 0.250 1.23E-03 0.254
BNIP1 37226_at 0.248 1.41E-02 0.311 2.96E-02 0.261 8.19E-04 0.192 1.92E-02 0.253
APH1B 221036_s_at 0.223 2.97E-02 0.308 3.15E-02 0.299 7.14E-05 0.178 3.34E-02 0.252
TRIM13 203659_s_at 0.265 8.69E-03 0.290 4.59E-02 0.248 1.63E-03 0.201 1.35E-02 0.251
MRPS30 218398_at 0.289 3.92E-03 0.304 3.49E-02 0.196 1.77E-02 0.211 8.62E-03 0.250
CLTA 204050_s_at 0.255 1.16E-02 0.327 2.04E-02 0.168 4.97E-02 0.241 2.00E-03 0.248
TAPBP 1555565_s_at 0.252 1.27E-02 0.337 1.63E-02 0.204 1.26E-02 0.194 1.76E-02 0.247
MGC50722 1554681_a_at 0.267 8.11E-03 0.343 1.41E-02 0.207 1.13E-02 0.171 4.35E-02 0.247




















Table 4.1: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents 
(con�nued)
E-MTAB-317 E-MTAB-363
IL6ST 204864_s_at 0.283 4.88E-03 0.328 1.94E-02 0.189 2.26E-02 0.187 2.40E-02 0.247
TOMM70A 201512_s_at 0.290 3.81E-03 0.295 4.21E-02 0.213 8.64E-03 0.188 2.31E-02 0.246
E2F5 221586_s_at 0.247 1.47E-02 0.295 4.19E-02 0.222 5.97E-03 0.215 7.10E-03 0.245
ANP32A 201051_at 0.215 3.62E-02 0.302 3.65E-02 0.253 1.26E-03 0.207 1.05E-02 0.244
NCK1 204725_s_at 0.226 2.71E-02 0.321 2.33E-02 0.176 3.71E-02 0.253 1.07E-03 0.244
RPS28 208902_s_at 0.243 1.64E-02 0.329 1.97E-02 0.215 8.02E-03 0.186 2.47E-02 0.243
TNFAIP8 208296_x_at 0.280 5.28E-03 0.292 4.52E-02 0.174 4.00E-02 0.227 4.15E-03 0.243
PPP1CC 200726_at 0.259 1.03E-02 0.291 4.49E-02 0.238 2.78E-03 0.173 4.09E-02 0.240
PSMB9 204279_at 0.285 4.46E-03 0.312 2.90E-02 0.182 2.97E-02 0.174 3.87E-02 0.238
RPS9 217747_s_at 0.247 1.47E-02 0.294 4.33E-02 0.171 4.39E-02 0.236 2.64E-03 0.237
RPL29 200823_x_at 0.209 4.09E-02 0.289 4.79E-02 0.208 1.06E-02 0.236 2.64E-03 0.236
SEC11A 216274_s_at 0.265 8.44E-03 0.295 4.08E-02 0.172 4.25E-02 0.205 1.15E-02 0.234
C19orf12 225863_s_at 0.214 3.67E-02 0.295 4.24E-02 0.184 2.73E-02 0.229 3.69E-03 0.231
RPS5 200024_at 0.234 2.15E-02 0.321 2.33E-02 0.186 2.53E-02 0.181 2.99E-02 0.231
RPS2 217466_x_at 0.214 3.65E-02 0.289 4.80E-02 0.183 2.90E-02 0.233 3.03E-03 0.230
RPS3 208692_at 0.203 4.85E-02 0.292 4.36E-02 0.208 1.09E-02 0.215 7.06E-03 0.230
SCAMP1 1552978_a_at 0.222 3.02E-02 0.300 3.81E-02 0.197 1.63E-02 0.178 3.31E-02 0.224
CTDSPL2 223271_s_at 0.203 4.85E-02 0.289 4.86E-02 0.180 3.19E-02 0.169 4.66E-02 0.210
1 Spearman's rank correla�on co-efficient
2 False discovery rate




















Table 4.1: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents 
(con�nued)
E-MTAB-317 E-MTAB-363



















PITPNC1 219155_at -0.421 6.54E-06 -0.488 4.76E-05 -0.435 0.00E+00 -0.415 3.83E-09 -0.440
C1orf56 223459_s_at -0.456 3.68E-07 -0.314 2.76E-02 -0.332 6.53E-06 -0.346 1.76E-06 -0.362
TMEM107 239824_s_at -0.307 1.91E-03 -0.401 2.20E-03 -0.355 9.06E-07 -0.287 1.33E-04 -0.337
RAPH1 225188_at -0.355 2.30E-04 -0.390 3.57E-03 -0.310 3.55E-05 -0.277 2.51E-04 -0.333
TCFL5 235694_at -0.236 2.03E-02 -0.433 6.47E-04 -0.336 4.25E-06 -0.283 1.74E-04 -0.322
SEC61A2 230215_at -0.278 5.67E-03 -0.372 6.15E-03 -0.337 4.38E-06 -0.276 2.63E-04 -0.316
HGSNAT 218017_s_at -0.275 6.16E-03 -0.331 1.90E-02 -0.273 4.22E-04 -0.384 6.50E-08 -0.316
XPR1 226615_at -0.248 1.42E-02 -0.366 7.61E-03 -0.294 1.04E-04 -0.288 1.18E-04 -0.299
ARF3 200734_s_at -0.301 2.37E-03 -0.326 2.05E-02 -0.206 1.19E-02 -0.357 7.49E-07 -0.297
SFN 33323_r_at -0.255 1.16E-02 -0.429 7.58E-04 -0.251 1.41E-03 -0.254 1.01E-03 -0.297
IFNA1 208375_at -0.280 5.20E-03 -0.334 1.73E-02 -0.286 1.69E-04 -0.275 2.92E-04 -0.294
POLA1 204835_at -0.244 1.60E-02 -0.336 1.63E-02 -0.299 7.08E-05 -0.243 1.77E-03 -0.281
ZNRF1 225959_s_at -0.311 1.64E-03 -0.338 1.60E-02 -0.290 1.29E-04 -0.184 2.70E-02 -0.281
PHC1 218338_at -0.302 2.33E-03 -0.311 3.01E-02 -0.226 4.82E-03 -0.272 3.41E-04 -0.278
SGPL1 212321_at -0.235 2.07E-02 -0.388 3.77E-03 -0.216 7.50E-03 -0.262 6.30E-04 -0.275
GSTA4 202967_at -0.263 9.10E-03 -0.312 2.93E-02 -0.168 4.84E-02 -0.332 5.49E-06 -0.269
C1orf93 231835_at -0.241 1.79E-02 -0.310 2.98E-02 -0.232 3.58E-03 -0.280 2.10E-04 -0.266
SLC44A2 224609_at -0.243 1.65E-02 -0.324 2.25E-02 -0.246 1.87E-03 -0.247 1.43E-03 -0.265
CD28 206545_at -0.266 8.31E-03 -0.351 1.01E-02 -0.227 4.70E-03 -0.210 9.08E-03 -0.263
CDKN1C 213348_at -0.292 3.43E-03 -0.290 4.72E-02 -0.187 2.45E-02 -0.282 1.83E-04 -0.263
C16orf93 231300_at -0.300 2.52E-03 -0.294 4.33E-02 -0.191 2.09E-02 -0.256 8.80E-04 -0.260
B3GALT6 1553959_a_at -0.223 2.90E-02 -0.396 3.07E-03 -0.195 1.85E-02 -0.224 4.63E-03 -0.260
DHX32 218198_at -0.225 2.78E-02 -0.300 3.81E-02 -0.264 6.86E-04 -0.235 2.81E-03 -0.256
IRF2BP2 224570_s_at -0.219 3.27E-02 -0.288 4.89E-02 -0.236 2.89E-03 -0.277 2.51E-04 -0.255
KCNN3 205903_s_at -0.228 2.52E-02 -0.315 2.69E-02 -0.214 8.34E-03 -0.262 6.16E-04 -0.255
APBB1IP 1554571_at -0.323 9.78E-04 -0.291 4.59E-02 -0.197 1.63E-02 -0.204 1.18E-02 -0.254
CDCA7 224428_s_at -0.232 2.27E-02 -0.385 3.78E-03 -0.193 1.92E-02 -0.204 1.16E-02 -0.254
DHTKD1 209916_at -0.280 5.24E-03 -0.297 3.95E-02 -0.214 8.31E-03 -0.214 7.50E-03 -0.251
SLC8A1 1556583_a_at -0.297 2.83E-03 -0.301 3.67E-02 -0.227 4.60E-03 -0.173 3.96E-02 -0.250
RGS5 1558785_a_at -0.258 1.03E-02 -0.315 2.69E-02 -0.180 3.19E-02 -0.186 2.51E-02 -0.235
ETV6 235056_at -0.255 1.16E-02 -0.292 4.43E-02 -0.186 2.61E-02 -0.198 1.51E-02 -0.233
EP400NL 229892_at -0.246 1.51E-02 -0.287 4.86E-02 -0.208 1.06E-02 -0.178 3.39E-02 -0.230
1 Spearman's rank correla�on co-efficient
2 False discovery rate
Table 4.2: Genes which inversely correlate with CDH2  expression in t(4;14)- MM pa�ents
E-MTAB-317 E-MTAB-363 E-GEOD-19784 E-GEOD-26863
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
114 
 
regulated in MM patients with hyperdiploidy amongst the inversely-correlating gene 
group (Supplementary Table 4.2).  
 In order to identify potential drivers of CDH2 expression in t(4;14)- MM 
patients, genes which significantly positively correlated with CDH2 expression in 
MMSETlow MM patients, and were significantly up-regulated in CD138+ BM MM PCs 
compared with CD138+ BM PCs from healthy individuals, were further short-listed. In 
silico analysis of publically-available microarray data (E-MTAB-363) revealed that, of 
the 186 genes which significantly positively correlated with CDH2 expression, 13 genes 
were significantly up-regulated in BM MM PCs compared with normal BM PCs (Table 
4.3). BTBD3, encoding for the putative transcriptional regulator BTB/POZ domain-
containing protein 3 (BTBD3), was the most highly up-regulated gene (log2 4.61-fold; p 
= 0.002) which positively correlated with CDH2 expression in t(4;14)- MM patients 
(mean correlation co-efficient = 0.375; FDR-adjusted P value < 0.001) (Figure 4.3A,B). 
Notably, BTBD3 expression was consistently up-regulated in MMSETlowCDH2high MM 
patients (GSE4581: 100 BTBD3high of 141 MMSETlowCDH2high patients, 70.9%; E-
MTAB-363: 43/60, 71.7%; E-GEOD-19784: 85/131, 64.9%; E-MTAB-317: 54/83, 
65.1%; E-GEOD-26863: 78/124, 62.9%), suggesting that it may be responsible for up-
regulating CDH2 expression in t(4;14)- MM patients (Figure 4.3A). In order to 
determine the clinical significance of BTBD3 up-regulation in BM MM PCs, we 
assessed the overall survival of newly-diagnosed MM patients, stratified on the basis of 
MMSET and BTBD3 expression, in the microarray dataset GSE4581. While overall 
survival was not significantly affected by BTBD3 expression in the MMSEThigh patients 
(p = 0.76), there was a trend towards poorer survival in MMSETlowBTBD3high MM 
patients, when compared with the MMSETlowBTBD3low patients (p = 0.064; HR: 1.64 
[95% CI: 0.97-2.77]) (Figure 4.3C). Taken together, these findings suggest that BTBD3 
may be a potential driver of CDH2 expression in t(4;14)- MM (Supplementary Figure 
4.2B) and may play a role in MM pathogenesis. 
 
4.4.3 Identification of miRNAs which may regulate CDH2 expression in t(4;14)- 
MM 
While BTBD3 is consistently up-regulated in BM MM PCs from MMSETlowCDH2high 
patients, there are a large proportion of MMSETlowCDH2low patients that also express 
BTBD3 (GSE4581: 71 BTBD3high of 199 MMSETlowCDH2low patients, 35.7%; E-
MTAB-363: 27/76, 35.5%; E-GEOD-19784: 57/162, 35.2%; E-MTAB-317: 37/109, 




1 Log2  
Mean






BTBD3 BTB/POZ Domain-Containing Protein 3 202946_s_at 5.01 0.81 9.62 2.10 1.94E-03 4.61
HIST1H2AC
Histone Cluster 1 H2A Family 
Member C
215071_s_at 7.94 0.74 11.70 1.27 1.94E-03 3.76
RPL35A Ribosomal Protein L35a 238026_at 6.68 0.55 9.83 1.07 1.94E-03 3.14
LOC346887 LOC346887 235205_at 6.06 0.40 8.79 1.01 1.94E-03 2.73
ELOVL7 ELOVL Fa�y Acid Elongase 7 227180_at 4.41 0.33 8.46 1.99 2.70E-03 4.05
STOM Stoma�n 201061_s_at 8.24 0.54 11.23 1.16 7.50E-03 2.99
PLSCR1 Phospholipid Scramblase 1 202430_s_at 5.21 0.93 7.70 1.29 1.29E-02 2.49
SSR3 Signal Sequence Receptor Subunit 3 217790_s_at 7.86 0.67 10.12 0.77 1.50E-02 2.26
RSAD2
Radical S-Adenosyl Methionine 
Domain Containing 2
242625_at 4.68 0.40 8.06 2.04 1.91E-02 3.38
FBXO22 F-Box Protein 22 225737_s_at 5.40 0.27 7.37 0.95 1.91E-02 1.97








204187_at 6.36 0.35 8.18 0.93 4.02E-02 1.82
1 Standard devia�on
2 LIMMA
Table 4.3: Genes which posi�vely correlate with CDH2  expression in t(4;14)- MM pa�ents and are 
significantly up-regulated in MM PCs compared with normal PCs
normal MM normal v MM
Figure 4.3.  BTBD3 expression positively correlates with CDH2 expression in 
t(4;14)-MM patients, and is significantly up-regulated in MM PCs. BTBD3 and 
CDH2 correlation in 4 independent, publicly available microarray datasets of CD138-
selected BM-derived MM PCs from newly-diagnosed individuals (E-MTAB-363, E-
GEOD-19784, E-MTAB-317 and E-GEOD-26863) (Spearman's rank correlation co-
efficient (R), FDR-adjusted P value <0.001 for each dataset) (A). BTBD3 expression in 
CD138-selected BM-derived PCs from normal individuals (n = 5), and newly-diagnosed 
MGUS (n = 5) and MM (n = 155) patients (E-MTAB-363). **P < 0.05 compared with 
normal individuals (LIMMA) (B). Kaplan-Meier plot of overall survival for newly-
diagnosed MM patients in GSE4581, stratified on the basis of MMSET and BTBD3 
expression (MMSETlow/BTBD3low patients, n = 169; MMSETlow/BTBD3high, n = 171; 
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33.9%; E-GEOD-26863: 58/146, 39.7%) (Figure 4.3A). Previous studies have 
demonstrated that N-cadherin gene and protein expression can be regulated by 
miRNAs, either by directly targeting the 3'-UTR of CDH2 or genes encoding for 
proteins which are known regulators of N-cadherin expression in cancer cells.22,63-73 In 
order to determine whether miRs may down-regulate CDH2 expression in t(4;14)- MM, 
we performed in silico analysis of a publicly available microarray dataset which 
included miRNA expression and mRNA expression in CD138-selected BM PCs from 
60 newly-diagnosed MM patients (GSE16558). Of the 60 patients in this dataset, 43 
(71.7%) were t(4;14)-, as determined by expression of MMSET and FGFR3 
(Supplementary Figure 4.1F) and by FISH (data not shown). Consistent with the data 
shown in Figure 4.3A, a large proportion (24/34, 70.6%) of t(4;14)- MM patients that 
express BTBD3 in this dataset do not express CDH2. In order to investigate whether the 
expression of specific miRNAs could be down-regulating CDH2 in these patients, we 
compared miRNA expression between the CDH2high (n = 14) and CDH2low (n = 29) 
t(4;14)- MM patients in this dataset. We identified 8 miRNAs that were more than two-
fold up-regulated in CDH2low t(4;14)- MM patients, when compared with CDH2high 
t(4;14)- MM patients (Table 4.4). In order to assess whether these miRNA could 
potentially directly regulate CDH2 expression, we examined the predicted targets for 
these miRNA in three independent databases (TargetScan, PicTar, miRdb) and 
identified those miRNA that were predicted to target CDH2 in at least two databases. 
Collectively, these miRNAs were predicted to target 40 genes identified in our CDH2 
correlative analysis, including BTBD3, IL6ST, FBXO22, COPS2 and E2F5 (Table 4.4). 
miR-190, which is up-regulated 2.26-fold in CDH2low t(4;14)- MM patients, is predicted 
to target CDH2. Notably, of the t(4;14)- MM patients that express miR-190, 10 of 11 
(91%) expressed low or undetectable levels of CDH2 (Supplementary Figure 4.3A and 
Table 4.5). Moreover, of the t(4;14)- MM patients that express CDH2, 13 of 14 (93%) 
expressed low or undetectable levels of miR-190. These data strongly suggest that miR-
190 may suppress CDH2 expression in t(4;14)- MM patients (Supplementary Figure 
4.2B). 
 We further hypothesised that expression of miR-190 may prevent the up-
regulation of CDH2 by BTBD3 in some t(4;14)- MM patients. In support of this, of the 
t(4;14)- MM patients that express both BTBD3 and miR-190, 8 of 8 (100%) expressed 
low or undetectable levels of CDH2 (Table 4.5). Moreover, of the t(4;14)- BTBD3high 
MM patients that express CDH2, 10 of 10 (100%) expressed low or undetectable levels 
hsa-miR-339 1.63 TAPBP
E2F5 FHAD1 BAI3 MTX3 ST8SIA4
COPS2 CMPK2 BTBD3
hsa-miR-6503 1.30 N/A
E2F5 IL6ST TRIM13 SIX4 CCDC85A
ZC3H12C BAI3 FBXO22 MTX3 FLI1
CADM1 SCN8A PALM2-AKAP2 SMOC1 TMEM161B
COPS2 CHSY3 CNTN5 SCAMP5 TRAT1
RPL37 COL4A5 CDH2 PCDH9
CTDSPL2 SIX4 FAM96A FLI1 CADM1
COPS2
SCAMP1 CCDC85A ZC3H12C RAB8B CMPK2
CNTN5 COL4A5 E2F5
NOL6 HOMER1 SMOC1 TMEM161B COL4A5
C21orf91
NCK1 ANP32A E2F5 MRPS30 SIX4
FBXO22 MTX3 CADM1 PIP5K1B RBM7
ZNF622 RAB8B CDV3 PALM2-AKAP2 COPS2
ELOVL7 CDC42SE2
1 miRNAs more than two-fold up-regulated in CDH2low t(4;14)- MM pa�ents, compared with CDH2high 
t(4;14)- MM pa�ents, and their predicted targets within the 218 genes which posi�vely or inversely
correlate with CDH2  expression in t(4;14)- MM pa�ents
2 Targets predicted in at least 2 of 3 databases (TargenScan; Pictar; MiRdb)







Table 4.4: miRNAs that are inversely associated with CDH2  expression in t(4;14)- MM pa�ents, 
and their predicted targets1
Predicted targets2
Log2 fold change 
(CDH2 low vs 
CDH2 high)
miRNA
Table 4.5: CDH2  and miR-190 expression in BTBD3 low and 
 BTBD3high t(4;14)- MM pa�ents
Total miR-190+ miR-190- miR-190+ miR-190-
CDH2 low 29 2 3 8 16
CDH2 high 14 1 3 0 10
t(4;14)-
BTBD3 low BTBD3 high
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of miR-190 (Table 4.5). These data suggest that, while BTBD3 may drive CDH2 
expression in t(4;14)- MM patients, this may be suppressed in some patients by 
expression of miR-190. 
 
4.4.4 Modulation of BTBD3 expression in HMCLs does not alter CDH2 
expression  
To investigate whether BTBD3 is a regulator of CDH2 expression in vitro, we 
modulated BTBD3 expression in HMCLs. The BTBD3 gene encodes for 6 mRNA 
transcript variants that encode 4 different isoforms of BTBD3 protein (a [522 aa], 
predicted to be translated from transcript variant 1; b [461 aa], from transcript variants 3 
and 4; c [371 aa], from transcript variants 5 and 6; d [565 aa] from transcript variant 2). 
Initially, we assessed total BTBD3 mRNA expression levels in a panel of t(4;14)- and 
t(4;14)+ HMCLs, using primers to a region common to all 6 BTBD3 transcript variants 
(Supplementary Figure 4.4A). Additionally, we screened a panel of BTBD3+ HMCLs to 
identify the prominent BTBD3 protein isoforms endogenously expressed in these cells, 
using an antibody specific for isoforms a, b and d (Supplementary Figure 4.4B). A band 
corresponding to the predicted molecular weight of isoform b (52 kDa) and isoform a 
(58 kDa) was detectable in LP-1 cells, while isoform b alone was detectable in RPMI-
8226, U266 and OPM2 cells. As the smallest BTBD3 isoform (c) (41 kDa) does not 
contain the epitope recognised by the anti-BTBD3 antibody used, we could not confirm 
whether this isoform is endogenously expressed in HMCLs. 
 To investigate whether BTBD3 regulates CDH2 expression in vitro, we over-
expressed BTBD3 in t(4;14)- HMCLs which endogenously express low levels of total 
BTBD3 (Supplementary Figure 4.4A) and CDH2 (Figure 4.1A), with high (RPMI-8226) 
or low (U266) levels of miR-190 (Supplementary Figure 4.3B). To this end, we over-
expressed the predominant BTBD3 isoforms detected in HMCLs (a and b), as well as 
isoform c, in these HMCLs using BTBD3 transcript variants 1 (for isoforms a and b) 
and 6 (for isoform c). Over-expression of BTBD3 transcript variant 1 or 6 in RPMI-
8226 (RPMI-8226-BTBD3var.1 and RPMI-8226-BTBD3var.6) and U266 cells (U266-
BTBD3var.1 and U266-BTBD3var.6) resulted in more than a 300-fold increase in total 
BTBD3 transcript levels, compared with empty vector (EV)-containing cells (RPMI-
8226-EV and U266-EV), as shown by qPCR (P < 0.0001) (Figure 4.4A,B). At the 
protein level, RPMI-8226-BTBD3var.1 and U266-BTBD3var.1 cells demonstrated 
marked up-regulation of BTBD3 protein bands corresponding to isoforms a and b, 
Figure 4.4.  BTBD3 over-expression does not up-regulate N-cadherin mRNA or 
protein expression in HMCLs. Total BTBD3 expression in RPMI-8226 (A) and U266 
(B) cells (normalised to ACTB expression), as assessed by qPCR, following over-
expression of BTBD3 transcript variant 1 or 6 (BTBD3var.1 and BTBD3var.6). Graphs 
depict mean ± SEM of 3 independent experiments. ****P < 0.0001 compared with 
empty vector (EV)-containing cells (EV) (one-way ANOVA with Dunnett's multiple 
comparisons test) (A,B). BTBD3 expression in RPMI-8226 (C) and U266 (D) cells 
following over-expression of BTBD3 transcript variant 1 (var.1) or 6 (var.6), relative to 
EV-containing cells (top panels), as assessed by Western blot. Histone H3 (H3) was 
utilised as a nuclear protein load control (bottom panels) (C,D). CDH2 expression in 
RPMI-8226 (E) and U266 (F) cells (normalised to ACTB expression), as assessed by 
qPCR, following over-expression of BTBD3 transcript variant 1 or 6. Graphs depict 
mean ± SEM of 3 independent experiments. ****P < 0.0001 compared with EV-
containing cells (one-way ANOVA with Dunnett's multiple comparisons test) (E,F). N-
cadherin expression in RPMI-8226-EV cells (blue line) and RPMI-8226-BTBD3var.1 
cells (orange line), as assessed by flow cytometry. Shaded area represents RPMI-8226-
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compared with the corresponding EV-containing cells (Figure 4.4C,D). Due to the 
limitation of the anti-BTBD3 antibody, we could not confirm over-expression of 
BTBD3 isoform c in RPMI-8226-BTBD3var.6 and U266-BTBD3var.6 cells at the 
protein level. qPCR revealed that CDH2 expression was down-regulated in RPMI-8226-
BTBD3var.1 and RPMI-8226-BTBD3var.6 cells, compared with RPMI-8226-EV cells 
(Figure 4.4E), while CDH2 expression was un-changed in U266-BTBD3var.1 and 
U266-BTBD3var.6 cells, compared with U266-EV cells (Figure 4.4F). In line with the 
qPCR data, N-cadherin expression was also reduced in RPMI-8226-BTBD3var.1 cells 
compared with RPMI-8226-EV cells, as shown by flow cytometry (Figure 4.4G). Taken 
together, these results suggest that BTBD3 over-expression in t(4;14)- HMCLs does not 
up-regulate N-cadherin gene or protein expression.  
 As miR-190 is expressed in both RPMI-8226 and U266 HMCLs, it is possible 
that miR-190 may be preventing the up-regulation of CDH2 in BTBD3-overexpressing 
t(4;14)- HMCLs. In order to independently investigate whether BTBD3 regulates CDH2 
expression in t(4;14)- MM, we performed siRNA-mediated knock-down studies using 
the t(4;14)- HMCL KMS-26 which co-expresses BTBD3 (Supplementary Figure 4.4A) 
and CDH2 (Figure 4.1A). Treatment of KMS-26 cells with BTBD3-targeting siRNA at 
days 0 and 2 resulted in a 62-68% knock-down of total BTBD3 mRNA levels at day 4 
using BTBD3 siRNA#1 and siRNA#2, compared with KMS-26 cells treated with 
negative control siRNA (P < 0.001) (Figure 4.5A). However, CDH2 expression was not 
significantly reduced at day 4 in KMS-26 cells following treatment with BTBD3-
targeting siRNA, compared with KMS-26 cells treated with negative control siRNA 
(Figure 4.5B). These data demonstrate that down-regulation of BTBD3 does not reduce 
CDH2 expression in a t(4;14)- HMCL, suggesting that miR-190 expression is therefore 
unlikely to account for the inability of BTBD3 over-expression to up-regulate N-
cadherin expression in t(4;14)- HMCLs. Taken together, these data demonstrate that 




Figure 4.5.  BTBD3 knock-down does not down-regulate CDH2 expression in the 
t(4;14)- HMCL KMS-26. Total BTBD3 (A) and CDH2 (B) expression in KMS-26 cells 
(normalised to ACTB expression), as assessed by qPCR, following transfection with 
BTBD3-targeting siRNA (siRNA#1, siRNA#2 and siRNA#3). Graphs depict mean ± 
SEM of 3-6 independent experiments. ***P < 0.001 compared with KMS-26 cells 
transfected with negative control siRNA (NC siRNA) (one-way ANOVA with 














































































In the solid tumour context, N-cadherin is up-regulated by a range of extracellular 
stimuli (e.g. TGF-β superfamily, ligands of receptor tyrosine kinases, chemokines and 
extracellular matrix proteins) and is often associated with the induction of a broader 
epithelial-to-mesenchymal cellular transition (EMT).74-84 These stimuli activate a 
number of intracellular signalling cascades which, in turn, orchestrate the activation of 
transcription factors Twist1 and Slug, which positively regulate N-cadherin 
expression.15,74,75,78,81-83,85-103 Previous studies have also shown that the histone 
methyltransferase MMSET promotes EMT in prostate cancer cells, including the up-
regulation of N-cadherin.38 Similarly, expression of the N-cadherin gene, CDH2, is up-
regulated in MM patients with the chromosomal translocation t(4;14), which leads to 
constitutive over-expression of MMSET and, in approximately 70% of patients, up-
regulation of FGFR3.26,41 In line with these findings, we found that CDH2 is up-
regulated in the majority of MMSEThigh MM patients irrespective of FGFR3 expression, 
suggesting that MMSET and not FGFR3 is responsible for up-regulation of CDH2 in 
these patients. Furthermore, we have demonstrated that MMSET is a bona fide regulator 
of CDH2 expression in MM, as evidenced by the up-regulation of CDH2 following the 
over-expression of MMSET in MMSETlow MM PCs, supporting previous findings.41 
Consistent with previous studies in human prostate cancer cells38, we demonstrated that 
mutation of the MMSET histone-binding domain abrogated MMSET-mediated up-
regulation of CDH2 in MM PCs, suggesting that the histone methyltransferase activity 
of MMSET is critical in regulating CDH2 expression in MM. Notably, studies in human 
prostate cancer cells have shown that Twist1 is a direct target of MMSET. However, 
while MMSET-over-expression has been shown to up-regulate both Twist1 and N-
cadherin expression in prostate cancer cells, siRNA-mediated knock-down of Twist1 
cells in MMSET-over-expressing cells did not reduce N-cadherin expression, 
suggesting that MMSET may directly target the N-cadherin gene, or activate an 
alternate inducer of N-cadherin expression.38 
 In addition to t(4;14)+ MM, our studies demonstrate that CDH2 is up-regulated 
in another 40-45% of newly-diagnosed patients despite having MMSETlow status. 
Previous studies have shown that CDH2 is up-regulated in a distinct population of MM 
patients in the hyperdiploidy-related sub-group.26 In line with these findings, our GSEA 
of genes which positively correlated with CDH2 expression in MMSETlow MM patients 
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revealed an enrichment in genes that are associated with a hyperdiploidy-related gene 
signature. Of the genes which positively correlated with CDH2 in MMSETlow MM 
patients, BTBD3 was the most strongly up-regulated in MM PCs, suggesting that 
BTBD3 may be a candidate 'driver' of CDH2 expression in t(4;14)- MM. Similar to 
CDH2 expression, gene expression profiling studies have previously reported an 
association between BTBD3 expression and hyperdiploidy-related MM patients 
subsets.104,105 Additionally, in MM patients, BTBD3 expression has previously been 
associated with elevated expression of NCAM1106, which also positively correlated with 
CDH2 expression in our analyses. On the basis of the observation that BTBD3 was 
consistently up-regulated in MMSETlowCDH2high MM patients and the up-regulation of 
BTBD3 in MM PCs, we hypothesized that BTBD3 may positively regulate CDH2 
expression in t(4;14)- MM. Collectively, however, our BTBD3 over-expression and 
siRNA-mediated BTBD3 knockdown studies in t(4;14)- HMCLs revealed that BTBD3 
is unlikely to be a key driver of CDH2 expression in t(4;14)- MM patients. 
 Further examination of our in silico analyses revealed other candidates which 
have previously been implicated in the regulation of CDH2 expression in other cancers. 
Janus kinase/signal transducer and activator 3 (JAK/STAT3) signalling is widely 
implicated in tumourigenesis, and has been shown to positively regulate N-cadherin 
expression in cancer cells.75,81,91,93,97,107 Indeed, studies have implicated an IL-
6/JAK/STAT3 signalling axis in the up-regulation of N-cadherin expression in 
melanoma and cancers of the pancreas, stomach, lung and ovary.75,81,91,93,97 In MM, IL-
6-mediated signalling also plays an important role in tumour cell growth and 
proliferation.108-112 Notably, our CDH2 correlative analyses identified several genes 
which functionally converge to participate in, or regulate, the JAK/STAT3 signalling. 
These include genes encoding for IL-6 signal transducer (IL6ST/gp130; IL6ST) and 
basic transcription factor 3 (BTF3; BTF3) (both positively correlated with CDH2 
expression) and the sphingolipid metabolism enzyme, sphingosine-1-phosphate lyase 1 
(S1PL; SGPL1) (inversely correlated with CDH2 expression). IL6ST is a critical 
signalling-transducer subunit of IL-6-family cytokine receptor complexes and has been 
shown to promote tumourigenesis in various cancers, including MM.113,114 The binding 
of IL-6 to its cognate IL-6 receptor-IL6ST complex activates JAK, which, in turn, 
activates STAT3-mediated gene transcription.107,113 BTF3 is an evolutionarily 
conserved transcription factor which is aberrently expressed in colorectal and prostate 
cancer.115-117 In addition to promoting cancer cell proliferation, recent studies have 
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shown that BTF3 positively regulates expression of CDH2 in a STAT3 signalling-
dependent manner, and promotes metastasis in vivo.118,119 Notably, down-regulation of 
CDH2 expression following BTF3 knock-down in gastric cancer cells was rescued 
following IL-6-induced activation of STAT3.119 Studies have also shown that the loss of 
S1PL, which degrades the cell signalling molecule, sphingosine-1-phosphate, 
potentiates STAT3 signalling and promotes oncogenesis.120-122 Thus, whether aberrant 
JAK/STAT3 signalling up-regulates CDH2 expression in t(4;14)- MM warrants 
investigation. 
 Other genes of interest emanating from our studies include PAK1 (p21-activated 
kinase-1; Pak1), FER (tyrosine-protein kinase Fer; Fer) and ZNF622 (zinc finger protein 
622; ZNF622) which positively correlate with CDH2 in t(4;14)- MM. In concordance 
with our findings, studies have recently reported a positive correlation between Pak1 
and N-cadherin levels in clinical samples of non-small cell lung carcinoma.123 In 
prostate cancer cells, the Rac1-Pak1 signalling axis has been shown to potentiate TGF-
β1-mediated up-regulation of N-cadherin, which can be suppressed by functional 
inhibition of Pak1.88 Notably, Fer is an upstream mediator of Rac1-Pak1 signalling124, 
suggesting a potential Fer-Rac1-Pak1-N-cadherin signalling axis may exist in MM. 
KRAS, mutated in approximately 20% of MM patients3, is another activator of Rac1-
Pak1 signalling in epithelial cancers125, further implicating Rac1-Pak1 in CDH2 
regulation in MM. ZNF622 is also of interest as it binds to and activates the 
transcription factor B-Myb.126 Previous studies have shown that B-Myb knock-down 
reduces N-cadherin expression in both glioma and breast cancer cells127,128, suggesting 
that ZNF622-mediated activation of B-Myb may be another mechanism whereby CDH2 
is up-regulated in MM. To date, however, a functional role for these genes in MM has 
not been investigated.  
 Our in silico analysis of miRNA expression profiles revealed an 8-miRNA 
expression signature which was inversely associated with CDH2 levels in newly-
diagnosed t(4;14)- MM patients. miR-190, previously implicated in colorectal, breast 
and pancreatic cancer129-131, is of particular interest as it is predicted to target the 3'-
UTR of CDH2. Tellingly, CDH2 expression was low or undetectable in over 90% (10 
of 11) of miR-190-expressing t(4;14)- MM patients in our analysis, suggesting that miR-
190 may suppress CDH2 expression in these patients. IL6ST is also a predicted target of 
miR-190, suggesting miR-190 may negatively regulate IL-6/JAK/STAT3 signalling in 
MM. Another candidate regulator of CDH2 expression in t(4;14)- MM is miR-214, 
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which was recently shown to negatively regulate N-cadherin expression in cervical 
cancer cells.132 miR-214 is also down-regulated, and inhibits tumour cell invasion and 
metastasis, in several cancers including liver, bladder and colon cancer.132-137 While not 
predicted to target CDH2, miR-339 and miR-193b may also be of interest, as down-
regulation of these miRNAs is associated with increased cancer invasivness.138-143 In 
addition, miR-545 is predicted to target ZNF622, suggesting that a miR-545/ZNF622/B-
Myb axis may regulate CDH2 expression in t(4;14)- MM. Notably, a number of other 
genes identified in our CDH2 correlative analyses are also predicted to be targeted by 
one or more miRNAs within the 8-miRNA expression signature, including E2F5 (E2F 
transcription factor 5) and FBXO22 (F-box protein 22). While a role for these genes in 
CDH2 regulation has not been demonstrated, their functional role as transcriptional 
regulators144-148 and their strong correlation with CDH2 expression in t(4;14)- MM, 
suggests that further investigation of their potential regulation of CDH2 in MM is 
warranted.  
 While our studies demonstrated that BTBD3 does not regulate CDH2 expression 
in HMCLs, our analyses show, for the first time, that BTBD3 expression is strongly up-
regulated in BM PCs from MM patients, compared with normal controls. Furthermore, 
we found that elevated BTBD3 expression in BM MM PCs is associated with a trend 
towards poorer overall survival in t(4;14)- patients, suggesting a role for BTBD3 in MM 
pathogenesis. Structurally, BTBD3 contains an evolutionarily-conserved BTB/POZ 
(Broad-complex, Tramtrak, Bric-a-brac/poxvirus and zinc finger; BTB) protein-protein 
interaction domain at the N-terminus, a postulated substrate adaptor for cullin3 E3 
ubiquitin ligase which targets proteins for proteasome-mediated degradation.149,150 
Cullin3 E3 ubiquitin ligase complexes are implicated in the destruction of a wide range 
of substrates including transcriptional regulators and signalling proteins, thereby 
regulating developmental and cancer-associated signalling pathways.151-154 BTB 
domains are also found in 5-10% of C2H2-type zinc-finger transcription factors (e.g. 
BCL6 and PLZF) which function as transcriptional repressors by interacting with co-
repressor complexes such as histone deacetylases.155,156 Towards its C-terminus, 
BTBD3 also contains a BACK domain and a PHR domain which are also speculated to 
play a role in cullin3 E3 ubiquitin ligase function.157,158 Thus, it is plausible that BTBD3 
also functions as a repressor of gene transcription or cell signalling. While the function 
of BTBD3 has not been fully elucidated, BTBD3 is highly expressed in the brain159-161 
and has been implicated in dendritic field orientation within the visual cortex162 and the 
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barrel cortex161,162 in mice. In cancer, BTBD3 knock-down has been reported to 
decrease the migration of hepatocellular carcinoma cells in vitro.163 Given our 
observation that BTBD3 is strongly up-regulated in MM patients, and may be associated 
with poor prognosis in at least some MM patients, further studies investigating the role 
of BTBD3 in MM are warranted. 
 In summary, we have demonstrated that MMSET, universally dysregulated in 
t(4;14)+ MM patients, is a bona fide regulator of CDH2 expression in MM cells, 
suggesting it is a key driver of up-regulated N-cadherin in t(4;14)+ MM. While our 
studies suggest that BTBD3 is unlikely to be a key driver of CDH2 expression in 
t(4;14)- MM, we have identified several other pathways that may represent previously 
unknown, MMSET-independent regulators of N-cadherin expression in MM. In 
addition, we have identified that miR-190 is strongly associated with down-regulation 
of CDH2 expression in t(4;14)- MM patients, which may represent an alternative 
mechanism of N-cadherin regulation in these patients. Finally, our studies have 
identified BTBD3 as a novel factor that may play a role in the pathogenesis of MM. To 























The authors would like to thank Prof. Jonathan Licht for providing the pRetroX-
MMSET-DsRed and pRetroX-DsRed vectors, and Dr Randall Grose for assistance with 
flow cytometry. This research was supported by a grant from the Cancer Australia 
Priority-driven Collaborative Cancer Research Scheme, co-funded by the Leukaemia 
Foundation. Kate Vandyke was supported by a fellowship from the Multiple Myeloma 
Research Foundation and by a Mary Overton Early Career Research Fellowship (Royal 
Adelaide Hospital). 
 




1. www.myeloma.org.au. Myeloma - a comprehensive guide. Vic, Australia; 2016. 
 
2. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat 
Rev Cancer. 2017; 17(9):543-556. 
 
3. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic 
complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 
2017; 14(2):100-113. 
 
4. Williams EJ, Furness J, Walsh FS, Doherty P. Activation of the FGF receptor 
underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin. Neuron. 1994; 
13(3):583-594. 
 
5. Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, Calvi LM. 
Osteoblastic N-cadherin is not required for microenvironmental support and regulation 
of hematopoietic stem and progenitor cells. Blood. 2012; 120(2):303-313. 
 
6. Navarro P, Ruco L, Dejana E. Differential localization of VE- and N-cadherins 
in human endothelial cells: VE-cadherin competes with N-cadherin for junctional 
localization. J Cell Biol. 1998; 140(6):1475-1484. 
 
7. Charrasse S, Meriane M, Comunale F, Blangy A, Gauthier-Rouviere C. N-
cadherin-dependent cell-cell contact regulates Rho GTPases and beta-catenin 
localization in mouse C2C12 myoblasts. J Cell Biol. 2002; 158(5):953-965. 
 
8. Sabatini PJ, Zhang M, Silverman-Gavrila R, Bendeck MP, Langille BL. 
Homotypic and endothelial cell adhesions via N-cadherin determine polarity and 
regulate migration of vascular smooth muscle cells. Circ Res. 2008; 103(4):405-412. 
 
9. Theveneau E, Marchant L, Kuriyama S, Gull M, Moepps B, Parsons M, Mayor 
R. Collective chemotaxis requires contact-dependent cell polarity. Dev Cell. 2010; 
19(1):39-53. 
 
10. Ouyang M, Lu S, Kim T, Chen CE, Seong J, Leckband DE, Wang F, Reynolds 
AB, Schwartz MA, Wang Y. N-cadherin regulates spatially polarized signals through 
distinct p120ctn and beta-catenin-dependent signalling pathways. Nat Commun. 2013; 
4:1589. 
 
11. Giampietro C, Taddei A, Corada M, Sarra-Ferraris GM, Alcalay M, Cavallaro 
U, Orsenigo F, Lampugnani MG, Dejana E. Overlapping and divergent signaling 
pathways of N-cadherin and VE-cadherin in endothelial cells. Blood. 2012; 
119(9):2159-2170. 
 
12. Lelievre EC, Plestant C, Boscher C, Wolff E, Mege RM, Birbes H. N-cadherin 
mediates neuronal cell survival through Bim down-regulation. PLoS One. 2012; 
7(3):e33206. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
125 
 
13. Hay E, Nouraud A, Marie PJ. N-cadherin negatively regulates osteoblast 
proliferation and survival by antagonizing Wnt, ERK and PI3K/Akt signalling. PLoS 
One. 2009; 4(12):e8284. 
 
14. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, 
Williams TM, Lisanti MP, Knudsen K et al. N-cadherin signaling potentiates mammary 
tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer 
Res. 2007; 67(7):3106-3116. 
 
15. Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I 
promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 
and up-regulating N-cadherin expression. Cancer Res. 2006; 66(24):11745-11753. 
 
16. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, 
Wada R, Huang J, Vessella RL et al. Monoclonal antibody targeting of N-cadherin 
inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010; 
16(12):1414-1420. 
 
17. Klymenko Y, Kim O, Loughran E, Yang J, Lombard R, Alber M, Stack MS. 
Cadherin composition and multicellular aggregate invasion in organotypic models of 
epithelial ovarian cancer intraperitoneal metastasis. Oncogene. 2017; 36(42):5840-5851. 
 
18. Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter 
H, Smit VT, van de Velde CJ, Liefers GJ, Kuppen PJ. Expression of cell adhesion 
molecules and prognosis in breast cancer. Br J Surg. 2013; 100(2):252-260. 
 
19. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin 
to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong 
and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007; 
13(23):7003-7011. 
 
20. Hui L, Zhang S, Dong X, Tian D, Cui Z, Qiu X. Prognostic significance of twist 
and N-cadherin expression in NSCLC. PLoS One. 2013; 8(4):e62171. 
 
21. Abufaraj M, Haitel A, Moschini M, Gust K, Foerster B, Ozsoy M, D'Andrea D, 
Karakiewicz PI, Roupret M, Briganti A et al. Prognostic Role of N-cadherin Expression 
in Patients With Invasive Bladder Cancer. Clin Genitourin Cancer. 2017. 
 
22. Zhou SJ, Liu FY, Zhang AH, Liang HF, Wang Y, Ma R, Jiang YH, Sun NF. 
MicroRNA-199b-5p attenuates TGF-beta1-induced epithelial-mesenchymal transition 
in hepatocellular carcinoma. Br J Cancer. 2017; 117(2):233-244. 
 
23. Zhang J, Cheng Q, Zhou Y, Wang Y, Chen X. Slug is a key mediator of hypoxia 
induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol. 
2013; 49(11):1043-1050. 
 
24. Okubo K, Uenosono Y, Arigami T, Yanagita S, Matsushita D, Kijima T, 
Amatatsu M, Uchikado Y, Kijima Y, Maemura K et al. Clinical significance of altering 
epithelial-mesenchymal transition in metastatic lymph nodes of gastric cancer. Gastric 
Cancer. 2017; 20(5):802-810. 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
126 
 
25. Vandyke K, Chow AW, Williams SA, To LB, Zannettino AC. Circulating N-
cadherin levels are a negative prognostic indicator in patients with multiple myeloma. 
Br J Haematol. 2013; 161(4):499-507. 
 
26. Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, 
Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL et al. N-cadherin-
mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. 
Haematologica. 2011; 96(11):1653-1661. 
 
27. Sadler NM, Harris BR, Metzger BA, Kirshner J. N-cadherin impedes 
proliferation of the multiple myeloma cancer stem cells. American journal of blood 
research. 2013; 3(4):271-285. 
 
28. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, 
Bhatia R. Microenvironmental protection of CML stem and progenitor cells from 
tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood. 
2013; 121(10):1824-1838. 
 
29. Zhi L, Wang M, Rao Q, Yu F, Mi Y, Wang J. Enrichment of N-Cadherin and 
Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance. 
Cancer Lett. 2010; 296(1):65-73. 
 
30. Qiu S, Jia Y, Xing H, Yu T, Yu J, Yu P, Tang K, Tian Z, Wang H, Mi Y et al. 
N-Cadherin and Tie2 positive CD34(+)CD38(-)CD123(+) leukemic stem cell 
populations can develop acute myeloid leukemia more effectively in NOD/SCID mice. 
Leuk Res. 2014; 38(5):632-637. 
 
31. Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase 
inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. 
Leukemia. 2007; 21(6):1189-1197. 
 
32. Marjon KD, Termini CM, Karlen KL, Saito-Reis C, Soria CE, Lidke KA, 
Gillette JM. Tetraspanin CD82 regulates bone marrow homing of acute myeloid 
leukemia by modulating the molecular organization of N-cadherin. Oncogene. 2016; 
35(31):4132-4140. 
 
33. Zhi L, Gao Y, Yu C, Zhang Y, Zhang B, Yang J, Yao Z. N-Cadherin Aided in 
Maintaining the Characteristics of Leukemic Stem Cells. Anat Rec (Hoboken). 2016; 
299(7):990-998. 
 
34. Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, Rollinson 
S, Rawstron AC, Rees-Unwin KS, Li C et al. A global expression-based analysis of the 
consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004; 
10(17):5692-5701. 
 
35. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, 
Pilarski LM. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor 
irrespective of FGFR3 expression. Blood. 2003; 101(4):1520-1529. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
127 
 
36. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. 
Improving overall survival and overcoming adverse prognosis in the treatment of 
cytogenetically high-risk multiple myeloma. Blood. 2013; 121(6):884-892. 
 
37. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) 
translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, 
resulting in IgH/MMSET hybrid transcripts. Blood. 1998; 92(9):3025-3034. 
 
38. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, Will C, 
Neri A, Kelleher NL, Yu J et al. The histone methyltransferase MMSET/WHSC1 
activates TWIST1 to promote an epithelial-mesenchymal transition and invasive 
properties of prostate cancer. Oncogene. 2012; 32(23):2882-2890. 
 
39. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, 
Heffner A, Will C, Lamy L, Staudt LM et al. The MMSET histone methyl transferase 
switches global histone methylation and alters gene expression in t(4;14) multiple 
myeloma cells. Blood. 2011; 117(1):211-220. 
 
40. Huang Z, Wu H, Chuai S, Xu F, Yan F, Englund N, Wang Z, Zhang H, Fang M, 
Wang Y et al. NSD2 is recruited through its PHD domain to oncogenic gene loci to 
drive multiple myeloma. Cancer Res. 2013; 73(20):6277-6288. 
 
41. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, 
Matsui W, Park BH. The multiple myeloma associated MMSET gene contributes to 
cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008; 111(2):856-864. 
 
42. Reme T, Hose D, Theillet C, Klein B. Modeling risk stratification in human 
cancer. Bioinformatics. 2013; 29(9):1149-1157. 
 
43. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs 
A, Stevens-Kroef M, Beverloo HB et al. Gene expression profiling for molecular 
classification of multiple myeloma in newly diagnosed patients. Blood. 2010; 
116(14):2543-2553. 
 
44. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, 
Harview CL, Brunet JP, Ahmann GJ, Adli M et al. Initial genome sequencing and 
analysis of multiple myeloma. Nature. 2011; 471(7339):467-472. 
 
45. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, Benner A, 
Shaughnessy JD, Jr., Barlogie B, Zhou Y et al. Proliferation is a central independent 
prognostic factor and target for personalized and risk-adapted treatment in multiple 
myeloma. Haematologica. 2011; 96(1):87-95. 
 
46. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby 
S, Sawyer J, Burington B et al. The molecular classification of multiple myeloma. 
Blood. 2006; 108(6):2020-2028. 
 
47. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, 
Garcia BA et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic 
programming. Mol Cell. 2011; 44(4):609-620. 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
128 
 
48. Vandyke K, Zeissig MN, Hewett DR, Martin SK, Mrozik KM, Cheong CM, 
Diamond P, To LB, Gronthos S, Peet DJ et al. HIF-2alpha Promotes Dissemination of 
Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. Cancer 
Res. 2017; 77(20):5452-5463. 
 
49. Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, 
Zannettino AC. PTTG1 expression is associated with hyperproliferative disease and 
poor prognosis in multiple myeloma. J Hematol Oncol. 2015; 8:106. 
 
50. Cheong CM, Chow AW, Fitter S, Hewett DR, Martin SK, Williams SA, To LB, 
Zannettino AC, Vandyke K. Tetraspanin 7 (TSPAN7) expression is upregulated in 
multiple myeloma patients and inhibits myeloma tumour development in vivo. Exp Cell 
Res. 2015; 332(1):24-38. 
 
51. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las 
Rivas J, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A et al. 
Deregulation of microRNA expression in the different genetic subtypes of multiple 
myeloma and correlation with gene expression profiling. Leukemia. 2010; 24(3):629-
637. 
 
52. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. 
The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 
2015; 1(6):417-425. 
 
53. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA 
target sites in mammalian mRNAs. Elife. 2015; 4. 
 
54. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, 
da Piedade I, Gunsalus KC, Stoffel M et al. Combinatorial microRNA target 
predictions. Nat Genet. 2005; 37(5):495-500. 
 
55. Wong N, Wang X. miRDB: an online resource for microRNA target prediction 
and functional annotations. Nucleic Acids Res. 2015; 43(Database issue):D146-152. 
 
56. Zhang X, Fitzsimmons RL, Cleland LG, Ey PL, Zannettino AC, Farmer EA, 
Sincock P, Mayrhofer G. CD36/fatty acid translocase in rats: distribution, isolation from 
hepatocytes, and comparison with the scavenger receptor SR-B1. Lab Invest. 2003; 
83(3):317-332. 
 
57. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25(4):402-
408. 
 
58. Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. 
SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia. 2014; 16(7):572-
585. 
 
59. Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, Gronthos 
S. TWIST family of basic helix-loop-helix transcription factors mediate human 
mesenchymal stem cell growth and commitment. Stem Cells. 2009; 27(10):2457-2468. 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
129 
 
60. Weber K, Bartsch U, Stocking C, Fehse B. A multicolor panel of novel lentiviral 
"gene ontology" (LeGO) vectors for functional gene analysis. Mol Ther. 2008; 
16(4):698-706. 
 
61. Smyth GK. Linear models and empirical bayes methods for assessing 
differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 
3:Article3. 
 
62. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, 
Currier T, Thiagarajan M et al. TM4: a free, open-source system for microarray data 
management and analysis. Biotechniques. 2003; 34(2):374-378. 
 
63. Mudduluru G, Abba M, Batliner J, Patil N, Scharp M, Lunavat TR, Leupold JH, 
Oleksiuk O, Juraeva D, Thiele W et al. A Systematic Approach to Defining the 
microRNA Landscape in Metastasis. Cancer Res. 2015; 75(15):3010-3019. 
 
64. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W. miR-194 is a 
marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. 
Hepatology. 2010; 52(6):2148-2157. 
 
65. Suzuki T, Mizutani K, Minami A, Nobutani K, Kurita S, Nagino M, Shimono Y, 
Takai Y. Suppression of the TGF-beta1-induced protein expression of SNAI1 and N-
cadherin by miR-199a. Genes Cells. 2014; 19(9):667-675. 
 
66. Mo D, Yang D, Xiao X, Sun R, Huang L, Xu J. MiRNA-145 suppresses lung 
adenocarcinoma cell invasion and migration by targeting N-cadherin. Biotechnol Lett. 
2017; 39(5):701-710. 
 
67. Ma T, Zhao Y, Wei K, Yao G, Pan C, Liu B, Xia Y, He Z, Qi X, Li Z et al. 
MicroRNA-124 Functions as a Tumor Suppressor by Regulating CDH2 and Epithelial-
Mesenchymal Transition in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2016; 
38(4):1563-1574. 
 
68. Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b 
modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive 
endometrial cancer cell lines. Mol Carcinog. 2014; 53(5):349-359. 
 
69. Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang 
YZ, Yun JP. miR-720 inhibits tumor invasion and migration in breast cancer by 
targeting TWIST1. Carcinogenesis. 2014; 35(2):469-478. 
 
70. Li W, Jiang G, Zhou J, Wang H, Gong Z, Zhang Z, Min K, Zhu H, Tan Y. 
Down-regulation of miR-140 induces EMT and promotes invasion by targeting Slug in 
esophageal cancer. Cell Physiol Biochem. 2014; 34(5):1466-1476. 
 
71. Zhou JN, Zeng Q, Wang HY, Zhang B, Li ST, Nan X, Cao N, Fu CJ, Yan XL, 
Jia YL et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets 
stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. 
Hepatology. 2015; 62(3):801-815. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
130 
 
72. Qiao P, Li G, Bi W, Yang L, Yao L, Wu D. microRNA-34a inhibits epithelial 
mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through 
transforming growth factor-beta/Smad pathway. BMC Cancer. 2015; 15:469. 
 
73. Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X, Yuan J, Chen S, Li M. Targeting 
Smad2 and Smad3 by miR-136 suppresses metastasis-associated traits of lung 
adenocarcinoma cells. Oncol Res. 2013; 21(6):345-352. 
 
74. Shiota M, Zardan A, Takeuchi A, Kumano M, Beraldi E, Naito S, Zoubeidi A, 
Gleave ME. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition 
and metastasis via Twist1 in prostate cancer cells. Cancer Res. 2012; 72(20):5261-5272. 
 
75. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, 
Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through 
JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J 
Cancer. 2009; 100(1):134-144. 
 
76. Liao G, Wang M, Ou Y, Zhao Y. IGF-1-induced epithelial-mesenchymal 
transition in MCF-7 cells is mediated by MUC1. Cell Signal. 2014; 26(10):2131-2137. 
 
77. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu 
K, Kimura H, Fujita Y et al. Sorafenib inhibits the hepatocyte growth factor-mediated 
epithelial mesenchymal transition in hepatocellular carcinoma. Molecular cancer 
therapeutics. 2011; 10(1):169-177. 
 
78. Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, 
Wang J et al. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and 
progression of colorectal cancer by activation of the Wnt/beta-catenin signaling 
pathway. Cancer Lett. 2014; 354(2):417-426. 
 
79. Zhang L, Wang D, Li Y, Liu Y, Xie X, Wu Y, Zhou Y, Ren J, Zhang J, Zhu H et 
al. CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell 
Metastasis via EMT and Erk/NF-kappaB Pathway. PLoS One. 2016; 11(8):e0158529. 
 
80. Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, Zhou J, Fan J, Gao Q, 
Wang XY. RANKL promotes migration and invasion of hepatocellular carcinoma cells 
via NF-kappaB-mediated epithelial-mesenchymal transition. PLoS One. 2014; 
9(9):e108507. 
 
81. Na YR, Lee JS, Lee SJ, Seok SH. Interleukin-6-induced Twist and N-cadherin 
enhance melanoma cell metastasis. Melanoma Res. 2013; 23(6):434-443. 
 
82. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. 
Expression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like 
phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol 
Cancer Res. 2012; 10(12):1597-1606. 
 
83. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. 
Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from 
integrins and discoidin domain receptor 1. J Cell Biol. 2008; 180(6):1277-1289. 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
131 
 
84. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, Feng 
X et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by 
hypoxia-inducible factor -1alpha in hepatocellular carcinoma. BMC Cancer. 2013; 
13:108. 
 
85. Yang H, Wang L, Zhao J, Chen Y, Lei Z, Liu X, Xia W, Guo L, Zhang HT. 
TGF-beta-activated SMAD3/4 complex transcriptionally upregulates N-cadherin 
expression in non-small cell lung cancer. Lung Cancer. 2015; 87(3):249-257. 
 
86. Park MK, You HJ, Lee HJ, Kang JH, Oh SH, Kim SY, Lee CH. 
Transglutaminase-2 induces N-cadherin expression in TGF-beta1-induced epithelial 
mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 
2A down-regulation. Eur J Cancer. 2013; 49(7):1692-1705. 
 
87. Brandl M, Seidler B, Haller F, Adamski J, Schmid RM, Saur D, Schneider G. 
IKK(alpha) controls canonical TGF(ss)-SMAD signaling to regulate genes expressing 
SNAIL and SLUG during EMT in panc1 cells. J Cell Sci. 2010; 123(Pt 24):4231-4239. 
 
88. Al-Azayzih A, Gao F, Somanath PR. P21 activated kinase-1 mediates 
transforming growth factor beta1-induced prostate cancer cell epithelial to 
mesenchymal transition. Biochim Biophys Acta. 2015; 1853(5):1229-1239. 
 
89. Zhao JH, Luo Y, Jiang YG, He DL, Wu CT. Knockdown of beta-Catenin 
through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-
1alpha. Cancer investigation. 2011; 29(6):377-382. 
 
90. Shin S, Im HJ, Kwon YJ, Ye DJ, Baek HS, Kim D, Choi HK, Chun YJ. Human 
steroid sulfatase induces Wnt/beta-catenin signaling and epithelial-mesenchymal 
transition by upregulating Twist1 and HIF-1alpha in human prostate and cervical cancer 
cells. Oncotarget. 2017; 8(37):61604-61617. 
 
91. Liu XL, Zhang XT, Meng J, Zhang HF, Zhao Y, Li C, Sun Y, Mei QB, Zhang F, 
Zhang T. ING5 knockdown enhances migration and invasion of lung cancer cells by 
inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget. 
2017; 8(33):54265-54276. 
 
92. Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao 
SW, He QY et al. Significance of PI3K/AKT signaling pathway in metastasis of 
esophageal squamous cell carcinoma and its potential as a target for anti-metastasis 
therapy. Oncotarget. 2017; 8(24):38755-38766. 
 
93. Meng J, Zhang XT, Liu XL, Fan L, Li C, Sun Y, Liang XH, Wang JB, Mei QB, 
Zhang F et al. WSTF promotes proliferation and invasion of lung cancer cells by 
inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal. 2016; 
28(11):1673-1682. 
 
94. Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, 
Takeda T, Ogawa N, Mashimo K et al. Activation of NF-kappaB by the 
RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
132 
 
to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013; 
32:62. 
 
95. Cheng ZX, Sun B, Wang SJ, Gao Y, Zhang YM, Zhou HX, Jia G, Wang YW, 
Kong R, Pan SH et al. Nuclear factor-kappaB-dependent epithelial to mesenchymal 
transition induced by HIF-1alpha activation in pancreatic cancer cells under hypoxic 
conditions. PLoS One. 2011; 6(8):e23752. 
 
96. Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, 
Cox ME, Naito S, Gleave ME et al. Insulin-like growth factor-I induces CLU 
expression through Twist1 to promote prostate cancer growth. Mol Cell Endocrinol. 
2014; 384(1-2):117-125. 
 
97. Wu YS, Chung I, Wong WF, Masamune A, Sim MS, Looi CY. Paracrine IL-6 
signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal 
transition via Stat3/Nrf2 pathway in pancreatic cancer cells. Biochim Biophys Acta. 
2017; 1861(2):296-306. 
 
98. Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom SW, Yoon SS. Role of Rac1 
Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell 
Phenotypes in Gastric Adenocarcinoma. Mol Cancer Res. 2017; 15(8):1106-1116. 
 
99. Mody HR, Hung SW, Naidu K, Lee H, Gilbert CA, Hoang TT, Pathak RK, 
Manoharan R, Muruganandan S, Govindarajan R. SET contributes to the epithelial-
mesenchymal transition of pancreatic cancer. Oncotarget. 2017; 8(40):67966-67979. 
 
100. Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, Park CG, Lee HY. 
A ROS/STAT3/HIF-1alpha signaling cascade mediates EGF-induced TWIST1 
expression and prostate cancer cell invasion. Prostate. 2014; 74(5):528-536. 
 
101. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RL. 
N-cadherin gene expression in prostate carcinoma is modulated by integrin-dependent 
nuclear translocation of Twist1. Cancer Res. 2006; 66(7):3365-3369. 
 
102. Qi Y, Wang N, He Y, Zhang J, Zou H, Zhang W, Gu W, Huang Y, Lian X, Hu J 
et al. Transforming growth factor-beta1 signaling promotes epithelial-mesenchymal 
transition-like phenomena, cell motility, and cell invasion in synovial sarcoma cells. 
PLoS One. 2017; 12(8):e0182680. 
 
103. Liu CC, Cai DL, Sun F, Wu ZH, Yue B, Zhao SL, Wu XS, Zhang M, Zhu XW, 
Peng ZH et al. FERMT1 mediates epithelial-mesenchymal transition to promote colon 
cancer metastasis via modulation of beta-catenin transcriptional activity. Oncogene. 
2017; 36(13):1779-1792. 
 
104. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, 
Morabito F, Callea V, Lombardi L et al. Molecular classification of multiple myeloma: 
a distinct transcriptional profile characterizes patients expressing CCND1 and negative 
for 14q32 translocations. J Clin Oncol. 2005; 23(29):7296-7306. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
133 
 
105. Li Y, Wang X, Zheng H, Wang C, Minvielle S, Magrangeas F, Avet-Loiseau H, 
Shah PK, Zhang Y, Munshi NC et al. Classify hyperdiploidy status of multiple 
myeloma patients using gene expression profiles. PLoS One. 2013; 8(3):e58809. 
 
106. Damgaard T, Knudsen LM, Dahl IM, Gimsing P, Lodahl M, Rasmussen T. 
Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis 
and clinical factors in multiple myeloma. Leuk Lymphoma. 2009; 50(2):236-246. 
 
107. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in 
cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14(11):736-
746. 
 
108. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth 
factor in patients with aggressive multiple myeloma. Blood. 1989; 74(1):11-13. 
 
109. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC. Blockade 
of mitogen-activated protein kinase cascade signaling in interleukin 6-independent 
multiple myeloma cells. Clin Cancer Res. 1997; 3(6):1017-1022. 
 
110. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann 
TA, Anderson KC. Multiple myeloma cell adhesion-induced interleukin-6 expression in 
bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996; 87(3):1104-
1112. 
 
111. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma 
cells through JAK / STAT rather than ras / MAP kinase pathway. Eur J Immunol. 1999; 
29(12):3945-3950. 
 
112. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple 
myeloma. Blood. 1995; 85(4):863-872. 
 
113. Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert 
Opin Ther Targets. 2013; 17(11):1303-1328. 
 
114. Dechow T, Steidle S, Gotze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, 
Bullinger L, Fend F, Soberon V et al. GP130 activation induces myeloma and 
collaborates with MYC. J Clin Invest. 2014; 124(12):5263-5274. 
 
115. Zheng XM, Black D, Chambon P, Egly JM. Sequencing and expression of 
complementary DNA for the general transcription factor BTF3. Nature. 1990; 
344(6266):556-559. 
 
116. Wang CJ, Franbergh-Karlson H, Wang DW, Arbman G, Zhang H, Sun XF. 
Clinicopathological significance of BTF3 expression in colorectal cancer. Tumour Biol. 
2013; 34(4):2141-2146. 
 
117. Symes AJ, Eilertsen M, Millar M, Nariculam J, Freeman A, Notara M, Feneley 
MR, Patel HR, Masters JR, Ahmed A. Quantitative analysis of BTF3, HINT1, NDRG1 
and ODC1 protein over-expression in human prostate cancer tissue. PLoS One. 2013; 
8(12):e84295. 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
134 
 
118. Liu Q, Zhou JP, Li B, Huang ZC, Dong HY, Li GY, Zhou K, Nie SL. Basic 
transcription factor 3 is involved in gastric cancer development and progression. World 
J Gastroenterol. 2013; 19(28):4495-4503. 
 
119. Zhang DZ, Chen BH, Zhang LF, Cheng MK, Fang XJ, Wu XJ. Basic 
Transcription Factor 3 Is Required for Proliferation and Epithelial-Mesenchymal 
Transition via Regulation of FOXM1 and JAK2/STAT3 Signaling in Gastric Cancer. 
Oncol Res. 2017; 25(9):1453-1462. 
 
120. Degagne E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, 
Yoshinaga Y, Nefedov M, de Jong PJ, Fong LG et al. Sphingosine-1-phosphate lyase 
downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. 
J Clin Invest. 2014; 124(12):5368-5384. 
 
121. Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O. First 
evidence of sphingosine 1-phosphate lyase protein expression and activity 
downregulation in human neoplasm: implication for resistance to therapeutics in 
prostate cancer. Molecular cancer therapeutics. 2012; 11(9):1841-1851. 
 
122. Colie S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC, Garcia 
V, Djavaheri-Mergny M, Bauvy C, Codogno P et al. Disruption of sphingosine 1-
phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through 
Bcl-2/Bcl-xL upregulation. Cancer Res. 2009; 69(24):9346-9353. 
 
123. Yang Z, Wang H, Xia L, Oyang L, Zhou Y, Zhang B, Chen X, Luo X, Liao Q, 
Liang J. Overexpression of PAK1 Correlates with Aberrant Expression of EMT 
Markers and Poor Prognosis in Non-Small Cell Lung Cancer. J Cancer. 2017; 
8(8):1484-1491. 
 
124. Fan G, Nicholas N. FER mediated HGF-independent regulation of HGFR/MET 
activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer. Small 
GTPases. 2017:0. 
 
125. Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, 
Tamanoi F. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer 
oncogenesis. BMC Cancer. 2015; 15:381. 
 
126. Seong HA, Kim KT, Ha H. Enhancement of B-MYB transcriptional activity by 
ZPR9, a novel zinc finger protein. J Biol Chem. 2003; 278(11):9655-9662. 
 
127. Zhang X, Lv QL, Huang YT, Zhang LH, Zhou HH. Akt/FoxM1 signaling 
pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J 
Exp Clin Cancer Res. 2017; 36(1):105. 
 
128. Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin H, Cao F. B-Myb regulates snail 
expression to promote epithelial-to-mesenchymal transition and invasion of breast 
cancer cell. Med Oncol. 2015; 32(1):412. 
 
129. Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ, 
Difilippantonio MJ, Harris CC, Ghadimi BM, Moller S et al. The rectal cancer 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
135 
 
microRNAome--microRNA expression in rectal cancer and matched normal mucosa. 
Clin Cancer Res. 2012; 18(18):4919-4930. 
 
130. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes 
V, Schmidt S, Blake J, Ball G et al. MicroRNA signatures predict oestrogen receptor, 
progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer 
Res. 2009; 11(3):R27. 
 
131. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C. Profiling of 95 
microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR 
analysis. World J Surg. 2009; 33(4):698-709. 
 
132. Wang JM, Ju BH, Pan CJ, Gu Y, Li MQ, Sun L, Xu YY, Yin LR. MiR-214 
inhibits cell migration, invasion and promotes the drug sensitivity in human cervical 
cancer by targeting FOXM1. Am J Transl Res. 2017; 9(8):3541-3557. 
 
133. Wang P, Chen S, Fang H, Wu X, Chen D, Peng L, Gao Z, Xie C. miR-
214/199a/199a* cluster levels predict poor survival in hepatocellular carcinoma through 
interference with cell-cycle regulators. Oncotarget. 2016; 7(1):929-945. 
 
134. Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, Du L, Wang C. 
MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting 
PDRG1 in bladder cancer. PLoS One. 2015; 10(2):e0118086. 
 
135. Long LM, He BF, Huang GQ, Guo YH, Liu YS, Huo JR. microRNA-214 
functions as a tumor suppressor in human colon cancer via the suppression of ADP-
ribosylation factor-like protein 2. Oncol Lett. 2015; 9(2):645-650. 
 
136. He GY, Hu JL, Zhou L, Zhu XH, Xin SN, Zhang D, Lu GF, Liao WT, Ding YQ, 
Liang L. The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis 
in human colorectal cancer. Br J Cancer. 2016; 115(11):1367-1378. 
 
137. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 
contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 
2012; 279(13):2393-2398. 
 
138. Zhou C, Liu G, Wang L, Lu Y, Yuan L, Zheng L, Chen F, Peng F, Li X. MiR-
339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells 
by targeting PRL-1. PLoS One. 2013; 8(5):e63142. 
 
139. Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, 
Zhang N, Xu XC. MiR-339-5p inhibits breast cancer cell migration and invasion in 
vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010; 
10:542. 
 
140. Li Y, Zhao W, Bao P, Li C, Ma XQ, Li Y, Chen LA. miR-339-5p inhibits cell 
migration and invasion in vitro and may be associated with the tumor-node-metastasis 
staging and lymph node metastasis of non-small cell lung cancer. Oncol Lett. 2014; 
8(2):719-725. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
136 
 
141. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance 
urokinase-type plasminogen activator (uPA) expression and tumor progression and 
invasion in human breast cancer. Oncogene. 2009; 28(44):3937-3948. 
 
142. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, Xing R, Jin Y, Sun Z, Zheng X. 
MicroRNA-193b regulates proliferation, migration and invasion in human 
hepatocellular carcinoma cells. Eur J Cancer. 2010; 46(15):2828-2836. 
 
143. Li J, Kong F, Wu K, Song K, He J, Sun W. miR-193b directly targets STMN1 
and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. Mol 
Med Rep. 2014; 10(5):2613-2620. 
 
144. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, 
Strano S, Blandino G. MicroRNA-128-2 targets the transcriptional repressor E2F5 
enhancing mutant p53 gain of function. Cell Death Differ. 2012; 19(6):1038-1048. 
 
145. Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors 
linking the TGFbeta receptor to c-myc repression. Cell. 2002; 110(1):19-32. 
 
146. Pierce AM, Schneider-Broussard R, Philhower JL, Johnson DG. Differential 
activities of E2F family members: unique functions in regulating transcription. Mol 
Carcinog. 1998; 22(3):190-198. 
 
147. Tan MK, Lim HJ, Harper JW. SCF(FBXO22) regulates histone H3 lysine 9 and 
36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated 
proteasomal degradation. Mol Cell Biol. 2011; 31(18):3687-3699. 
 
148. Tian X, Dai S, Sun J, Jin G, Jiang S, Meng F, Li Y, Wu D, Jiang Y. F-box 
protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote 
hepatocellular carcinoma progression. Oncotarget. 2015; 6(26):22767-22775. 
 
149. Geyer R, Wee S, Anderson S, Yates J, Wolf DA. BTB/POZ domain proteins are 
putative substrate adaptors for cullin 3 ubiquitin ligases. Mol Cell. 2003; 12(3):783-790. 
 
150. Xu L, Wei Y, Reboul J, Vaglio P, Shin TH, Vidal M, Elledge SJ, Harper JW. 
BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase 
containing CUL-3. Nature. 2003; 425(6955):316-321. 
 
151. Genschik P, Sumara I, Lechner E. The emerging family of CULLIN3-RING 
ubiquitin ligases (CRL3s): cellular functions and disease implications. Embo J. 2013; 
32(17):2307-2320. 
 
152. Pae J, Cinalli RM, Marzio A, Pagano M, Lehmann R. GCL and CUL3 Control 
the Switch between Cell Lineages by Mediating Localized Degradation of an RTK. Dev 
Cell. 2017; 42(2):130-142 e137. 
 
153. Pintard L, Willems A, Peter M. Cullin-based ubiquitin ligases: Cul3-BTB 
complexes join the family. Embo J. 2004; 23(8):1681-1687. 
 
CHAPTER 4: The regulation of N-cadherin in t(4;14)+ and t(4;14)- MM 
137 
 
154. Chen HY, Chen RH. Cullin 3 Ubiquitin Ligases in Cancer Biology: Functions 
and Therapeutic Implications. Front Oncol. 2016; 6:113. 
 
155. Collins T, Stone JR, Williams AJ. All in the family: the BTB/POZ, KRAB, and 
SCAN domains. Mol Cell Biol. 2001; 21(11):3609-3615. 
 
156. Wong CW, Privalsky ML. Components of the SMRT corepressor complex 
exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-
RARalpha, and BCL-6. J Biol Chem. 1998; 273(42):27695-27702. 
 
157. Stogios PJ, Prive GG. The BACK domain in BTB-kelch proteins. Trends 
Biochem Sci. 2004; 29(12):634-637. 
 
158. Sampathkumar P, Ozyurt SA, Miller SA, Bain KT, Rutter ME, Gheyi T, Abrams 
B, Wang Y, Atwell S, Luz JG et al. Structures of PHR domains from Mus musculus 
Phr1 (Mycbp2) explain the loss-of-function mutation (Gly1092-->Glu) of the C. elegans 
ortholog RPM-1. J Mol Biol. 2010; 397(4):883-892. 
 
159. Schonrock N, Humphreys DT, Preiss T, Gotz J. Target gene repression mediated 
by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-beta. J 
Mol Neurosci. 2012; 46(2):324-335. 
 
160. Mashiko H, Yoshida AC, Kikuchi SS, Niimi K, Takahashi E, Aruga J, Okano H, 
Shimogori T. Comparative anatomy of marmoset and mouse cortex from genomic 
expression. J Neurosci. 2012; 32(15):5039-5053. 
 
161. Wang CF, Hsing HW, Zhuang ZH, Wen MH, Chang WJ, Briz CG, Nieto M, 
Shyu BC, Chou SJ. Lhx2 Expression in Postmitotic Cortical Neurons Initiates 
Assembly of the Thalamocortical Somatosensory Circuit. Cell Rep. 2017; 18(4):849-
856. 
 
162. Matsui A, Tran M, Yoshida AC, Kikuchi SS, U M, Ogawa M, Shimogori T. 
BTBD3 controls dendrite orientation toward active axons in mammalian neocortex. 
Science. 2013; 342(6162):1114-1118. 
 
163. Xiao W, Zhao W, Li L, Wu Q, Zhu L, Zhang Q, Dai W, Wang Y, Zhang B. 
Preliminary investigation of the role of BTB domain-containing 3 gene in the 
proliferation and metastasis of hepatocellular carcinoma. Oncol Lett. 2017; 14(2):2505-
2510. 
 
Supplementary Figure 4.1. MMSET and FGFR3 expression in MM patients. 
Newly-diagnosed MM patients were categorised as MMSETlow or MMSEThigh, and 
FGFR3low or FGFR3high, based on their expression of MMSET/NSD2 (209053_s_at) and 
FGFR3 (204379_s_at) in CD138-selected BM MM PCs, as determined by microarray 
analysis. The cut-off (grey line) used to delineate high and low MMSET and FGFR3 
expression is shown for microarray datasets GSE4581 (MMSEThigh/FGFR3high, n = 55 
patients; MMSEThigh/FGFR3low, n = 19; MMSETlow, n = 340), E-MTAB-363 
(MMSEThigh/FGFR3high, n = 15; MMSEThigh/FGFR3low, n = 4; MMSETlow, n = 136), E-
GEOD-19784 (MMSEThigh/FGFR3high, n = 23; MMSEThigh/FGFR3low, n = 12; 
MMSETlow, n = 293), E-MTAB-317 (MMSEThigh/FGFR3high, n = 26; 
MMSEThigh/FGFR3low, n = 8; MMSETlow, n = 192), E-GEOD-26863 
(MMSEThigh/FGFR3high, n = 24; MMSEThigh/FGFR3low, n = 10; MMSETlow, n = 270) and 
GSE16558 (MMSEThigh/FGFR3high, n = 14; MMSEThigh/FGFR3low, n = 3; MMSETlow, n 
= 43). 
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Supplementary Figure 4.2.  A schematic overview of the hypothesised CDH2 
regulatory mechanisms in MM based on in silico analysis of publicly available 
microarray data of CD138+ BM PCs from newly-diagnosed MM patients. MMSET 
is hypothesised to be a key positive regulator of CDH2 expression in t(4;14)+ MM (A). 
In t(4;14)- MM, BTBD3 is hypothesised to be a potential driver of CDH2 expression, 









Supplementary Figure 4.3.  miR-190 and CDH2 expression in t(4;14)- MM 
patients, and expression of miR-190 in a panel of t(4;14)- HMCLs. Newly-diagnosed 
MM patients were categorised as miR-190low or miR-190high, and CDH2low or CDH2high, 
based on their expression of miR-190 and CDH2 (203440_at) in CD138-selected BM 
MM PCs, as determined by microarray analysis. The cut-off (grey line) used to 
delineate high and low miR-190 and CDH2 expression is shown for the microarray 
dataset GSE16558 (A). miR-190 expression levels (normalised to the U6 snRNA 
reference gene), as assessed by qPCR, in a panel of t(4;14)- HMCLs. Graph depicts 


























































































Supplementary Figure 4.4.  Expression of BTBD3 mRNA and protein in a panel of 
HMCLs. BTBD3 expression (normalised to ACTB expression), as assessed by qPCR, in 
a panel of HMCLs, stratified based on t(4;14) status. Graph depicts mean ± SEM of 3 
independent experiments (A). Expression of BTBD3 isoforms in representative HMCLs 
(top panel), as assessed by Western blot. Histone H3 was utilised as a nuclear protein 




































































# Genes in 
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k/K
FDR          
q-value
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RPL36 RSL24D1 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
RPL27A RPL18 RPL35 RPL35A 
RPS13 RPL36 RSL24D1 RPS5 
RPS11 RPL31 RPS28 RPS2 
FAU 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
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RPS13 RPL36 EIF3K EIF3G 
RPS5 RPS11 RPL31 RPS28 
RPS2 FAU SEC11A SSR3 
EEF1D 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
RPL27A RPL18 RPL35 RPL35A 
RPS13 RPL36 EIF3K EIF3G 
RPS5 RPS11 RPL31 RPS28 
RPS2 FAU 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
RPL27A RPL18 RPL35 RPL35A 
RPS13 RPL36 RPS5 RPS11 
RPL31 RPS28 RPS2 FAU 
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RPS17 RPL13A RPL37 GTF2F2 
RPS3 RPL29 RPL4 RPS19 
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Supplementary Table 4.1: GSEA of genes which posi�vely correlate with CDH2  expression in 
t(4;14)- MM pa�ents
ZHAN_MULTIPLE_MYELOMA HP_UP1 24 0.49 1.92E-41
REACTOME_SRP_DEPENDENT 
COTRANSLATIONAL
PROTEIN TARGETING TO MEMBRANE6
22 0.12
REACTOME_INFLUENZA VIRAL RNA 
TRANSCRIPTION AND REPLICATION7
21 0.12
KEGG_RIBOSOME3 21 0.24 1.96E-28




RPS17 RPL13A RPL37 GTF2F2 
RPS3 RPL29 RPL4 RPS19 
RPS9 RPL27A RPL18 RPL35 
RPL35A RPS13 RPL36 CLTA 
RPS5 RPS11 RPL31 RPS28 
RPS2 FAU 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
RPL27A RPL18 RPL35 RPL35A 
RPS13 RPL36 RPS5 RPS11 
RPL31 RPS28 RPS2 FAU 
RPS17 RPL13A RPL37 RPS3 
RPL29 RPL4 RPS19 RPS9 
RPL27A RPL18 RPL35 RPL35A 
RPS13 RPL36 RPS5 RPS11 
RPL31 RPS28 RPS2 FAU 
1. Top 50 up-regulated genes in cluster HP of mul�ple myeloma samples characterized by a hyperploid signature. 
2. Protein biosynthesis, transport or catabolism genes up-regulated in hyperploid mul�ple myeloma (MM)
compared to the non-hyperploid MM samples. 
3. Ribosome 
4. Genes involved in Transla�on 
5. Genes involved in 3' -UTR-mediated transla�onal regula�on 
6. Genes involved in SRP-dependent cotransla�onal protein targe�ng to membrane 
7. Genes involved in Influenza Viral RNA Transcrip�on and Replica�on 
8. Genes involved in Influenza Life Cycle 
9. Genes involved in Pep�de chain elonga�on 
10. Genes involved in Nonsense Mediated Decay Enhanced by the Exon Junc�on Complex 
20
20 0.13 8.06E-22
REACTOME_INFLUENZA LIFE CYCLE8 22 0.11 2.84E-22
0.11 1.32E-20
REACTOME NONSENSE MEDIATED DECAY 
ENHANCED BY THE EXON JUNCTION 
COMPLEX10
REACTOME PEPTIDE CHAIN 
ELONGATION9
Gene set name
# Genes in 
overlap
k/K
FDR          
q-value
Genes
Supplementary Table 4.1: GSEA of genes which posi�vely correlate with CDH2  expression in 
t(4;14)- MM pa�ents (con�nued)
Gene set name
# Genes in 
overlap
k/K
FDR          
q-value
IRF2BP2 SGPL1 RAPH1 TMEM107
KCNN3 TCFL5 APBB1IP
IRF2BP2 CDCA7 GSTA4 RGS5
ARF3 POLA1 XPR1
SGPL1 CDCA7 HGSNAT B3GALT6
SEC61A2 SLC44A2
RAPH1 GSTA4 RGS5 HGSNAT
PITPNC1
CDCA7 ARF3 POLA1 B3GALT6
SEC61A2 DHTKD1 ETV6
1. Top 50 down-regulated genes in cluster HP of mul�ple myeloma samples characterized by a hyperploid signature.
2. Genes up-regulated in hepatocellular carcinoma (HCC) compared to normal liver samples.
3. Transcripts depleted from pseudopodia of NIH/3T3 cells (fibroblast) in response to haptotac�c migratory s�mulus 
by fibronec�n, FN1.
4. Genes down-regulated in anaplas�c thyroid carcinoma (ATC) compared to normal thyroid �ssue.
5. Genes down-regulated in nasopharyngeal carcinoma (NPC) compared to the normal �ssue.
RODRIGUES_THYROID_CARCINOMA_    
ANAPLASTIC_DN4
5 0.01 3.53E-02
DODD_NASOPHARYNGEAL_            
CARCINOMA_DN5
7 0.01 3.53E-02
PATIL_LIVER_CANCER2 7 0.01 1.64E-03
MILI_PSEUDOPODIA_HAPTOTAXIS_DN3 6 0.01 9.64E-03
ZHAN_MULTIPLE_MYELOMA_HP_DN1 7 0.15 1.16E-11
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5.1 General discussion 
In Australia alone, approximately 10,000 individuals are living with MM, with 
approximately 1,700 new cases of MM diagnosed each year.1 The advent of so-called 
'novel' anti-MM agents, including the immunomodulatory drugs thalidomide and 
lenalidomide, and the proteasome inhibitor bortezomib, has significantly changed the 
therapeutic landscape of MM patient management over the past 15-20 years.2,3 The use 
of bortezomib, the first-in-class proteasome inhibitor approved by the US FDA in 2003, 
is considered to be a major breakthrough in the treatment of patients with MM. 
Currently, bortezomib forms an integral backbone of many chemotherapeutic regimens 
in MM, used as induction therapy in both autologous stem cell transplantation (ASCT)-
eligible and -ineligible patients, as a maintenance therapy and in the relapse setting.4-7 
Notably, the use of bortezomib-based treatment regimens in newly diagnosed MM 
patients appears to overcome the poor prognosis associated with high-risk cytogenetic 
features (e.g. t(4;14)+ status or deletion of chromosome 17p) and improves overall 
survival (OS) rates in both ASCT-eligible and -ineligible patients, in comparison to 
non-bortezomib-based therapies.8-12 Importantly, such advancements in the therapeutic 
management of MM continue to improve the OS prospects of individuals diagnosed 
with the disease.13-15 Currently, the median overall survival (OS) of newly diagnosed 
MM patients is approximately 6-10 years.4,15 
 While some patients achieve long-term disease remission, with OS of greater 
than 15 years, approximately 15-20% of patients experience rapid disease relapse, or 
respond poorly to induction therapy, resulting in early death.15-17 The identification of 
MM patients who are likely to do poorly, namely those with 'high-risk' disease, is 
paramount to the success of therapeutically managing these patients in order to 
maximise their survival prospects.15 A combination of determinants are used to 
clinically define high-risk MM including advanced disease stage (ISS stage III), poor 
genetic profile (e.g. t(4;14), t(14;16), del(17p), 1q21 amplification) and the presence of 
extramedullary disease.15 Other features associated with high-risk disease include high 
numbers of circulating tumour cells (CTCs) and failure to respond to an induction 
therapy containing a proteasome inhibitor or immunomodulatory agent.18 Notably, 
studies emanating from our laboratory have shown that stratification of newly 
diagnosed MM patients based on plasma N-cadherin levels identify a subset of 
individuals (> 6ng/ml plasma N-cadherin) with increased risk of earlier death, 
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irrespective of ISS stage, tumour burden or poor cytogenetic features.19 N-cadherin gene 
(CDH2) expression in CD138+ PCs is also up-regulated in approximately 50% of newly 
diagnosed MM patients, compared with CDH2 levels in normal individuals.19,20 
Collectively, these findings raise several important issues, including how N-cadherin 
expression is dysregulated in MM, what functional role(s) N-cadherin plays in MM 
pathogenesis and whether N-cadherin represents a potential therapeutic target in MM. 
 
5.2 The regulation of N-cadherin expression in t(4;14)+ and t(4;14)- 
MM 
A key aim of this thesis research was to determine how N-cadherin expression is 
dysregulated in both t(4;14)+ and t(4;14)- MM (Chapter 4). CDH2 is highly expressed in 
approximately 85% of patients featuring the reciprocal chromosomal translocation 
t(4;14), observed in 10-15% of MM cases, whereby the genes MMSET (encoding for the 
histone methyltrasferase MMSET) and FGFR3 (encoding for fibroblast growth factor 
receptor 3) are placed under the control of strong enhancers.20-22 This translocation 
universally results in the over-expression of MMSET and, in 70% of cases, the over-
expression of FGFR3.23,24 Given t(4;14)+ status in MM is an adverse prognostic factor, 
independent of FGFR3 expression, MMSET dysregulation is considered to be the 
primary mediator of oncogenesis and aberrant gene expression in this subset of MM 
patients.25-27 Using a combination of in silico and in vitro analyses, we have confirmed 
that MMSET is a key regulator of CDH2 expression in MM cells, suggesting it is an 
important driver of up-regulated N-cadherin in t(4;14)+ MM. 
 In addition to t(4;14)+ MM patients, CDH2 up-regulation is a feature in another 
35-40% of newly diagnosed patients despite having t(4;14)- status.20 In particular, a 
distinct population of CDH2-overexpressing MM patients is observed in the 
hyperdiploidy subset, accounting for approximately 50% of patients in the subset.20,28 
Owing to the genetic heterogeneity between CDH2+ patients in the t(4;14)- MM 
subsets29, little is currently known regarding the mechanism(s) by which CDH2 
expression is up-regulated in these patients. To this end, we performed in silico analysis 
of newly diagnosed t(4;14)- MM patients to reveal potential regulators of CDH2 
expression in t(4;14)- MM PCs. While in vitro studies in HMCLs did not validate our 
leading candidate, BTBD3, as a critical regulator of CDH2 expression in MM, our 
studies revealed several other mechanisms by which CDH2 expression may be 
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regulated in t(4;14)- MM. For example, several genes identified as being significantly 
associated with CDH2 expression in t(4;14)- MM patients (IL6ST, BTF3 and SGPL1) 
functionally converge to regulate the JAK/STAT3 signalling cascade30-32, which is 
implicated in MM PC growth and survival33-35, and has previously been shown to 
positively regulate N-cadherin expression in solid tumours.36-39 Other potential 
mechanisms of CDH2 up-regulation in t(4;14)- MM include the Fer/Rac1/Pak1 and 
ZNF622/B-myb signalling axes, which have previously been implicated in positively 
regulating N-cadherin expression in other cancers.40-44 miR-190 is also of particular 
interest, as the majority of t(4;14)- MM patients which express miR-190 have low or 
undetectable CDH2 expression. Moreover, miR-190 is predicted to target the CDH2 3'-
UTR. Further studies are required to investigate whether these pathways and molecules 
regulate N-cadherin expression in t(4;14)- MM.  
 While BTBD3, a putative transcriptional regulator45-52, is unlikely to be a critical 
regulator of CDH2 expression in MM, our analyses show, for the first time, that BTBD3 
expression is strongly up-regulated in bone marrow (BM) PCs from MM patients, 
compared with normal controls. Moreover, the up-regulation of BTBD3 in MM PCs is 
associated with a trend towards poorer overall survival in t(4;14)- MM patients, 
suggesting a role for BTBD3 in MM pathogenesis. Thus, future studies investigating the 
functional role of BTBD3 in MM are also warranted. 
 
5.3 The therapeutic utility of ADH-1 in the prevention of MM PC 
dissemination 
The development and progression of MM is underpinned by the continuous trafficking, 
or dissemination, of MM PCs from one tumour site to distant BM sites via the 
circulation. For instance, MM PCs egress from a primary BM site and disseminate to 
multiple skeletal sites to form micrometastases, leading to the asymptomatic precursor 
stage of MM, called monoclonal gammopathy of undermined significance (MGUS). 
The subsequent growth of these metastases results in the transition to symptomatic 
MM53, which occurs at a relatively slow rate in individuals with MGUS (1% per 
annum).54 Elevated numbers of CTCs are also associated with more rapid progression 
from MGUS, or the pre-malignant stage of MM called smouldering MM, to overt 
MM.55,56 Further growth and dissemination of MM PCs promotes disease progression 
and, in advanced cases, the development of plasma cell leukaemia and extramedullary 
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disease.53,57-61 The dissemination of MM PCs is also likely to facilitate the re-population 
and growth of therapy-resistant MM PCs within the BM, thereby promoting disease 
relapse. Indeed, elevated numbers of CTCs in previously treated MM patients are 
associated with inferior prognosis.62 
 Therapeutic targeting of tumour cell adhesion to endothelium has been 
suggested as a modality to prevent the extravasation and dissemination of MM PCs. For 
example, functional inhibition of PSGL-1-mediated MM PC interaction with P-selectin, 
important in leukocyte tethering to endothelial cells (ECs), inhibits MM PC adhesion to 
ECs and reduces MM PC extravasation and BM homing in vivo.63 In addition, studies 
have shown that blocking MM PC adhesion to ECs with an anti-CD44v10 antibody 
inhibits the homing of circulating MM PCs to the BM and reduces tumour 
development.64 In line with the aforementioned studies, we found that pre-treatment of 
C57Bl/KaLwRij mice with the N-cadherin antagonist ADH-1 (N-Ac-CHAVC-NH2) 
inhibited tumour development following intravenous injection of 5TGM1 MM PCs. 
This effect was not seen in mice treated with ADH-1 1 week after injection of tumour 
cells, suggesting that N-cadherin plays a role in the initial BM homing or establishment 
of the tumour cells within the BM. While our in vivo studies did not specifically 
investigate the role of N-cadherin in extravasation and BM homing, we have shown that 
N-cadherin mediates the adhesion of MM PCs to ECs, which is likely to play a role in 
the extravasation and intravasation of MM PCs (Chapter 2).65 In support of this, pre-
clinical studies have previously demonstrated that N-cadherin knock-down in MM PCs 
decreases the capacity of CTCs to home to the BM in vivo, resulting in increased 
residual cells within the peripheral blood.20 As well as preventing the establishment of 
MM PCs within the BM, the inability of circulating MM PCs to rapidly extravasate and 
home to the BM is likely to increase their vulnerability to anoikis (a form of 
programmed cell death induced by the lack of integrin-mediated cell adhesion), shear 
stress and attack by immune cells66,67, thereby potentially inhibiting MM disease 
progression.  
 Although we found that ADH-1 treatment did not decrease tumour development 
in C57Bl/KaLwRij mice with established MM, the limited sensitivity of 
bioluminescence imaging (BLI) prevented the assessment of the effects of ADH-1 on 
MM PC dissemination and the formation of micro-metastases in this model. In addition, 
recent bar-coding studies conducted in our laboratory have demonstrated that while the 
systemic dissemination of individual 5TGM1 cell clones is a feature of the 
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C57Bl/KaLwRij model, it does not contribute to the bulk of the tumour burden 
observed at the conclusion of the study.68 Thus, any inhibitory effects of ADH-1 on the 
ability of 5TGM1 cells to disseminate in C57Bl/KaLwRij mice with established disease 
is unlikely to result in decreased BLI signal at the conclusion of the study. In addition to 
ECs, ADH-1 may also antagonise N-cadherin function in other host-derived cell types, 
including BM stromal cells that support MM PC proliferation and survival.69-72 
However, our in vitro co-culture studies suggest that N-cadherin-mediated adhesion 
between 5TGM1 cells and BM stromal cells is unlikely to play a critical role in 5TGM1 
cell proliferation. Moreover, in the context of MM pathogenesis, the inability of ADH-1 
treatment to inhibit MM progression in C57Bl/KaLwRij mice with established disease 
suggests that N-cadherin-mediated adhesion between 5TGM1 cells and BM stromal 
cells in the BM microenvironment is less important than N-cadherin-mediated 5TGM1 
cell-EC interactions. 
 Further studies are warranted to determine whether therapeutic targeting of N-
cadherin may be useful as a maintenance therapy in the clinical MM setting. To this 
end, ADH-1 could be used to prevent the dissemination of residual therapy-resistant 
MM PCs, thereby inhibiting or delaying tumour re-population of the BM and limiting 
disease relapse. Theoretically, the introduction of ADH-1 as a maintenance therapy 
could be particularly useful for those 50% of MM patients in which N-cadherin 
expression in MM PCs is elevated. In addition to MM, the extravasation of CTCs plays 
a critical role in dissemination and metastasis formation in many solid tumours.73-76 
Notably, N-cadherin has been implicated in the adhesion of breast cancer cells and 
melanoma cells to ECs and in the formation of lung metastases following intravenous 
injection of melanoma cells in mice.77-80 Thus, it is possible that ADH-1 may be 
therapeutically useful in the context of preventing tumour cell dissemination and 
metastasis formation in solid tumours.     
 
5.4 The use of LCRF-0006 as a novel vascular disrupting agent 
Unlike normal blood vessels, which consist of a layer of tightly associated ECs that are 
structurally supported by mural cells (e.g. pericytes and smooth muscle cells), tumour-
associated vasculature is structurally abnormal, characterised by gaps between adjacent 
ECs and loosely attached or absent mural cells.81-83 These structural abnormalities, in 
addition to the disorganised, tortuous nature of tumour-associated vasculature, and the 
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defective lymphatic drainage in tumours, result in abnormal pressure gradients and 
heterogeneous perfusion which can limit drug delivery to the tumour.81,84,85  
 Paradoxically, however, these structural abnormalities can lead to increased 
permeability of tumour-associated vasculature which, combined with the paucity of 
lymphatic drainage in tumours, is thought to contribute to the passive and selective 
accumulation of macromolecules (> 40 kDa) in sites of tumour, known as the enhanced 
permeability and retention (EPR) effect.81,86,87 Notably, augmentation of the EPR effect 
is widely recognised, and increasingly investigated, as a potential therapeutic strategy to 
increase tumour delivery, and therefore efficacy, of macromolecular drugs or drug 
complexes.87-93 To this end, augmentation of the EPR effect may be therapeutically 
useful for tumour delivery of large drugs such as monoclonal antibodies (e.g. rituximab, 
daratumamab and elotuzamab)94-96, or drugs with high affinity (> 80%) for large plasma 
proteins (e.g. albumin), including tyrosine kinase inhibitors (e.g. imatinib and nilotinib), 
proteosome inhibitors (e.g. bortezomib and carfilzomib) and melphalan.97-101 
Additionally, augmentation of the EPR effect may also increase tumour delivery of 
drugs in nanoparticle delivery systems.91,102 Importantly, pre-clinical studies suggest 
that agents which augment the EPR effect may improve the efficacy of anti-cancer 
agents in tumours characterised by either inherently low, or high, vascular 
permeability.90,103 Notably, recent studies have demonstrated the ability of vascular 
disrupting agents to increase tumour accumulation, and anti-cancer efficacy, of 
macromolecular drugs and drug complexes in vivo, suggesting that such agents can 
augment the EPR effect.91,104 
 LCRF-0006 is a synthetic, metabolically stable compound which structurally 
mimics the HAV domain of ADH-1.105 Synthetic small molecule mimetics of peptide 
drugs are thought to offer increased therapeutic efficacy in comparison to their peptide 
counterparts, due to enhanced proteolytic stability, bio-availability and potency.106,107 
Indeed, LCRF-0006 has been found to inhibit N-cadherin-dependent processes four-fold 
more potently than ADH-1 (Orest Blaschuk; personal communication). N-cadherin is 
expressed by both ECs and mural cells and is a critical regulator of vascular integrity 
and endothelial barrier function.104,108-111 To this end, in vitro studies have demonstrated 
that endothelial barrier permeability to macromolecules can be enhanced by functional 
perturbation of N-cadherin in blood vessels.104,111 Moreover, ADH-1 has been shown to 
rapidly enhance tumour blood vessel permeability to macromolecules in vivo.104 
Notably, we found that LCRF-0006 acts as a vascular disrupting agent which increases 
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blood vessel permeability to macromolecules, as evidenced by LCRF-0006-mediated 
extravasation of 70 kDa FITC-dextran in mouse retinal tissues (Chapter 3). In contrast 
to vascular disrupting agents such as microtubule-depolymerizing agents which induce 
necrosis of tumour vasculature84,112,113, the disruptive effects of LCRF-0006 on ECs are 
transient and reversible, which is consistent with the proposed role of N-cadherin in 
endothelial barrier closure.79,114 Thus, the effects of LCRF-0006 may be more 
comparable to the transient effects of inflammatory mediators (e.g. histamine and 
thrombin) which induce reversible cell retraction and inter-endothelial gap 
formation.115-117 
 In line with the ability of ADH-1 to increase the efficacy of melphalan104, the 
data presented here shows that LCRF-0006 synergistically increased the depth of MM 
tumour response in C57Bl/KaLwRij mice to the anti-MM agent bortezomib. We 
speculate that these synergistic effects may, at least in part, be mediated by LCRF-0006-
enhanced tumour delivery of bortezomib, potentially by augmentation of the EPR 
effect. As bortezomib is highly bound to plasma proteins in vivo99, we hypothesise that 
an increase in the permeability of tumour-associated vasculature caused by pre-
treatment with LCRF-0006 may enhance accumulation of plasma protein-bound 
bortezomib in sites of tumour, consistent with the ADH-1-mediated increase in delivery 
of melphalan in a pre-clinical model of melanoma.104 Given LCRF-0006 synergistically 
increased MM tumour response to a sub-therapeutic dose of bortezomib, these findings 
may also be clinically relevant in increasing MM patient depth of response to low doses 
of bortezomib, thereby potentially alleviating detrimental side-effects such as peripheral 
neuropathy. In support of this, recent studies using a pre-clinical mouse model of colon 
cancer demonstrated the ability of an EPR-augmenting agent to increase the anti-tumour 
efficacy of albumin-bound paclitaxel, without increasing the myelosuppressive effects 
of paclitaxel treatment.90 An important observation emanating from our endothelial tube 
disruption assays was that the initial effects of LCRF-0006 on EC retraction and 
rounding were more rapid in immature (5-hour-old) endothelial tubes than established 
(24-hour-old) tubes, suggesting that tumour-associated vasculature may have increased 
propensity to LCRF-0006-mediated disruption. However, given our findings that 
LCRF-0006 increased the permeability of normal micro-vessels to macromolecules, 
further studies are warranted to determine whether LCRF-0006 may selectively enhance 
the delivery of anti-cancer agents such as bortezomib to tumour sites while minimising 
side-effects on healthy tissues. 
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5.5 The use of LCRF-0006 to increase MM PC sensitivity to anti-
cancer agents  
In addition to increasing vascular permeability, LCRF-0006 acted synergistically with 
bortezomib to directly induce 5TGM1 MM PC apoptosis in vitro, which may further 
contribute to the synergism observed in vivo. In line with these findings, ADH-1 has 
previously been shown to significantly increase melanoma tumour response to the 
chemotherapeutic agent temozolamide in vivo, without altering tumour up-take of the 
drug.104 To date, a role for N-cadherin in MM PC resistance to chemotherapeutics has 
not been demonstrated. One potential mechanism by which LCRF-0006 and bortezomib 
may synergistically induce MM tumour cell apoptosis is by differential inhibition of the 
Bcl-2-family pro-survival proteins Bcl-2 and Mcl-1, shown to mediate MM PC 
survival.118-121 In other cancer cell types, N-cadherin engagement has been shown to 
activate Bcl-2 by enhancing PI3K/Akt-mediated phosphorylation of the pro-apoptosis 
protein Bad.78,122,123 Interestingly, the combination of the Bcl-2 inhibitor venetoclax and 
bortezomib has recently shown promising efficacy in relapsed/refractory MM and is 
now being evaluated in Phase III clinical trials.124 These studies were conducted on the 
basis of encouraging pre-clinical findings which demonstrated that venetoclax increased 
MM tumour sensitivity to bortezomib, despite having limited single-agent efficacy.119 
Further studies are required to assess the mechanisms whereby LCRF-0006 synergises 
with bortezomib and induces apoptosis in MM cells. 
N-cadherin has also been implicated in the resistance of other cancer cell types to 
anti-cancer agents. For example, studies have shown that N-cadherin potentiates 
prostate cancer cell resistance to metformin in vitro and in vivo, by activation of NF-кB 
signalling.125 In addition, studies have demonstrated the ability of N-cadherin 
antagonists, including ADH-1, to decrease micro-environmental protection of chronic 
myeloid leukaemia cells to the tyrosine kinase inhibitor imatinib.126,127 In line with these 
findings, N-cadherin silencing has been shown to induce apoptosis in lung cancer cell 
lines resistant to the tyrosine kinase inhibitor gefitinib.123 To this end, further studies are 
warranted to determine whether LCRF-0006-mediated inhibition of N-cadherin function 
can increase tumour cell sensitivity to tyrosine kinase inhibitors. 
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5.6 Future directions and concluding remarks 
MM is still largely considered to be incurable with most patients relapsing and 
ultimately succumbing to the disease.6 However, it is evident that deeper tumour 
responsiveness to induction therapy results in more durable responses and improved 
long-term prospects for MM patients.128-132 Thus, an important goal of modern 
combination therapy regimens in the management of MM patients is to achieve the 
maximum possible depth of tumour response to induction therapy.6 To this end, our 
finding that a significantly deeper tumour response was achieved in mice which 
received the LCRF-0006-bortezomib combination therapy, suggests that the addition of 
LCRF-0006 to current chemotherapeutic regimens incorporating bortezomib may 
represent a novel strategy to increase the depth of MM patient response to bortezomib 
therapy. To this end, LCRF-0006 may therapeutically be useful in newly diagnosed 
patients, during maintenance therapy and in the relapse setting. Furthermore, the 
potential ability of LCRF-0006 to augment the EPR effect, increasing extravasation of 
macromolecular drugs and drug complexes (e.g. plasma protein-bound drugs), suggests 
that it could also improve the efficacy of 75% of the pharmaceutical industry's current 
20 top-selling anti-cancer drugs.133 
 In addition to initial response to treatment, the subsequent rapidity of the 
outgrowth and spread of resistant clones is an important determinant of the outcomes 
for myeloma patients.134-137 Treatment relapse is likely to be dependent upon the ability 
of therapy-resistant MM PC to re-enter the circulation, disseminate and repopulate sites 
throughout the BM.62 Therefore, limiting the dissemination of MM PCs presents a 
promising opportunity to prevent overt relapse and improve overall survival. Our 
findings demonstrate that N-cadherin is likely to facilitate the adhesion of circulating 
MM PCs to ECs during extravasation, a critical step in the BM homing cascade.65 To 
this end, ADH-1 could be utilised to prevent the dissemination of MM PCs via the 
circulation, thereby inhibiting MM disease relapse in those 50% of MM patients that 
express up-regulated levels of N-cadherin. 
 
 This thesis research demonstrates that MMSET, universally dysregulated in 
t(4;14)+ MM patients, is a critical regulator of CDH2 expression in MM PCs, suggesting 
it is the key driver of up-regulated N-cadherin in t(4;14)+ MM. This thesis has also 
identified several potential molecules and pathways which may represent previously 
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unknown, MMSET-independent regulators of N-cadherin expression in t(4;14)- MM. 
While BTBD3 is unlikely to be a critical regulator of CDH2 in t(4;14)- MM, this thesis 
suggests that BTBD3 is potentially important in MM pathogenesis, which warrants 
future investigation. In addition, this thesis research suggests that therapeutic targeting 
of N-cadherin using the antagonist ADH-1 could potentially be utilised to prevent the 
dissemination of PCs, thereby delaying MM progression and relapse.65 Finally, this 
thesis research has identified a small molecule peptidomimetic of ADH-1, LCRF-0006, 
as a novel vascular disrupting agent which enhances vascular permeability and 
synergistically increases the efficacy of the anti-MM agent bortezomib in a pre-clinical 
mouse model of established MM disease. To this end, LCRF-0006 may be clinically 
useful in increasing the depth of MM tumour response to bortezomib, which is currently 
used in MM patients as induction therapy, maintenance therapy, and in the relapsed 
setting. In addition, we speculate that the potential ability of LCRF-0006 to augment the 
EPR effect could be utilised to increase the delivery, and anti-cancer efficacy, of various 
chemotherapeutic agents in MM and other cancers in the clinical setting. Together with 
our collaborators, we are currently developing next-generation small molecules which 
inhibit N-cadherin-dependent processes more potently than LCRF-0006 or ADH-1. 
These will be explored more extensively in the context of dissemination and 
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